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Abstract 
 
The C"terminal tensin"like (Cten) gene is a member of the tensin family and is 
localised at the cytoplasmic tail of β"integrin. It is involved in various biological 
events although the role of in the development of colorectal cancer (CRC) is uncertain. 
In order to study this, the expression of Cten during the development of CRC was 
initially evaluated using immunohistochemistry (IHC) on colorectal adenomas and 
carcinomas. Positive immunoreactivity for Cten was observed in 317/342 (92.6%) of 
CRC and 19/20 (90%) of colorectal adenoma. High Cten expression was significantly 
associated with advance Dukes stage (p=0.001), lymph node metastasis (p<0.001), 
extra"mural vascular invasion (p=0.001) and distant metastases (p=0.008). Survival 
analysis demonstrated that patients with high Cten expression had significantly shorter 
disease free survival (DFS) on univariate analysis (p<0.001) a trend towards Cten 
expression as an independent predictor of DFS on multivariate analysis (p=0.071). To 
further test the association with metastasis, the role of Cten in metastasis was tested by 
(a) intrasplenic injection of CRC cells stably transfected with Green Fluorescent 
Protein (GFP) tagged Cten into nude mice and (b) testing a series of primary CRCs 
and their metastases by IHC. Compared with control mice (injected with cells 
transfected with GFP empty vector), mice injected with cells expressing Cten 
developed larger tumours in the spleen (p=0.03) and liver (p=0.05). Compared with 
primary tumours, the metastatic deposits had a significantly higher frequency of 
nuclear localisation of Cten (p=0.002). To further investigate the potential role of Cten 
in metastasis, invitro models were used to investigate Cten function. Ectopic 
expression of Cten in the HCT116 CRC cell line (which expresses low levels of Cten) 
caused changes in cell morphology and increased cell motility (both migration and 
invasion). Conversely, the reciprocal Cten knock"down experiments in SW620 CRC 
cell line (which expresses high levels of Cten) resulted in inhibition of both cell 
migration and invasion. Since Cten is in complex with integrins at focal adhesions, its 
interactiosn with integrin"linked kinase (ILK), focal adhesion kinase (FAK) and CD24 
were tested. Cten was shown to regulate ILK, FAK and CD24. Moreover, inhibition of 
CD24 after forced expression of Cten abrogated the Cten"mediated effects on both cell 
motility and protein levels of ILK and FAK. The studies were expanded and Cten 
expression was tested by IHC in another cancer model i.e. breast cancer (BC). 
Consistent with the data from CRC, increased Cten expression in BC was found to be 
associated with poor prognostic variables and shorter disease free survival. 
 
In conclusion, Cten expression is associated with poor prognosis in CRC and BC. This 
may be consequent to an ability to enhance metastasis which is related to promotion of 
cell motility. The activities of Cten are probably consistent across different tumour 
models. 
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Literature review 
Chapter 1. Literature review 
1.1 gene family 
1.1.1 Introduction 
The tensin gene family consists of four members: tensin1 (TS1), tensin2 (TS2),
 
tensin3 (TS3) and Cterminal tensinlike (Cten) encoding proteins which are localised 
to the cytoplasmic tail of β integrins at focal adhesions (1). These genes are highly 
homologous and encode multi"domain proteins that can bind to several structural and 
signalling molecules including vinculin,
 
paxillin, Src, focal adhesion kinase (FAK), 
phosphotidylinositol 3"kinase (PI3K) and
 
Crk"associated substrate (p130Cas). Tensin 
binds to the actin cytoskeleton at multiple sites, enabling tensin both to cap the barbed 
ends and to cross"link actin stress fibers (2, 3). In addition, it is phosphorylated in 
response to several factors, such as extracellular matrix (ECM), platelet"derived 
growth factor (PDGF), angiotensin, thrombin, and by certain oncogenes like v"Src or 
BCR/ABL on its tyrosine, serine and threonine residues (4"7). Tensin appears to be 
critical in controlling cell adhesion and migration, but is also thought to participate in 
regulating other crucial biological events such
 
as proliferation, differentiation
 
and 
apoptosis (8). Therefore, it is believed that tensin can be an essential component 
linking the ECM to the actin cytoskeleton and thereby mediating signalling for cell 
shape and motility associated with cytoskeletal reorganisation (9).  
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1.1.2 Genomic structure 
A search of the available human genomic sequence databases using the human TS1 
(OMIM ref. no. 600076) cDNA shows that the length of human TS1 is about 150 kb 
and is localised at 2q35"q36. The total composed cDNA is 10,276 bp which encodes a 
1,735 amino acid protein. It has 33 exons; the putative start
 
codon is in exon 6, 
whereas the stop codon is in exon 33. Exon 33 is the largest exon with 4,815 bp,
 
but 
only 145 bp comprise the coding sequence, whereas the rest
 
is the 3' untranslated 
region. Exon 21 is the smallest exon
 
with 24 bp (10).  
 
Compared to TS1, TS2 gene (OMIM ref. no. 607717) is shorter, it is about 12,5 kb 
in length and maps to chromosome 12. The total composed cDNA is 5,009 bp which 
encodes 1,285 amino acid protein. It has 29 exons; the putative start
 
codon is in exon 7, 
whereas stop codon is in exon 28. Exon 18 is the largest exon with 1,212 bp, while 
exon 28 is the smallest exon
 
with 30 bp. Exons 5"15 in TS2 are similar in size to 
exons 6"16 in TS1. These exons encode the actin"binding domain (ABD). In addition, 
Exons 21"28 in TS2 are identical in size to exons 25"32 in TS1. These exons encode 
the Src"homology 2 (SH2) and phosphotyrosine"binding (PTB) domains. These 
conserved genomic structures of human TS1 and TS2 confirm that they represent a 
single gene family (10).  
 
The TS3 gene (OMIM ref. no. 606825) is about 264 kb in length and is localised at 
7p12.3. It is composed of 4,415 bp cDNA which encode 1,445 amino acid protein, and 
has 31 exons. The putative start codon is in exon 6, whereas stop codon is in exon 31. 
Exon 31 is the largest exon with 3,067 bp,
 
but only 145 bp comprise the coding 
sequence, whereas the rest
 
is the 3' untranslated region. Exon 30 is the smallest exon
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with 27 bp. In contrast to TS1 and TS2, exons 6"15 (encoding the ABD) and exons 
23"30 (encoding the SH2 and PTB domains) in TS3 are almost identical, supporting 
the idea that TS3 is
 
related to the tensin gene family (11). 
 
The Cten gene (OMIM ref. no. 608385) is about 21 kb in length and is localised at 
17q21.2. It is composed of 4,090 bp cDNA which encode 715 amino acid protein, and 
has 13 exons. The putative start
  
codon is in exon 2, whereas stop codon is in exon 13. 
Exon 13 is the largest exon with 1,900 bp,
 
but only 141 bp comprise the coding 
sequence, whereas the rest
 
is the 3' untranslated region. Exon 12 is the smallest exon
 
with 27 bp. Exons 5–12 encode the SH2 and PTB domains are identical
 
to other tensin 
genes, confirming the fact that they represent a single gene family (8). 
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1.1.3 Protein structure 
Generally, tensin proteins are composed of three regions that are each involved in 
mediating protein"protein interactions, the C"terminal regions, middle and the N"
terminal regions (Figure 1) (3, 5).  
 
The C"terminus of tensin contains an SH2 domain, allowing tensin to interact with 
certain tyrosine"phosphorylated proteins, such as PI3K, FAK and p130Cas (5, 12). 
This binding is critical for tensin"mediated increased cell migration (13). The C"
terminus contains a PTB domain, which allows tensin to bind to the NPXY motif on 
the cytoplasmic tail of β integrin (Figure 1) (14).  
 
The N"terminus of tensin contains an ABD, which allows tensin to interact with actin 
filaments (Figure 1) (3). It also contains sequences which share homology with auxilin, 
a coat protein of brain clathrin coated vesicles, cyclin G associated kinase (GAK), 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN), putative 
transmembrane tyrosine phosphatase (TPTE) and mutated in multiple advanced 
cancers1 (MMAC1). However, the significance of this sequence similarity is not clear, 
because none of these molecules bind to actin filaments (15"19).  
 
The C"terminal and the N"terminal regions of tensin also contain two focal adhesion"
binding (FAB) domains which seem to be crucial for tensin"mediated biological 
effects, such as cell adhesion and migration (Figure 1) (13).  
 
Analysis of the cDNA and genomic sequences of the tensin family
 
genes shows an 
extensive homology within the tensin members at their amino and carboxy terminals. 
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The arrangement and size of exons encoding
 
for the functional
 
domains, such as ABD, 
SH2 and PTB domains of TNS1, TNS2, TNS3 and Cten are
 
almost identical, 
indicating that these domains have been conserved through evolution (Figure 2, 3) (10, 
11). However, during
 
evolution Cten has lost its actin"binding ability (8). In contrast to 
other tensin molecules, TNS2 is the only tensin family member harbouring
 
a protein 
kinase C (PKC) domain at its amino terminus (Figure 2) (20). 
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Figure 1. Schematic structure of tensin. The C"terminus of tensin contains SH2 and PTB domains, 
allowing tensin to interact with tyrosine"phosphorylated proteins and β integrin respectively. Tensin can 
also bind actin via ABD present in its N"terminus. The central region of tensin contains actin"capping 
domain (ACD), which allows tensin to regulate the actin polymerization rate. Two FAB domains are 
present in the C"terminal and the N"terminal regions, and these involved in mediating binding of tensin 
to other focal adhesion molecules. 
 
 
Figure 2. Alignment of functional domains of tensin family members. TNS1, TNS2, TNS3 and cten 
are highly conserved at C" and N"terminal regions although the central regions are very diverse. TNS2 is 
the only tensin family member contains
 
PKC domain at its amino terminus.  
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Figure 3. Alignment of amino acids sequences of tensin family members. Alignment of human 
tensins amino acids sequences showing conserved functional ABD, SH2 and PTB domains. Red colour 
indicates similar residues. Non"similar residues are shown in black. 
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Despite the high sequence similarities at the N and C"terminal regions of tensin family 
proteins, the center regions show no sequence homology. The central region of TNS1 
contains an insertin or actin"capping domain (ACD), which allows TNS1 to regulate 
actin polymerisation through capping the barbed ends of actin filaments and 
facilitating the cross"linking of actin filament processes (3). In comparison, TNS2 is 
lacking this sequence, so, it is not able to interfere with the actin polymerisation 
process (3). However, its central region is very rich in proline residues, which provides 
potential binding sites for protein"protein interaction modules Src"homology 3 (SH3)  
and WW domains (21). This shows that each tensin member may have an additional 
unique biological role. 
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1.1.4 Tissue expression 
TNS1 is broadly expressed in a wide variety of human tissues, including heart, lung, 
skeletal muscle, small intestine, colon, liver, kidney, prostate, testis, and ovaries. In 
contrast, very low expression was observed in thymus, brain and circulating leukocytes 
(22). The expression pattern of TNS2 is very similar to that of TNS1 (10). This 
similarity of expression may indicate a potential functional overlap between these 
tensin family members. In contrast, TNS3 is expressed at high levels in thyroid, kidney 
and placenta. Very low expression of TNS3 was reported in lung, skeletal muscle, 
brain, pancreas, liver and heart (11, 23). Cten messenger RNA (mRNA) expression in 
normal tissues was evaluated by K. Sakashita et al using the human total RNA master 
panel and revealed that Cten is expressed at high levels in prostate, oesophagus, breast 
and salivary glands. Moderate Cten expression was found in the thyroid and trachea. In 
contrast, very low expression was reported in colon, lung, small intestine, spleen, 
kidney, stomach and testis (Figure 4) (24). 
 
Figure 4.  mR'A expression in the human total R'A master panel. Evaluation of Cten 
expression in the human total RNA master panel using quantitative real time PCR (Q"RT"PCR) reveled 
that Cten shows different expression patterns for different organs, contributing to adverse biological 
behaviors in at least some types (24).  
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1.1.5 Biological function 
Focal adhesion localisation is the common feature of all tensin members. Giving the 
extensive homology the tensin family genes share at their C" and N"terminal regions, 
where the functional domains such as PTB, SH2 and ABD domains are encoded, it is 
likely that they may have a similar biological role (10). Knockout (KO) mice for TNS1 
and TNS3 show cystic kidney disease and renal failure (25, 26). Furthermore, a 
frameshift mutation of the TNS2 gene in ICR"derived glomerulonephritis (ICGN) 
mice, a model for human idiopathic nephrotic syndrome, was shown to be responsible 
for morphologic changes of the glomerulus and proteinuria consistence with features 
of nephrotic syndrome (27). These data clearly suggest that TNS1, TNS2 and TNS3 
expressions are necessary for maintaining normal renal function (26). In addition, KO 
of TNS3 in mice results in growth retardation and post"natal lethality accompanied 
with a combination of developmental defects in the small intestine, lung and bone and 
indicates that TNS3 might regulate normal growth and is essential for normal 
development and functions of the small intestine, lung and bone (25).  
 
It has been reported that the protein binding activity of the SH2 domain is a critical 
factor for regulating TNS1"mediated cell migration effects (28). Another important 
factor is the focal adhesion localisation of TNS1 since non"focal adhesion"localised 
mutant TNS1 has no effect on cell migration. Isolated fibroblasts from TNS1"KO mice 
as well as normal mouse embryos were analysed and showed that TNS1"KO cells 
migrated significantly slower than their normal counterparts (10). Functional analysis 
also demonstrates that ectopic expression of TNS2 resulted in promoting cell 
migration on fibronectin in a cell migration assay (10). In comparison with other tensin 
members, TNS3 up"regulation in the normal human mammary cell line, MCF10A was 
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coupled to more cytoskeletal stability and consequently, rendering the cell less motile 
(29). Conversely, stimulation by epidermal growth factor (EGF) appears to induce 
expression of Cten, thereby causing a switch from TNS3 to Cten at focal adhesions. 
This stimulates migration through disruption of the link between integrins and cortical 
actin fibres (Figure 5) (30).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A model representing the role of T'S32Cten expression switch in promoting EGF2
induced cell migration. In normal epithelial cell, the integrity of foal adhesions was maintained, at least 
in part, via TNS3 which bind integrin through its PTB and cytoskeletal actin filaments through its ABD 
domain. Upon EGF stimulation, Cten is up"regulated and competes with TNS3 at cytoplasmic site of 
β integrin. This result in dissociation of TNS3 from focal adhesions and stimulates migration through 
disruption of the link between integrins and cortical actin fibres.  
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In addition to focal adhesions, TNS1 is also localised at fibrillar adhesions (or ECM 
contacts), where it can form a complex with α5β1 integrin, fibronectin fibrils and actin 
filaments (31). Previous data has demonstrated that integrin can be translocated from 
focal adhesions to fibrillar adhesions through the interference of TNS1. Therefore, 
TNS1 is crucial for fibronectin fibrillogenesis, which converts soluble fibronectin into 
insoluble fibronectin matrix (32). This fibronectin matrix provides positional 
information for cell migration during early embryogenesis and plays an important role 
in cell growth, differentiation, survival and oncogenic transformation (33). 
 
The localisation of TNS1 at the dense plaques of smooth muscles as well as at 
neuromuscular, myotendinous junctions and along the sarcolemma of skeletal muscles, 
suggest that TNS1 may play a role in the maintenance of normal muscle function (34, 
35). Previous data show that TNS1 is not essential for myogenesis, since TNS1"KO 
mice seemed to develop normal muscle fibers (26). However, the regeneration process 
in experimentally damaged skeletal muscle fibers was much slower in TNS1"KO mice 
compared to wild"type (WT) skeletal muscle fibers. Moreover, this regeneration delay 
was accompanied by an increase in the population of premature skeletal muscle fibers 
and defects in cell activation, proliferation, differentiation and fusion in TNS1"KO 
skeletal muscles compared to WT muscle fibers, implying the role of TNS1 in wound 
healing processes (36). 
The close localisation of TNS1 and calpain II at focal adhesion sites raises the 
possibility that there might be an interaction between these two molecules (37). It has 
been reported that calpain II, a calcium"dependent cysteine protease, is involved in 
integrin"mediated signalling pathways and cytoskeletal reorganisation (38). Previous 
data showed the ability of calpain II to cleave TNS1 into small fragments in a time" 
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and dose"dependent manner, and this cleavage eventually leads to cell morphological 
changes, indicating an abnormality in both reorganisation of the actin cytoskeleton and 
focal adhesion complexes (22).  
TNS1 is also cleaved by caspase"3, a member of the caspase family, at the DYPD
1226
G 
sequence, releasing the C"terminal region containing the SH2 domain away from the 
N"terminal region containing the actin binding domain. The resultant C"terminal 
fragment is unable to bind PI3K and transduce cell survival signalling. On the other 
hand, the released N"terminal fragment can induce disruption of the actin cytoskeleton 
organisation at focal adhesions. Therefore, caspase"mediated cleavage of TNS1 
contributes to the interruption of ECM"mediated survival signals through PI3"K and is 
considered a critical step for disrupting the structure of focal adhesions during 
apoptosis (39). Cten has also been reported to be a caspase"3 substrate, similarly to 
TNS1. It has been shown that caspase"3 is able to cleave Cten at the DSTD
570
S 
sequence, thereby releasing a fragment, Cten 571–715, which contains the PTB 
domain and is able to reduce cell growth by inducing apoptosis through binding to the 
β
 
integrin tails and disruption of the link between integrins and cortical actin fibres. 
This might lead to disruption of cell adhesions and eventually facilitate cell death (40). 
 
Previous reports have shown that TNS1 over"expression activates both c"Jun N"
terminal kinase (JNK) and p38 mitogen"activated protein kinase (MAPK) pathways, 
and this activation was independent of the activities of the small GTP binding proteins 
Rac and Cdc42, but was dependent on Sek, a receptor tyrosine kinase involved in the 
JNK pathway (41).  
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1.1.6 Role in human tumours 
Deleted in liver cancer 1 (DLC1) is a recently cloned gene mapped to chromosome 
8p21.3"22, a region shown to harbour tumour suppressor genes. It is frequently deleted 
in various human cancers, such as liver, breast, lung, brain, stomach, colon, and 
prostate cancers. It is widely expressed in normal human tissues, but frequently down"
regulated in human hepatocellular carcinoma (HCC) and various cancer cell lines. 
Given that, a growing body of evidence suggests that DLC1 acts as a tumour 
suppressor gene (42"51).  
 
It has been reported that TNS2 directly interacts, via its SH2 domain, with DLC1 in 
vitro and in vivo, and the formation of a DLC1"TNS2 complex
 
brings DLC1 in close 
proximity to Rho GTPases and facilitates the inactivation of Rho proteins. The Rho 
proteins regulate the remodelling of the actin cytoskeleton, focal adhesion turnover and 
promote
 
cell proliferation and metastasis through the
 
Rho GTPases"activating protein 
(RhoGAP) activity of DLC1. These data, in conjunction with the finding that TNS2 
expression was down"regulated in HCC, clearly demonstrates the tumour suppressor 
activity of TNS2 in HCC (52). However, expression of the splice variant of TS2 
(variant 3) has been shown to be up"regulated in human HCC, and this over"expression 
was significantly associated with venous invasion, tumour microsatellite formation and 
tumour non"encapsulation. In addition, forced expression of variant 3 caused 
significant increase in cell migration, invasion and proliferation of HCC cells, 
demonstrating the oncogenic role of variant 3 in hepatocarcinogenesis (53). 
 
Evaluation of the expression level of TNS3 in thyroid tissue has revealed that in 
addition to normal thyroid tissue, TNS3 is also up"regulated in benign thyroid lesions, 
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such as adenomatous goitres and functional follicular adenomas. However, its 
expression is decreased in papillary and follicular carcinomas and even markedly 
decreased in anaplastic thyroid carcinomas. These data clearly show that abundant 
expression of TS3 mRNA is observed in tissues that produce thyroid hormone, 
suggesting that TNS3 may play a fundamental role in thyroid function and may relate 
to thyroid diseases (23, 54).  
 
Previously published data suggest that the function of Cten is tissue"specific. It has 
been reported, that Cten is down"regulated in prostate cancer compared to normal 
prostate, and therefore acts as a tumour suppressor in the prostate (8). Moreover, the 
localisation of Cten at chromosome 17q21, a region frequently deleted in prostate 
cancer, and the interaction of mutant DLC1 with the Cten SH2 domain, which 
facilitates the recruitment of DLC1 to focal adhesion sites, and in turn restore its 
tumour suppression activities, clearly demonstrate the tumour suppressor behaviour of 
Cten in prostate and liver cancers (55). However, in thymomas and lung tumours, Cten 
has been described as an oncogene with progressive up"regulation correlating with 
increasing tumour stage (56, 57). In addition, evaluation of the expression of Cten in 
gastric cancer cases using immunohistochemistry (IHC) revealed that Cten over"
expression was significantly associated with histologically poorer grade, deeper 
invasion into the serosa, lymph node metastasis and peritoneal dissemination. Patients 
with high Cten expression tended to show shorter survival than patients had a lower 
expression of Cten (24).  
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1.1.7 Medical applications 
Several aspects of the function of tensin genes are of medical interest. Evaluation of 
the renal histology of TNS1 and TNS2"KO mice showed tubular basement membrane 
disintegration, tubular atrophy with cyst development and interstitial cell infiltration 
with fibrosis, lesions commonly seen in human nephronophthisis disorders. Thus, 
TNS1 and TNS2"KO mice could be a useful animal model for human 
nephronophthisis or similar renal diseases (20).  
 
Silver"Russell dwarfism, also called Silver–Russell syndrome (SRS) is a growth 
disorder occurring in children, with an incidence of approximately 1:10,000 births. The 
major phenotypic features are growth retardation, short limbs, and triangular face. Its 
exact cause is unknown, but previous research shows it is usually caused by a maternal 
uniparental disomy (UPD) on chromosome 7p11.2–13. Having shown that TNS3 is 
essential for normal development and functions of the small intestine, lung and bone as 
its KO in mice results in growth retardation accompanied with a combination of 
developmental defects in the small intestine, lung and bone. These phenotypes of the 
TNS3"KO mice are similar to some clinical features of SRS. In addition, the 
localisation of TS3 at chromosome 7p12.3, these data suggesting a potential link 
between TNS3 and SRS. 
 
Inflammatory breast cancer (IBC) is a subtype of highly aggressive breast cancer (BC) 
characterised by HER2 over"expression and showing a large degree of lymphovascular 
invasion (58, 59). Recently, it has been found that Cten expression is up"regulated in 
56% of IBC patients, and this over"expression is found to be strongly correlated with 
epidermal growth factor receptor (EGFR) phospholoration (P"EGFR). Analysis of 
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Cten expression in tumour biopsies from P"EGFR positive IBC patients prior to and 
during lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor (Tykerb), monotherapy 
revealed that after a 21"day treatment with the drug, Cten expression was significantly 
down"regulated in most tumours. Similarly P"EGFR, P"HER2 and P"Erk levels were 
reduced following lapatinib treatment. Taken together, this data demonstrates that Cten 
expression in BCis highly dependent on EGFR activation, and may predict the 
response to EGFR/HER2"targeted therapy (30). 
 
Furthermore, evaluation of the Cten expression in prostate cancer (PC"3) and 
paclitaxel"resistance prostate cancer (PC"3"TxR) cell lines, has revealed that Cten"KO 
in PC"3 cells and Cten forced expression in PC"3"TxR cells is associated with induced 
paclitaxel resistance and restored paclitaxel sensitivity respectively, possibly through 
elevation of F"actin which modifies the cytoskeletal cell structure to confer resistance 
to paclitaxel. These results strongly suggest that Cten plays an important role in 
paclitaxel sensitivity in prostate cancer (60). 
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1.2 Focal adhesions 
Adhesive interactions between cells and the ECM play a crucial role regulating a wide 
variety of dynamic cellular processes, such as cell motility, cell proliferation, cell 
differentiation, regulation of gene expression and cell survival. Perturbing this 
coordination can lead to cell transformation and cancer development (61, 62). Focal 
adhesions are specialised areas of the plasma membrane allowing cells to attach to the 
ECM through transmembrane receptors of the integrin family that link intracellularly 
to the actin cytoskeleton (61, 62). In addition to structural molecules which participate 
in maintaining the integrity of the structural link between membrane receptors and the 
actin cytoskeleton, focal adhesions also contain several types of signalling molecules, 
including different protein kinases and phosphatases, their substrates, and various 
adapter proteins which suggest a considerable functional diversity (63, 64). Upon 
engagement of integrins with their ECM ligands and subsequent integrin clustering, 
the cytoplasmic tail of β−integrins triggers signal transduction events such as tyrosine 
phosphorylation of cytoplasmic tyrosine kinases (e.g. FAK) and serine/threonine 
kinases (such as those in the MAPK cascade), and induced phosphatidylinositol–4,5– 
biphosphate (PIP2) synthesis (65"67), forming large intracellular protein complexes 
clustered at the cytoplasmic tails of β"integrins and linked to the actin cytoskeleton. 
Thus focal adhesions not only provide a structural link between ECM components and 
actin cytoskeleton, but also play a key role in mediating signal transduction. In 
addition, focal adhesions play crucial roles in the creation, mediation and sensing of 
tension (68). 
 
Based on their adhesion maturation state, focal adhesions can be classified into 
different structural categories including: focal points which are formed at the periphery 
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of the cells and linked to an F"actin network; focal complexes—mid"size stationary 
adhesion sites which are linked to the actin meshwork at the leading edge of the cell 
within lamellipodia; focal adhesions—large elongated adhesions connected to the actin 
stress fibers; fibrillar adhesions—elongated contact sites that connect extracellular 
fibronectin fibers to microfilament stress fibers; and podosomes—invasive ring 
structures composed of adhesion machinery and actin filaments (69). 
 
Cell migration is an emergent process that ultimately derives from a vast diversity of 
molecular interactions between, ECM components, integrins, adaptor proteins, actin 
and kinases at focal adhesions. These combine progressively to produce recognisable 
sub"cellular systems of intermediate complexity which control actin polymerisation, 
cytoskeletal tension, and focal adhesions organisation and turn"over and eventually 
produce adhesive and migratory cellular behaviours (69).  
 
Cell migration occurs in response to chemokines and growth factors that are captured 
by transmembrane receptors on the cell surface. In addition cell migration can also be 
initiated more directly by focal adhesions and their interaction with ECM components 
(69). These signalling systems are designed to induce cell shape changes accompanied 
by formation of actin"dependent cellular protrusions such as filopodia and lamellipodia 
at the front of the migrating cell that form the molecular scaffold formed by the 
polymerised actin cytoskeleton to the ECM and required for the initiation and 
maturation of further focal complexes (70). Once the actin cytoskeleton is linked to the 
ECM, the newly added actin molecules to the actin cytoskeletal scaffold can serve to 
push the plasma membrane at the leading edges of filopodia and lamellipodia forward 
(71). The second phase of cell migration is initiated when focal complexes start to 
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mature into focal adhesions which results in the compaction of the actin cytoskeleton 
and integrin receptors, creating a robust link between actin stress fibers and the ECM 
(68, 72). This is followed by sliding of the focal adhesions in the direction of migration 
accompanied with dispersion of integrin dependent adhesion sites at the rear and 
formation of integrin dependent adhesion sites at the proximal edge of sliding focal 
contacts respectively (73, 74).  
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1.3 Focal adhesion molecules 
1.3.1 Integrins 
Among the several proteins involved in cell attachment, is a family of cell surface 
receptors known as integrins, named for maintaining the integrity of the cytoskeletal"
ECM linkage, play a fundamental role in mediating these molecular interactions (75, 
76). Whereas the extracellular domain of integrins binds ECM proteins, their 
cytoplasmic tail anchors to the actin cytoskeleton. This linkage is dynamic " while the 
integrin binding to ECM changes the composition and morphology of the cell 
cytoskeleton, the actin networks itself controls avidity and affinity of the integrins 
extracellular domain, thereby modulating the ECM (77).    
 
A key feature of integrin is that in addition to binding ECM molecules, they bind other 
proteins including growth factors, cytokines and matrix"degrading proteases. The 
signals are integrated and adapted to play a critical role in regulating many vital 
cellular events, including gene expression, tissue development, inflammation, 
angiogenesis, tumour cell growth and metastasis. Therefore, integrins appear as a 
cornerstone in many cellular biological processes (78). 
 
Another important feature of integrin is that they are able to coordinate with and 
regulate the informational outputs of receptor tyrosine kinases (RTKs). For example, 
in response to integrin αvβ3"ECM binding combined with low concentrations of EGF 
exposure, EGFR is phosphorylated in a c"Src and p130Cas"dependent fashion leading 
to downstream signalling for cell survival and proliferation. In the absence of integrin–
ECM interactions, the EGF responsiveness of EGFR is significantly reduced (79). 
Another example is phosphorylation and significant signal enhancement of vascular 
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endothelial growth factor receptor 2 (VEGFR2) upon its direct interaction with αvβ3 
integrin (80). 
Typically, integrins are obligate heterodimers composed of α and β subunits in close 
non"covalent association that form structural and functional bridges between the ECM 
and intracellular cytoskeleton. There are 18 α and 8 β subunits that have been 
characterised, forming 22 different heterodimeric receptor complexes and despite this 
high redundancy level, most integrins have unique and specific biological roles (81"
83).   
Integrins do not themselves possess kinase activity, however, they rely on cytoplasmic 
proteins such as talin, paxillin, vinculin and alpha"actinin which in turn interact with 
the actin cytoskeleton (84). At focal adhesions, the cytoplasmic proteins act by 
regulating cytoplasmic kinases such as FAK and Src family kinases, which in turn bind 
and phosphorylate adaptor proteins, such as p130Cas, thereby recruiting signalling 
molecules and activating intracellular signalling pathways. These eventually promote 
cell migration, proliferation and survival in both normal and tumorigenic cell contexts. 
Therefore, integrins are not only structural proteins, but also play a key role in 
mediating signal transduction (85). 
The close localisation of Cten with integrin"linked kinase (ILK), FAK and CD24 
molecules at cytoplasmic tails of integrins and the finding that Cten contains an SH2 
domain that allows Cten to bind phosphotyrosine"containing proteins at focal 
adhesions, raise the possibility that there might be a potential link between these 
molecules and prompted us to focus on ILK, FAK and CD24 as secondary down 
stream targets of Cten. These secondary molecules play a key role in various biological 
functions such
 
as cell adhesion, migration, proliferation, differentiation,
 
apoptosis and 
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invasion. Their protein structure, downstream signalling pathways and biological role 
in cancer will be discussed in details in the following sections.  
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1.3.2 FAK 
FAK is a 125 kDa non"receptor and non"membrane associated protein tyrosine kinase 
(PTK), which was shown to be localised at focal adhesions and involved in many 
critical cellular events including adhesion, migration, proliferation and survival (86).  
 
FAK contains three different structural domains: the C"terminal, the central and the N"
terminal domains (Figure 6). The central tyrosine kinase domain is flanked on the N"
terminus by a band 4.1, ezrin, radixin, and moesin (FERM) domain, which may serve 
as a binding site for growth factors receptors such as EGFR, and PDGFR, ezrin, a 
cytoskeletal linker and JSAP1, a component of the JNK pathway (87"89), and on its C"
terminus by the focal adhesion targeting (FAT) domain. The FAT domain modulates 
FAK localisation to focal adhesions via interactions with the integrin"associated 
proteins, such as talin and paxillin (90, 91). It also promotes activation of Rho GTPase 
via direct interactions with p190Rho GEF (92). The proline"rich regions present in 
both the C"terminal and N"terminal domains of FAK act as binding sites for a variety 
of SH3"containing proteins, including p130Cas adaptor protein, GTPase regulator 
associated with FAK (Graf), Arf GTPase"activating protein (ASAP1) and Trio proteins 
(93"96).   
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Figure 6. Schematic structure of FAK. FAK contains centrally located tyrosine"kinase domain flanked 
by the C"terminal domain that consists of a FAT, which modulates FAK interactions with the integrin"
associated proteins, including talin and paxillin as well as activation of Rho GTPase via direct 
interactions with p190Rho GEF and the N"terminal domain that consists of a FERM domain, which 
facilitates FAK interactions with growth factors receptors, ezrin and JSAP1. Three proline"rich regions 
are present in both the C"terminal and N"terminal domains of FAK and modulate FAK association with 
p130Cas, Graf, ASAP1 and Trio proteins. Important tyrosine phosphorylation sites of FAK are shown. 
Phosphorylation of FAK at Tyr397 serves as a binding site for SH2"containing proteins, including Src, 
Shc, PI3K, Grb7 and PLCγ. FAK is also phosphorylated by Src at Tyr925 residue, allowing FAK to 
interact with the adaptor protein Grb2. 
  
 
Upon engagement of integrins with their ECM ligands, the cytoplasmic tail of β"
integrins (β1, β3 and β5) mediates FAK activation and recruitment to focal adhesions 
possibly via facilitating the interactions between FAK and the integrin"binding 
proteins such as talin and paxillin (97). This results in phosphorylation of FAK at 
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Tyr397, which creates a high"affinity binding site for SH2"containing proteins such as 
Src, Shc, PI3K, growth factor receptor bound protein 7 (Grb7) and phospholipase Cγ 
(PLCγ). The binding of Src to FAK can lead to formation of FAK–Src signalling 
complex which facilitates tyrosine phosphorylation of p130Cas, enabling it to bind Crk 
adaptor protein (98"102). Interestingly, it has been reported that up"regulation of Crk is 
associated with the activation of FAK and this activation is dependent on p130Cas 
activity (103). Furthermore, over"expression of p130Cas can enhanced tyrosine 
phosphorylation of FAK and paxillin, suggesting that these multiple feedback 
interactions between FAK, Src and p130Cas can lead to stabilisation of the FAK–Src 
signalling complex (Figure 7) (104).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 An investigation of the role of C"terminal tensin"like (Cten) gene in colorectal cancer       
Literature review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic illustration of binding interactions between β2integrins, FAK, Src and 
p130Cas proteins. FAK is recruited to the cytoplasmic tail of β"integrin via interactions with integrin"
binding proteins talin and paxillin. This results in activation and phosphorylation of FAK at Tyr397, 
which creates a binding site for SH2"containing protein Src. The FAK–Src complex then promotes 
tyrosine phosphorylation of p130Cas at YXXP motifs in its substrate domain (SD), enabling it to bind 
Crk adaptor protein. P130Cas SH3 domain binds to proline domains in the FAK C"terminal.  
 
In addition to autophosphorylation of FAK on Tyr397 residue, FAK can also be 
phosphorylated by Src at Tyr925 residue, allowing FAK to interact with the adaptor 
protein growth factor receptor bound protein 2 (Grb2). The SH3 domain of Grb2 binds 
to son of sevenless (SOS), a guanine nucleotide exchange factor for Ras, which in turn 
bridges FAK and the integrin"initiated signals to the Ras/MAPK pathway (105, 106). 
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The binding between Crk adaptor protein and phosphorylated p130Cas is negatively 
regulated by Abl family tyrosine kinase, a protein that is activated by integrin 
aggregation and localised at focal adhesions (107). Activated Abl protein 
phosphorylates Crk at Y221 residue, thereby inducing the intramolecular binding of 
the Crk SH2 to phosphorylated Y221 in its C"terminal region and preventing Crk from 
binding to the docking protein p130Cas (108). Disruption of CAS"Crk molecular 
coupling blocks downstream signals regulating focal adhesion assembly and actin 
cytoskeleton organisation, thereby decreasing cell motility (Figure 8) (109). Another 
new protein reported to regulate p130Cas function is Ajuba, which is required to 
maintain both stabilisation of p130Cas localisation to integrin clustering sites and 
effective p130Cas–Crk coupling, and results in Rac activation and promoting cell 
migration (Figure 8) (110). 
 
Integrin"mediated activation of the FAK"Src complex signalling pathway regulates 
various biological processes and contributes to tumour progression. Previous data has 
shown that FAK expression resulted in promoting cell survival possibly through 
enhancing PI3K"mediated activation of the AKT pathway, which in turn increased 
expression of inhibitor of apoptosis proteins (IAPs) through NFκB and protected the 
cells from oxidative"stress induced apoptosis and suppressing p53"mediated apoptosis 
(Figure 8) (111"113). FAK may limit p53 activity through its N"terminal FERM 
domain which localised to the nucleus and directly interacted and suppressed 
transcriptional activation of a number of p53 target genes including p21, Mdm2 and 
Bax that are important mediators of p53"induced apoptosis, which would propose the 
anti"apoptotic signal of FAK FERM"domain"initiated pathway (114, 115).  
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Another way whereby FAK may control cell survival is through association with the 
FAK interacting protein 200 kDa (FIP200), which localises with integrins at focal 
adhesions. It has been reported that FIP200 can bind p53, and enhance its half"life and 
expression. In addition, it can also increase the expression of p21waf, a cell cycle 
inhibitor, which reduces the activity of cyclin/cyclin"dependent kinase complexes, 
promoting cell cycle progression, leading to G1"S arrest. Thus, it is possible that FAK 
may enhance survival signals through FIP200"FAK association, which compete with 
FIP200"p53 binding, thereby limiting the ability of FIP200 to bind p53 and enhance its 
activity (116, 117).  
 
Several studies have shown over"expression of FAK in many human tumours and its 
association with aggressive tumour phenotype (118). As recently revealed, the 
formation of a FAK–Src signalling complex enhances E"cadherin internalisation 
during tumour progression, thereby promoting an epithelial"to"mesenchymal transition 
(EMT) and enhanced cell migration (119"121). In addition, FAK–Src signalling 
complex formation regulates protease secretion and expression by tumour cells (122). 
Upon activation, these proteases are localised at the leading edge of migrating tumour 
cells and promote ECM degradation which can facilitate cell invasion and metastasis 
(123, 124).  The findings that FAK–Src complex can activate endophilin A2 protein, 
extracellular signal regulated kinase 2 (ERK"2) and JNK pathways, which in turn 
promote increased gene transcription of target proteins leading to enhanced protease 
expression, clearly demonstrate that the activated FAK–Src signalling complex may 
positively regulate tumour growth and spread and lead to an aggressive tumour 
phenotype (Figure 8) (118, 125, 126).  
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Previous publications have reported a role of FAK–Src signalling in promoting tumour 
angiogenesis and this is one likely way by which FAK may enhance tumour growth 
(127). The binding of FAK with a Grb2"SOS complex leads to Ras small GTPase and 
Raf kinase activation which phosphorylate mitogen activated protein kinase kinase 1 
(MEK1) and ERK2 at S217/S221 and at T185/Y187 residues respectively, thereby 
activating them. Activated ERK2 in turn enhances transcription of vascular endothelial 
growth factor (VEGF) gene and thereby promoting tumour growth through stimulating 
angiogenesis (Figure 8) (128, 129). 
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Figure 8. Schematic diagram of FAK downstream signalling pathways. Upon phosphorylation of 
FAK at Tyr397 by integrins, this result in creation a high"affinity binding site for Src. The FAK"Src 
complex then triggers multiple downstream pathways to regulate migration, invasion and 
survival/apoptosis of the cells. FAK can also be phosphorylated by Src at Tyr925 residue, allowing FAK 
to interact with a Grb2"SOS complex, that lead to MEK1 and ERK2 activation which in turn enhance 
transcription of VEGF gene and thereby stimulating angiogenesis.  
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1.3.3 ILK 
ILK was identified in a search for proteins present in some integrin"containing focal"
adhesion plaques and capable of binding to the cytoplasmic domains of the integrin β1 
and β3 subunits (130, 131). The localisation of ILK at focal adhesions allows it to play 
an essential role in transduction of many biochemical signals that are initiated by cell"
ECM interactions and that regulate various biological cellular events, including cell 
survival, differentiation, proliferation, migration, invasion and angiogenesis (132, 133).  
 
Previous studies using recombinant ILK and immunoprecipitation kinase assays 
showed that ILK is an intracellular structural serine/threonine protein kinase capable of 
phosphorylation of the β1 integrin at highly conserved serine/threonine residues, and 
this appeared crucial in maintaining the stabilisation of β1 localisation to focal 
adhesions (130, 134).  
 
Whereas ILK interacts with integrins via its integrin"binding domain present in its C"
terminus, the N"terminus of ILK contains four ankyrin repeats (ANK) which are 
involved in mediating protein–protein interactions, and which allow ILK to interact 
with other signalling molecules. Through its ankyrin repeats, ILK can interact with the 
LIM domain of particularly interesting Cys"His"rich protein (PINCH), which co"
localises with integrins at focal adhesions and stabilises the localisation of ILK at focal 
adhesion sites (135, 136). Furthermore, PINCH can interact with the NCK adaptor 
protein"2 (Nck2) via its LIM domain and the PINCH"Nck2 complex is recruited to 
activated EGFR and PDGFR, thereby bridging ILK to growth"factor receptors (Figure 
9) (137, 138). 
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In addition to binding integrins, the C"terminal domain of ILK also interacts with 
actin"binding adaptor proteins, such as paxillin and parvins, which interact directly 
with actin networks, allowing ILK to bridge the effects of growth factors and ECM 
through growth factor receptors and transmembrane integrins to the actin cytoskeleton 
and regulate cytoskeletal reorganisation and cell migration processes (139"141).  
 
The central pleckstrin homology (PH)"like domain containing phosphoinositide"
binding motifs is located between the C"terminal and the N"terminal regions of ILK 
and is involved in the binding of ILK to Phosphatidylinositol (3, 4, 5)"trisphosphate 
(PIP3), produced by PI3K, which activate ILK. It has been shown that 
inhibition/activation of PI3K is associated with decreased/increased activity of ILK 
respectively, suggesting that ILK is regulated in a PI3K"dependent manner (Figure 9) 
(142, 143). 
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Figure 9. Schematic structure of ILK. ILK consists of three domains, a C"terminal kinase domain, a 
PH"like domain and ANK at N"terminal. The kinase domain allows ILK to bind with the cytoplasmic 
tails of β"Integrins, the kinase substrate Akt, the phosphoinositide"dependent kinase"1 (PDK"1) and the 
actin"binding adaptor proteins, such as paxillin and parvins. β"parvin binds to PAK"interactive exchange 
factor (PIX), which promotes actin cytoskeletal reorganisation through the GTPases, Rac1 and CDC42. 
The PH domain of ILK binds to PIP3. The tumour suppressor PTEN dephosphorylates PIP3 to PIP2, 
resulting in the inhibition of ILK activity. Through its ankyrin repeats, ILK can interact with the LIM 
domain of PINCH, which binds to the Nck2, thereby coupling growth factor signalling to Integrin 
signalling through ILK. 
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The expression and activity of ILK are increased in many human tumours. Although 
the causes of its over"expression remain to be fully elucidated, several lines of 
evidence have clearly demonstrated that ILK’s oncogenic capacity derives from it 
regulating a diverse set of downstream effectors and signalling pathways that promote 
anchorage"dependent cell growth, survival, proliferation, EMT, migration, invasion 
and tumour angiogenesis (144"148).  
 
It has been shown that ILK phosphorylates PKB/Akt on Ser473 and increases its 
activity, stimulating signalling pathways which negatively regulate caspase activation 
and stimulation of nuclear factor B (NF"κB), leading to the suppression of apoptosis 
and enhanced cell survival (149"152). In addition, ILK may promote the activity of the 
β"Catenin/Lef complex and activator protein 1 (AP1) transcription factors, possibly 
through phosphorylation and inhibition of glycogen synthase kinase 3 (GSK"3), which 
stimulates expression of the genes encoding cyclin D1 and MMP9 respectively, 
thereby promoting tumour proliferation and invasion (Figure 10) (153"156). 
 
It has previously been shown that ILK over"expression can modulate cytoskeletal 
organisation and promotes cell migration via ILK"binding proteins β"parvin and 
paxillin, which activate PAK"interactive exchange factor (PIX), a guanine"nucleotide 
exchange factor (GEF) for Rac1 and Cdc42. This indicates a potential link between 
ILK and these small GTPases which subsequently influence cell motility and 
spreading. In addition, ILK can phosphorylate myosin light chain (MLC) and myosin 
phosphatase target subunit, resulting in myosin"mediated contractility and cell motility 
(Figure 10) (157"159). 
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Recent evidence has shown that ILK up"regulation can lead to ablation of cellular 
adhesions in terms of loss of cell–cell or cell–ECM contacts. This appears to be due to 
a dramatic decrease in E"cadherin expression caused by ILK"induced stimulation of 
Snail expression, the transcriptional repressor of E"cadherin, and enhanced activity of 
the transcription factor partner of β"catenin, Lef"1, which in turn promotes 
transcriptional activity of the β"catenin/Lef complex, consequently result in down"
regulation of E"cadherin and loss of cell adhesion (160"165). Taken together with the 
observations that ILK over"expression in epithelial cells can induce EMT, 
accompanied by enhanced fibronectin matrix assembly, increased vimentin expression 
and loss of keratin 14 and 18 expression, these results clearly demonstrate that 
activated ILK may promote EMT and enhances tumour invasion and metastasis 
(Figure 10) (166). 
 
Previous studies have implicated a significant role of ILK in tumour angiogenesis. 
ILK"mediated phosphorylation of AKT has been found to stimulate mammalian target 
of rapamycin (mTOR) expression, which in turn activates hypoxia inducible factor"1 
alpha (HIF1α), thereby enhancing VEGF expression and promoting angiogenesis 
(Figure 10) (147). 
 
The kinase activity of ILK is negatively regulated by several protein phosphatases, 
such as ILK"associated protein (ILKAP), a serine/threonine phosphatase which inhibits 
integrin"mediated phosphorylation of GSK"3, and PTEN which inhibits PI3K"
mediated ILK activation, (154, 167"169).  
 
 
37 An investigation of the role of C"terminal tensin"like (Cten) gene in colorectal cancer       
Literature review 
 
 
 
Figure 10. Schematic diagram of ILK downstream signalling pathways. Upon engagement of 
integrins with ECM, ILK is activated and induces phosphorylation of Akt, which in turn negatively 
regulate caspase activation and stimulation of NF"κB, leading to the suppression of apoptosis and 
enhanced cell survival. P"Akt can also activate mTOR, which in turn enhances VEGF expression and 
promoting angiogenesis. Activated ILK can also enhance the β"Catenin/Lef complex and AP1 activity, 
possibly through phosphorylation of GSK"3, which stimulates expression of cyclin D1 and MMP9 
respectively, thereby promoting tumour proliferation and invasion. In addition, ILK also induces EMT 
accompanied with loss of E"cadherin possibly through Snail activation. ILK can also modulates cell 
motility via activation MLC and PIX proteins.  
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1.3.4 CD24 
CD24 is a small heavily glycosylated mucin"type cell surface protein that is bound to 
the cell membrane via a glycosylphosphatidylinositol (GPI) anchor. It has a 
heterogeneous molecular weight ranging from 30 to 70 kDa with a mature protein core 
of only 27 to 30 amino acids long, suggesting that most of the molecular weight of the 
protein consists of extensive N" and O"linked glycosylated residues. CD24 is localized 
in lipid"rafts, which are microdomains that serve as platforms for the regulation of cell 
adhesion and signalling. Within these rafts, it is closely associated with src"kinases, G"
proteins and calcium channels (170).  
 
CD24 is normally expressed on a wide variety of cells including polymorphs, B"
lymphocytes, ganglion cells, keratinocytes, renal tubules and adrenal medulla (171, 
172). Studies are accumulating to show that CD24 is considered an adhesion molecule, 
conveys a function in cell"to"cell interaction and regulation of proliferation and 
adhesion. CD24 has been identified as a ligand of P"selectin, an adhesion receptor on 
activated endothelial cells and platelets, suggesting the role of CD24 in marginal 
adhesion and migration of cells under shear forces in the blood stream (173). CD24 
can also serve as a ligand of of L1, a member of the immunoglobulin superfamily that 
is expressed on neural and lymphoid cells. CD24"deficient mice displayed an 
impairment of B cell differentiation suggesting that CD24 expression influences the 
cell"cell interactions and maturation of B cells (173). 
 
An expanding body of literature revealed the role of CD24 in the regulation of tumour 
growth, invasion and metastatic tumour progression. CD24 over"expression has been 
reported not only in haematologic malignancies, but also in several different types of 
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solid tumours, including non"small cell lung cancers, pancreatic and gastric 
adenocarcinomas, ovarian cancer and BC and, in general, its over"expression has been 
associated with poor prognostic outcomes (174"178). In the colon, previous studies 
have reported patchy focal CD24 expression in the crypt bases in normal mucosa 
(179). In comparison, CD24 expression is up"regulated in colorectal adenomas and it is 
thus an early event in colorectal cancer (CRC) carcinogenesis (180). High expression 
of CD24 is reported in CRC, and this over"expression is associated with poor 
prognostic outcomes (179). In addition, treatment of CRC cell lines with anti"CD24 
antibodies inhibits cell proliferation in a dose" and time"dependent manner in both in
vitro and invivo models (181). Furthermore, forced CD24 expression and knock"down 
in CRC cell lines expressing low and high levels of CD24 protein is associated with 
enhanced and suppressed colony forming, transwell migration and invasion abilities 
respectively, showing the oncogenic role of CD24 in CRC (182).  
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1.4 Colorectal Cancer 
The role of Cten in CRC is currently unknown. This is the third most common form of 
cancer and the second leading cause of cancer"related deaths in the Western world. In 
the UK, every year around 35,000 individuals are diagnosed with CRC and more than 
16,000 will die from this malignancy (183, 184). CRC usually follow a well 
established pattern of early non"invasive adenomatous growth, succeeded by the 
ability to invade locally into the adjacent tissues and ultimately by acquisition of 
metastatic features. The mechanisms by which tumour cells acquire the ability to 
invade and metastasize are unclear, although many consider that these processes 
require disruption of cell–cell and cell–matrix adhesion and epithelial–mesenchymal 
transition (EMT). 
 
The etiology of CRC is not completely understood. However, certain risk factors 
substantially increase the likelihood of developing CRC. Among these are IBDs (such 
as Crohn's disease (CD) and ulcerative colitis (UC)) and adenomatous polyps (AP). 
The association between IBDs and CRC has been confirmed in several studies (185). 
For instance, 8% of UC patients develop CRC after 20 and 18% after 30 disease"years, 
respectively (186). Recently, it has been shown that the risk of developing CRC in CD 
patients is similar to that in patients with UC (186). Moreover, patients with APs have, 
in general, an increased risk of developing CRC compared to the general population. 
However, the risk of developing CRC in addition of colonic APs depends mainly on 
the size and the histological type of adenomas (187, 188). 
 
Most people are treated by surgery which, if undertaken when the tumour is at an early 
stage, is usually curative. For advanced disease, surgery alone may be insufficient and 
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adjuvant chemotherapy may be necessary. Administration of adjuvant therapy depends 
on identification of poor prognostic features in the resection specimen. This however 
can be prone to variation (189) and there is a need for reliable biomarkers which add to 
the information obtained by routine pathological analysis. 
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Chapter 2. Aims of the thesis 
Review of the literature suggests that activity of Cten is probably context"dependent 
and may vary in tumours of different origin (see chapter 1). In addition, there is no 
available information concerning Cten expression in CRC.  We hypothesized that Cten 
might contribute to tumour progression in CRC. The overall aim of this thesis is to 
evaluate the expression and biological role of Cten in the colon, especially during the 
development of CRC. Studies are also designed to characterise novel Cten"regulated 
genes and their involvement in CRC.  
 
Specific objectives include:  
1. Evaluation of the expression and the role of Cten in benign colorectal diseases, CRC 
and cancer metastasis using immunohistochemical, quantitative real time PCR (Q"RT"
PCR) approaches and invivo models (chapter 4). 
 
2. Investigating the functional role of Cten in CRC using a dual approach of forced 
Cten expression and Cten knock"down in CRC cell lines, in order to analyse if 
modulating levels of Cten expression can influence cellular processes such as cell 
proliferation, resistance to staurosporine induced apoptosis, cell migration and cell 
invasion using the appropriate assay (chapter 5).  
 
3. Exploring the potential downstream signalling targets of Cten in CRC through 
evaluating the relationships between Cten expression and other secondary molecules 
associated with cancer metastasis, such as CD24, ILK, FAK and phosphorylated FAK 
(P"FAK) in both CRC cell lines and tissue samples using IHC and Western blot 
(chapter 6).   
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5. Evaluating the Cten expression in other tumour types such as breast cancer (BC) and 
pancreatic cancer using IHC on tissue microarray (TMA) platforms and correlate this 
with prognosis (chapter 7).    
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Chapter 3. Materials and methods 
3.1 Cell culture and transfection 
Twenty"nine well established CRC cell lines (170) were obtained from Molecular and 
Population Genetics Laboratory, London Research Institute, Cancer Research UK, 
London and cultured in tissue culture"treated 75cm
2 
flasks (Costar, UK) in growing 
Dulbeco’s Modified Eagle Medium (DMEM) (Invitrogen, UK) supplemented with 
10% Foetal Calf Serum (FCS) (Invitrogen, UK) and Penicillin/Streptomycin 
(Invitrogen, UK) at an atmospheric carbon dioxide content of 5%. Cells were allowed 
to grow until they reached approximately 90% confluence level and then passaged. 
Cells were detached from the flasks through washing with Phosphate buffered saline 
(PBS) (Sigma, USA)  followed by incubation for 5 minutes at 37°C incubator in 2ml 
of trypsin/EDTA (0.5% trypsin, 1 mM EDTA, Sigma, USA). Cells were resuspended 
in 5ml of DMEM and then plating into new flasks containing 10ml of growing media 
with 0.1 – 1ml of the cell suspension. The general properties of these cell lines are 
summarised in Table 1 (Appendix 9.1). 
 
3.2 Gene knock2down  
RNA interference (RNAi) is a post"transcriptional gene silencing (PTGS) process in 
which double stranded RNA (dsRNA) is cleaved by an ATP"dependent ribonuclease 
(Dicer) into duplexes of 21 or 23 nucleotides short interfering RNAs (siRNAs). 
Consequently, these siRNAs are incorporated into a second enzyme complex, 
designated RNA"induced silencing complex (RISC), thereby allowing RISC to 
recognise and to cleave the target mRNA.  
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Transfection of cells with siRNA duplexes were carried out using Lipofectamine 2000 
according to the manufacturer’s protocol. Briefly, 5 X 10
4
 cells were seeded per well 
in a six well plate (Costar, UK). The following day cells were transfected with 100nM 
siRNA, 5l lipofectamine 2000 in 500l medium. Six hours post transfection the 
supernatant was replaced by fresh media. Cells were analysed 72 hours later by 
Western blot or functional assays. The siRNAs used in this investigation were obtained 
from (Invitrogen, UK) and include: siCTEN, UUC UCA UUG ACA UGG UGC UCU 
GGG C, siCont, CCC GUA UAC GAC ACC GAG UAG UCU U, siCD24, CCU ACC 
CAC GCA GAU UAU UCC AGU and siCont, CCU CAC CGA CGU UUA CUU 
ACC AAG U. The possibility of scrambled control nucleotide sequence off"target 
effects were assessed, using the BLAST nucleotide"nucleotide database (NCBI), by 
comparing the scrambled control nucleotide sequence to the sequence of protein of 
interest. 
 
3.3 Forced gene expression  
Construction of the Green Fluorescent Protein (GFP) tagged Cten (GFP" Cten) 
expression vector has been previously described (40) and was kindly provided by Dr 
Su Hao Lo, Department of Biochemistry and Molecular Medicine, University of 
California" Davis, USA. The expression vector was transfected into cells using 
Lipofectamine 2000 (Invitrogen, UK) in accordance with the manufacturer’s 
instructions. Briefly, 1 X 10
5
 cells were seeded per well in a six well plate (Costar, 
UK) and transfected with 4g of GFP"Cten, 10l lipofectamine 2000 in 500l 
medium. Control cells were transfected with an empty GFP vector (kindly provided 
from Dr Su Hao Lo, Department of Biochemistry and Molecular Medicine, University 
of California" Davis, USA). For establishment of stably transfected HCT116, cells 
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were grown for 4 weeks in selection media containing 800Vg/ml G418 (Sigma, USA). 
For stable transfection of SW480, cells were initially transfected with GFP"Cten as 
above. After 48 hours, the cells were washed with PBS (Sigma, USA) and then 
detached by incubating with TE buffer (10 mM Tris"HCl (pH 8), 1 mM EDTA, Sigma, 
USA) for 5 " 10 minutes. These then underwent fluorescence associated cell sorting 
(FACS) in an Epics Altra Flow cytometer (Beckman Coulter, Fullerton, CA).  
 
3.4 R'A extraction 
Total RNA was extracted from cells using the RNeasy Mini Kit (Stratagene, UK). 
Approximately 1 X 10
7 
cells were prepared for mRNA extraction. Cell were washed 
with PBS, 500Vl of Detaching Buffer (7Vl of Beta2Mercaptoethanol in 1ml of lysis 
buffer, supplied with kit) was applied to the cells, and then 500Vl of the mixture was 
transferred into RNAase MicroSpin columns placed in Eppendorf tubes and 
centrifuged at 13,000 rpm for 1 minute. After discarding the supernatant, 500Vl of 70% 
ethanol was added and the mixture was vortexed and centrifuged at 13,000 rpm for 5 
minutes. Simultaneously, RNase"Free DNase enzyme was prepared by mixing 50Vl of 
DNase buffer with 5Vl of DNase enzyme (supplied with Kit) and incubated with the 
mixture at 37°C incubator for 15 minutes. The mixture was then washed once in 600Vl 
High Salt Buffer (10mM Tris"HCL(PH7.5), 1mM EDTA, 0.5M NaCl) and twice in 
600Vl and 300Vl Low Salt Buffer (10mM Tris"HCL(PH7.5), 1mM EDTA, 0.1M NaCl) 
respectively and centrifuged at 13,000 rpm for 1 minute each time. Lastly, the mRNA 
was eluted by applying 50Vl of Elution Buffer and lifted stand for 2 minutes at room 
temperature and then centrifuged at 13,000 rpm for 1 minute. The final eluted mRNA 
was stored into fresh sterile tubes in "80°C freezer. Samples of RNA derived from 
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normal colonic mucosa were obtained following a previous study on IBD undertaken 
by Prof Ilyas (Division of Pathology, University of Nottingham, UK).  
 
3.5 Complementary D'A (cD'A) preparation and reverse transcriptase  
In order to achieve RNA denaturation, 1Vg of total RNA was made up to 12.5µl with 
water and heated at 70°C for 10 minutes. Complementary DNA (cDNA) was then 
synthesized by incubating 1Vg of denatured RNA at 37°C for 60 min in a mixture 
containing 1 VM of random hexamers (pDN6), 200 units of M"MLV reverse 
transcriptase (Invitrogen, UK), 10mM DTT (Invitrogen, UK) and 0.5mM each dNTP.  
 
3.6 Q2RT2PCR 
Quantitation of Cten and E"cadherin expression was performed using the standard 
curve method. All experiments were conducted in triplicate and Cten and Cadherin
1(CDH1) values were normalised to the housekeeping gene Homo sapiens 
hypoxanthine phosphoribosyltransferase (HPRT). For each reaction, 10ng of cDNA 
template was tested in a final volume of 25Vl containing 1x SYBR Green Master Mix 
(Stratagene, UK) and primers at a final concentration of 250nM. The reaction was 
allowed to run in a thermal cycler (MX3005P Stratagene, UK) and the cycling 
conditions were 5 minutes initial denaturation at 95°C followed by 40 cycles of: 30 
seconds denaturation at 95°C / 30 seconds annealing (60°C for CTE / 59ºC for HPRT 
/ 50ºC for CDH1) / 30 seconds extension at 72°C and a single final extension for 10 
minutes. The data for Q"PCR were analysed using the MxPro"QPCR software for 
Mx3005P QPCR system. All PCR primers were designed using universal probe library 
software (190) and their specificities were assessed, using the BLAST database, by 
comparing the primer pairs to the Homo sapien genome sequence. The molecular 
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biology core facilities (MBCF) software (191) was used to determine the melting 
temperature and the G/C contents for each primer pair and subsequently the primers 
were ordered from (MWG"Biotech AG, UK). The primers sequences and reaction 
conditions are summarised in Table 2. 
 
Table 2. Characterisation of PCR primers.   
 
Primer 
 
Sequence 
 
Tm 

Binding site 

%GC 
 
 
  CTEN Forward 
 
 
5’"GCGTCTGCTCAGAATCGAC"3’ 
 
 
53ºC 
 
 
1605"1623 
 
 
58 
 
  CTEN Reverse 
 
5’"GATGAGGAAGTGTCGGATGAG"3 
 
54ºC 
 
1664"1644 
 
52 
 
 
  HPRT Forward 
 
 
5’"TGACCTTGATTTATTTTGCATACC"3’ 
 
 
51ºC 
 
 
136"159 
 
 
33 
 
  HPRT Reverse 
 
5’"TGAGGAATAAACACCCTTTCCA"3 
 
51ºC 
 
201"180 
 
41 
 
 
  E"Cadherin Forward 
 
  E"Cadherin Reverse 
 
 
 
5'"TCCCATCAGCTGCCCAGAA"3' 
 
5'"TGACTCCTGTGTTCCTGTTA"3' 
 
 
54ºC 
 
54ºC 
 
 
477"496 
 
976"957 
 
 
 
55 
 
45 
 
 
3.7 Polymerase chain reaction (PCR) 
Since GFP protein is a large protein consisting of over two hundred amino acids, it 
can possibly cause some functional problems, such as interference in the folding of 
the target protein or reporting on only a part of the target protein providing false 
positives or incorrect data. Thus, it was necessary to clone the Cten into a small 
tagged"Myc vector. In order to amplify a full length 2,148 bp product corresponding to 
Cten protein coding sequence, the following primers were designed (using universal 
probe library software) to introduce a BamH1 and HindIII sites at the 5’ and the 3’ 
ends of the PCR product respectively. The primer pairs used were forward primer: 5’"
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AT TCC CAG GTG ATG TCC AGC CCA CT"3’ and reverse primer: 5’"
AT CTA CAT CCT TTC TGC GTC CTG CAG "3’. The Webcutter 2.0 
software (192) was use to ensure that sticky ends are actually created at the 5’ and 3’ 
ends of the full length Cten PCR product and BamH1 and HindIII enzymes do not cut 
within Cten coding sequence. pEGFPC"1 plasmid containing the complete coding 
sequence of Cten was used as a template. 
For amplifying a full length 657 bp product corresponding to HPRT protein coding 
sequence, the following primers were designed using universal probe library software: 
forward primer: 5’"ATG GCG ACC CGC AGC CCT GGC"3’ reverse primer: 5’"TTA 
GGC TTT GTA TTT TGC TTT"3’. Conventional PCR was done using SW480 CRC 
cell line cDNA as a template. 
 
The standard reaction was performed in a final volume of 25Vl consisting of: 10ng 
DNA templates, 2x (Mix Taq) Master Mix (New England BioLabs, UK), 1.5mM 
MgCl2  and HPRT, Cten full length primers at a final concentration of 250nM. The 
reaction was allowed to run in a thermal cycler (Perkin Elmer GeneAmp PCR system 
2400) for 40 cycles in the following set up, 95ºC for 5 minutes (activation), 95ºC for 1 
minute (denaturation), 60ºC for 1 minute (annealing), 72ºC for 3 minutes (elongation) 
and 72ºC for 7 minutes (final extension). PCR product was resolved on a 1% agarose 
gels.   
 
3.8 Agarose gel electrophoresis 
100ml of a 1% agarose (Gibco"BR Life Technologies, USA) gel was prepared in 1% 
Tris Borate EDTA (TBE) buffer (Sigma, USA) and heated in a microwave for ~60 
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seconds. After the agarose had fully dissolved with intermittent agitation, the mixture 
was then cooled at room temperature. Once the mixture had cooled, 10Vl of Sybersafe 
dye (1000x) (Sigma, USA) was added and the gel was then poured into the gel 
apparatus and an appropriate comb was inserted. The gel was then left at room 
temperature to allow the agarose to set. Gels were run using 1x TBE solution as 
running buffer. 10Vl PCR product / DNA samples were mixed with 2Vl loading dye 
and loaded into the gel wells. Gels were run at ~100 Volts for 45 minutes. Analysis of 
electrophoresed samples was assessed by viewing on an ultraviolet transilluminator 
(UVP Inc., USA) and sized according to the 1kb DNA ladder (New England BioLabs, 
UK). If further band separation was required, the gel was placed in the electrophoresis 
equipment and electrophoresed for the desired time. 
 
3.9 D'A extraction from agarose gel 
Electrophoresed DNA was visualised under ultraviolet light and appropriate bands 
(2.1kb) were excised from the gel with clean scalpel. The DNA was then isolated from 
agarose gel using the QIAquick Gel Extraction system (QIAGEN, UK), following the 
manufacturer’s standard protocol. After weighing, the excised gel fragments 
containing the band of interest were dissolved in 3x volumes of Buffer QG (supplied 
with the Kit), then incubated at 50ºC for 10 minutes. After the gel slice had been 
dissolved completely, 1x gel volume of isopropanol (Sigma, USA) was added and 
mixed with the samples which were then washed with 750Vl of Buffer PE (supplied 
with the Kit) to remove all traces of agarose and finally the DNA was eluted with 30Vl 
of elution buffer. The quantity of the extracted DNA was evaluated by running 1Vl of 
the samples on an agarose gel.  
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3.10 D'A/R'A quantification by spectrophotometry 
The final extracted DNA/RNA were quantified on a NanoDrop ND"1000 UV"Vis 
Spectrophotometer (LabTech International Ltd, Ringmer, UK) (Appendix 9.2). Using 
a spectrophotometer, a ‘blank’ measurement was obtained reading sterile water at 
λ260nm. Samples were analysed at λ260nm compared to the ‘blank’ result and all 
readings were measured by the ratio of λ260/λ280nm to check the purity of the 
samples. A ratio of 1.8 – 2 was considered an indication of relative purity. 
 
3.11 TA cloning and ligation of plasmids vectors and inserts 
Cloning of HPRT and Cten coding sequences into pCR2.1 vector was done in order to 
use pCR2.1"HPRT and pCR2.1"Cten plasmids as templates to monitor their levels 
quantitatively in CRC cell lines. In addition, a pCR2.1"Cten plasmid was used to 
shuttle the Cten coding sequence into pCMVTag3B expression vector. In order to 
clone HPRT and Cten coding sequences in pCR2.1 vector, we follow the 
manufacturer’s instructions applied with the TA Cloning Kit (Invitrogen, UK) which 
utilises the pCR2.1 vector which has single 3´"thymidine (T) overhangs that facilities 
cloning of Taq polymerase"amplified PCR products into a plasmid vector. A 10Vl 
ligation reaction volume was done using 1Vl of pCR2.1 vector, 1Vl 10x Ligation 
Buffer, 1Vl of T4 DNA Ligase (4 Weiss units) and finally water was added to make a 
total volume of 10Vl reaction.  
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The amount of insert (i.e. PCR product needed to ligate with 50ng of pCR2.1 vector) 
was calculated using the following formula:  
 
     (Y bp PCR product) (50ng pCR2.1 vector) 
             Xng insert =      
(size in bp of the pCR2.1 vector) 
 
Where Xng is the amount of PCR product of Y base pairs to be ligated for a 1:1 
(vector:insert) molar ratio. The reaction mixture was then placed in ice for overnight. 
 
3.12 Plasmid transfection 
Plasimd transfection of competent bacterial cells (INVαF’) (Invitrogen, UK) was done 
using the heat shock method. Fifty Vl vial of competent cells which were stored in "
80ºC freezer, were thawed on ice for 15 minutes. Two Vl of ligation reaction were 
added to the cells and gently mixed with a pipette tip. The cells were then incubated on 
ice for 30 minutes. Cells were then heat shocked by placing the tubes in a 42ºC water 
bath for 30 seconds and directly transferred to ice. SOC media (supplied with Kit) was 
heated to 37ºC and 250Vl were added to the transformed cells which were then placed 
in a shaking incubator (New Brunswick Scientific Co. Ltd., USA) at 37ºC for 1 hour. 
Between 50 – 250 Vl of the mixture were seeded onto 10cm Petri dishes (Costar, UK) 
containing 25ml LB agar (Sigma, USA), 25mg/ml ampicillin (Sigma, USA), 25mg/ml 
5"bromo"4"chloro"3"indolyl"β"D"galactopyranoside (X"GAL), (Promega, UK) and 
25mM Isopropyl β"D"1"thiogalactopyranoside (IPTG), (Promega, UK) for Blue"White 
screening before picking"up positive colonies. Seeded plates were then incubated at 
37ºC for overnight.  
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3.13 Plasmid Miniprep and Midiprep production 
In order to generate plasmid DNA, the Gen Elute Plasmid Miniprep and Midiprep Kits 
were utilised following the standard manufacturer’s protocol. For ‘Miniprep’ 
preparations, white positive colonies containing the desired plasmid were spiked with 
pipette tips and used to inoculate 5ml of LB broth (Sigma, USA), containing ampicillin 
(Sigma, USA) at a final concentration of 5mg/ml. For ‘Midiprep’, 1ml of the Miniprep 
growth was added to 500ml growth medium containing 50mg/ml ampicillin. The 
media was then incubated in the shaking incubator for overnight at 37ºC to allow 
culture of the selected bacteria. 
For ‘Miniprep’ preparations, the culture (3"5ml) was centrifuged for 1 minute at 
13,000 rpm and the cell pellet was resuspended in 200Vl of resuspension solution. This 
was then followed by alkaline lysis of the cell pellet through adding 200Vl of Lysis 
solution. Then 350Vl of Neutralizing/Binding solution was added to precipitate the cell 
debris and samples were centrifuged at 13,000rpm for 10 minutes, and then the 
supernatant was passed through a Gen Elute Miniprep Binding column. The columns 
were then washed by 750Vl of washing solution and the DNA, which binds to the 
columns, was eluted by 50Vl of Elution buffer.  
For ‘Midiprep’ preparations, 100ml of bacterial cultural was used to obtain DNA 
plasmids using the same solutions used in Minipreps with slightly modified protocol in 
order to prepare greater volumes of plasmid DNA.  
 
3.14 Glycerol stock preparation of bacterial cultures 
LB broth cultures which had been used for generation of plasmid DNA were used to 
make cell stocks. Seven hundred and fifty Vl aliquots of culture were mixed with 250Vl 
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sterile 60% glycerol (Biomatik Corp, USA). Samples were placed in cryovials, 
labelled and stored at "80ºC freezer. 
 
3.15 Enzyme restriction digests  
A single enzyme digest of the pCR2.1"Cten plasmid was done for plasmid screening to 
check for the presence of cloned PCR products. EcoR1 enzyme had been chosen, it 
cuts twice in the pCR2.1 vector before and after the insert. A 20Vl restriction digest 
reaction volume was done using 2Vg DNA, 1Vl (EcoR1) restriction enzyme, 2Vl 
enzyme specific 10X reaction buffer, 1Vl BSA, and 10Vl of sterile water to make a 
total reaction volume 20Vl. The reaction mixture was then incubated at 37ºC water 
bath for 3hours and run on a 1% agarose gel. 
 
3.16 Cloning Cten coding sequence into an expression vector 
Sequential 5’"BamH1 and 3’"HindIII enzyme digestion of pCR2.1"Cten plasmid and 
pCMVTag3B vector was done for shuttling the Cten insert from pCR2.1"Cten plasmid 
into pCMVTag3B expression vector as well as for creating sticky ends on 
pCMVTag3B expression vector respectively. The reactions were performed by follow 
the same protocol used in TA cloning. The corresponding bands were viewed and 
excised under Ultraviolet light and gel"purified using QIAquick Gel Extraction Kit 
according to the manufacturer’s protocol as described before. The isolated Cten insert 
was ligated into pCMVTag3B vector at 1:1, 1:3 and 1:5 vector:insert ratios. Two 
negative controls (vector only and insert only) were also set up to make sure that 
pCMVTag3B was completely digested and did not religate again. Bacterial 
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transformation, Purification of pCMVTag3B"Cten plasmid DNA, and Enzyme digest 
were done according to the manufacturer’s protocol as described before. 
 
3.17 Sequencing 
In order to know the orientation of the insert within the pCR2.1 vector and detect any 
mutations, 12Vl from pCR2.1"Cten plasmid had been sent for sequencing. Since the 
size of PCR products using the pCR2.1"Cten plasmid and pCR2.1 vector T7 forward 
and M13 reverse primers were about 800 base pairs for each and giving that the size of 
Cten mRNA coding sequence was 2.1 KB, other primers that encode the rest of Cten 
coding sequence were designed and sent with pCR2.1"Cten plasmid for sequencing. 
The data for sequencing were analysed using chromas lite program (193).  
 
3.18 Protein extraction and quantitation 
Cells were grown to confluence in 75cm
2 
flasks (Costar, UK), washed with cold PBS 
to remove excess culture medium. The PBS was then removed and the whole cell 
extraction was prepared in 465l lysis buffer [(20 mM Tris, pH 7.5, 150 mM NaCl, 
1% TritonX"100, 0.5% sodium deoxycholate, 1 mM EDTA, 0.1% SDS, supplemented 
with 30l protease and 5l phosphatase inhibitors (Sigma, UK)]. The mixture was then 
incubated at an angle in ice for 10 minutes, and then collected together using a cell 
scraper (Costar, UK), transferred to a 1.5ml eppendorf tubes and centrifuged at 
13,000rpm at 4ºC for 20 minutes. Finally, the supernatant was collected, aliquoted into 
0.5ml eppendorf tubes and store at "20ºC.  
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Protein quantitation reactions were done using BCA Protein Assay Kit (Thermo 
scientific, UK). A series of bovine serum albumin (BSA) solutions in the concentration 
range of 25–2000 Vg/ml was used as a standard reference range. The buffer solution 
was used as a blank sample. Ten Vl of each sample, standard and blank was pipetted 
into the 96 microplate wells (Costar, UK) as triplicates. Then 200Vl of a 1:50 dilution 
of Reagent B: Reagent A was added to each well and the plate was shaken for 30 
seconds and then incubated at 37°C for 30 minutes. After cooling the plate to room 
temperature, the absorbance at λ550nm was measured on SpectraMax microplate 
reader (Molecular Devices, USA). 
 
3.19 Western Blotting (WB) 
The SDS"polyacrylamide gel used in WB consisted of two parts: a lower resolving gel 
and an upper stacking gel. The lower resolving gel consisted of 10% polyacrylamide 
(Bio"Rad Laboratories, UK) in buffer solution (1.5M Tris"base (Bio"Rad Laboratories, 
UK) / 0.4% SDS, pH 8.8). The upper stacking gel consisted of 5% polyacrylamide in 
buffer solution (0.5M Tris"base / 0.4% SDS, pH 6.8). The gel was then left at room 
temperature for 30 minutes to be polymerised and then transferred to the 
electrophoresis unit containing 500ml 1x Tris"Glycine electrophoresis buffer (0.025M 
Tris base / 0.192M Glycine (Bio"Rad Laboratories,  UK) / 0.1% SDS). Thirty g 
proteins were prepared by adding an equal volume of 2x SDS loading buffer (100mM 
Tris"HCl (pH 6.8), 200mM DTT, 4% SDS, 0.2% glycerol and 0.2% bromophenol 
blue) containing 5% Beta2Mercaptoethanol. The samples were boiled for 5 minutes 
and then run on an SDS"polyacrylamide gel at 60mA. After electrophoresis, the 
protein samples were transferred onto PVDF membranes (Stratagene, USA) by the 
process of semi"dry transfer at 66mA for 2 hours. After blocking in 5% Marvel dried 
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milk dissolved in 0.1% Tris. Tween. Buffered Saline (20 mM Tris, pH 7.5, 0.1 M 
NaCl, 0.1 %)  (Bio"Rad Laboratories, UK) for 1 hour, membranes were incubated 
overnight at room temperature with the following primary antibodies. Rabbit anti"Cten 
(1:1500) (40), rabbit anti"ILK antibody (Abcam, UK, ab2283, 1:500), rabbit anti"FAK 
antibody (Cell signalling, USA, 1:1000), rabbit anti"phospho"FAK (Cell signalling, 
USA, 1:1000), mouse anti"E"Cadherin (Abcam, UK, ab1416, 1:500), mouse anti"
CD24 SWA11 (a kind gift from Prof. Peter Altevogt, 1:1000) and mouse anti"β−actin 
(Dako, UK, 1:2000). After three washes in 0.05% Tris. Tween. Buffered Saline, blots 
were incubated for 1 hour at room temperature with the appropriate horseradish 
peroxidase"linked secondary antibody. After three further washes, detection was 
performed using the Enhanced Chemiluminescence Kit (Pierce, USA). Bands were 
visualised using X"Ray films (Kodak, UK). In order to ensure accurate evaluation of 
protein loading, whenever possible (i.e. when the molecule of interest was sufficiently 
separated from the loading control), the membrane was cut in half and each section 
was blotted probed separately for the molecule of interest and the loading control 
(usually β"actin). This was performed for E"cadherin, Cten, CD24, ILK and 
FAK.  However, occasionally, the amount of total protein loaded in order to identify 
the molecule of interest had to be considerable which resulted in the β"actin appearing 
over"exposed (despite minimum exposure to the x"ray film). This did not affect data 
interpretation. All experiments to demonstrate changes in expression of specific 
molecules were performed on at least two separate occasions. 
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3.20 Epifluorscence Microscopy 
 
Stably transfected HCT116 cells were grown on glass coverslips and then fixed with 3. 
7% paraformaldehyde (PFA) for 15 minutes at room temperature. Cells were 
permeabilized with 0. 1% Triton X"100 for 10 minutes and then incubated with DAPI 
(0. 04Vg/ml, Dako) for 5 minutes. After rinsing with PBS, coverslips were mounted on 
glass slide using Dako aqueous mountant and fluorescence was visualised with an 
epifluorscence microscope (Leica microsystems, Switzerland). Images were taken 
using green fluorescence 590nm emission filter for GFP and blue fluorescence 515nm 
emission filter for DAPI.  
 
3.21 Proliferation Assay 
Proliferation experiments were performed to monitor cell growth over a period of up to 
7 days. Each well of a 6 well plate (Costar, UK) was seeded with 1 X 10
5 
cells and cell 
numbers measured at specific time points using the Methylene Blue assay (194). Cells 
were firstly fixed in 100Vl methanol for 30 minutes. Methanol was then removed and 
cells air dried for 5minutes followed by addition of 100Vl of 1% Methylene Blue 
(Sigma, USA) for 30 minutes. The methylene blue solution was aspirated and wells 
washed 4x with distilled water. Finally 100Vl of 0.1% HCl in ethanol was added to 
release the methylene blue and absorbance measured at 620 nm wavelength on a 
platereader (Labsystems, UK).  Each assay was performed in triplicate and repeated in 
at least two independent experiments. 
 
3.22 Staurosporine induced apoptosis 
Staurosporine is commonly used to induce apoptosis in cells and was used to test the 
resistance to apoptosis conferred by Cten. Each well of a 96 well plate (Costar, UK) 
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was seeded with 5 X 10
4
 cells which were incubated with staurosporine (Sigma, USA) 
at a final concentration of 6 VM for 24 hours. After this period, floating cells were 
aspirated from each well, spun down, resuspended in 100Vl of TBS and an equal 
volume of 0.1% Trypan blue (Sigma, USA) added. Cells showing positive staining for 
Trypan blue (i.e. apoptotic cells) were counted manually using a haemocytometer 
(Sigma, USA). Living cells attached to the bottom of the wells were counted using the 
Methylene Blue assay as described above. The apoptosis assay was performed in 
triplicate and repeated in at least two independent experiments. 
 
3.23 Cell Migration / Invasion Assays 
Cell migration was measured using the transwell migration assay and cell wounding 
assay. The transwell migration assay used a Boyden chamber containing a 
polycarbonate filter with an 8 Vm pore size (Costar, UK). The lower chamber was 
filled with 200Vl of DMEM with 20% FCS; the upper chamber was filled with 100Vl 
of DMEM with 10% FCS and seeded with 1 X 10
5
 cells. Migration was assessed after 
48 hours by fixing the cells attached to the lower surface in 10% methanol for 30 
minutes, staining for 30 minutes with Methylene Blue and manually counting the 
stained cells. Cell invasion was measured in the same way as described for migration 
except that the upper chamber was prepared by coating the filter with 100Vl of 
Matrigel (5mg/ml, BD Biosciences, USA). Cell migration was also measured using a 
cell wounding assay performed in 6 well plates (Costar, UK). Cells were grown to 
confluence and then starved for 24 hours in serum free medium. A sterile 200Vl pipette 
tip was used to create three separate parallel wounds and migration of the cells across 
the wound line was assessed after 24 hours. Photographs were taken using a charge 
coupled device (CCD) camera (Canon, Japan) attached to the inverted phase"contrast 
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microscope at a power of 40x. In order to statistically analyse cell migration in the 
wounding assay, images were taken from three separate wounds 24 hours after 
commencement of the assay. All images were taken at the same magnification and 
converted into binary images using the ImageJ image analysis program (195) and the 
area of the wound was measured. Experiments were repeated on two separate 
occasions. Cell motility assays were performed in triplicate and on two separate 
occasions. 
 
3.24 Construction of TMA sets 
A TMA set had been generated for pancreatic cancer. H&E slides of 64 cases 
(including 44 cases of pancreatic adenocarcinoma and 20 cases of chronic pancreatitis 
from (1996"2007) had been reviewed to confirm a histological type of tumour, as well 
as lymph nodes (LN) metastasis. Normal pancreatic tissue was obtained from the 
resection specimens in a total of 30 patients.After matching areas on the slides with 
their corresponding areas on the blocks, marker pen was used to mark those 
representative areas on the blocks from which the array core will ultimately be taken. 
Preparation of recipient blocks was done by pouring paraffin wax into a mould, and 
placing a histopathological tissue cassette on top, when the wax became cold, the 
mould was removed. Excess wax was trimmed from the cassette using a microtome to 
produce a flat surface that made TMA easier and accurate. 
Once all donor blocks were marked, and the recipient blocks had been prepared, 
templates for the array were prepared in order to accommodate 144 samples or cores 
(12x12) per slide. Samples were done in triplicate and spaced 1.25mm apart to avoid 
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cracking of the paraffin. The orientation was determined by adding 2 cores of lung 
tissues at the starting corners. 
Before sectioning, the array blocks were placed in a 37ºC incubator for 10 minutes. 
This warmed the paraffin wax thereby promoting adherence of the tissue cores to the 
walls of the holes in the array blocks, and makes the wax flexible to handle. After that 
a clean glass microscopic slides were placed on top of the array blocks, and applied 
even pressure to push all tissue cores level with the top surface of the array. Finally the 
blocks have been sectioned using standard laboratory microtome techniques. 
 
Another TMA set was also prepared for this study. This contained matched tissue 
samples from primary colorectal adenocarcinoma and their corresponding liver 
metastases which collected from 40 patients, diagnosed between 1993 and 2009 and 
entered into the Nottingham Colorectal Carcinoma Series and prepared as a TMA 
series. 
 
A BC TMA set, kindly provided by Prof. Ian Ellis (Division of Pathology, University 
of Nottingham, UK), was available for this study and prepared from a series of 1,409 
cases of primary operable invasive breast carcinoma form patients under the age of 70 
years, diagnosed between 1987 and 1998 and entered into the Nottingham Tenovus 
Primary Breast Carcinoma Series. Patients’ clinical and pathological data including 
patients’ age, histological tumour type, primary tumour size, LN status, mitotic count, 
histological grade, Nottingham prognostic index (NPI), vascular invasion (VI), and 
development of recurrence and distant metastases (DM) were available and maintained 
on a prospective basis. Survival data including breast cancer specific survival (BCSS) 
and disease"free interval (DFI) were available. The BCSS is defined as the time (in 
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months) from the date of the primary surgery to the time of death from breast cancer. 
DFI is defined as the duration (in months) from the date of the primary surgical 
treatment to the appearance of first loco"regional or distant metastasis. The data on 
other biomarkers of known clinical and biological relevance to BCincluding estrogen 
receptor (ER), progesterone receptor (PR), androgen receptor (AR), BRCA1, p53, the 
proliferation marker MIB1, E"cadherin, P"cadherin, EGFR, HER1, HER2, basal and 
luminal cytokeratins (CKs) (CK5/6, CK14, CK18, CK19) were also available (196"
201). The patients’ characteristics are summarised in Table 3 (Appendix 9.3).  
 
A CRC TMA set, kindly provided by Prof. Lindy Durrant (Division of Oncology, 
University of Nottingham, UK), was also prepared from a series of 462 cases of 
primary operable CRC form patients underwent elective surgery at Nottingham 
University Hospital between 1994 and 2000 as has been previously described (202). 
All patients with radical (R0) resected CRC were included. Patients’ clinical and 
pathological data including primary tumour site, TNM stage, histological tumour type, 
histological grade and the presence of VI were available and maintained on a 
prospective basis. Adjuvant chemotherapy consisting of 5"flurouracil and folinic acid 
was administered to patients with LN metastasis. The UK Office for National Statistics 
has provided comprehensive disease specific and follow"up data for all cases in the 
study. The length of follow"up was calculated from the date of surgery, with surviving 
cases censored for analysis on the 31st December 2003. Disease"specific survival was 
used as the primary end"point. Ethical review of the study was conducted by the 
Nottingham Local Research and Ethics Committee, who granted approval for the study 
as previously described (203). The patients’ characteristics are summarised in Table 4 
(Appendix 9.4).  
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3.25 IHC 
Slides were immunohistochemically stained using the standard streptavidin–biotin 
complex method as previously described (204). Water bath"induced method for 
retrieval of antigen was performed in EDTA buffer, at pH 8.0. Endogenous peroxidase 
activity was blocked with 0.3% hydrogen peroxide (Dako, UK) for 10 minutes and 
non"specific antibody binding with normal swine serum (NSS) (Dako, UK) for an 
additional 10 minutes at room temperature. Then primary antibodies Cten (Abcam, 
UK, ab57940, 1:75) and P"FAK (Cell signalling, USA, 1:100) were applied for 45 
minutes at room temperature. After washing with TBS, biotinylated secondary (C) 
antibody (Dako, UK) (diluted 1/100 in NSS) was applied and incubated for 30 minutes 
at room temperature. Slides were then washed with TBS and preformed Strept AB 
Complex (AB) (Dako, UK) (diluted 1/100 in NSS) was applied for 55 minutes at room 
temperature. After washing with TBS, slides were incubated using freshly prepared 
Diaminobenzidine (DAB) (Sigma, USA) solution for 10 minutes at room temperature. 
After that, copper sulphate (Dako, UK) solution was applied for 10 minutes at room 
temperature. After immunostaining, slides were counterstained with haematoxylin 
(Dako, UK). Histochemical score (H"score) was used to assess the intensity and 
percentage of stained cells across the TMA sets. Only staining of the malignant cells 
within the tissue cores was considered. Staining intensity was scored from zero to 
three, (zero equals no staining, one equals weak, 2 equals moderate, three equals 
strong). The percentage of positive cells was subjectively estimated and scored from 0 
to 100%. Percentage staining was multiplied by corresponding intensity with products 
added representing the H"score ranging from 0"300. Samples were done in triplicate 
and the average score was taken to represent each patient’s tumour score. Sections 
from normal kidney tissue, which represent an internal positive control for Cten were 
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used to standardised the intensity of scoring across replicates of the array. 
Immunostaining was reviewed by two Histopathologists (M. Ilyas, A. Albasri) without 
prior knowledge of the clinicopathologic data or the patient outcome. This was done 
independently and the average score was taken. The semi"quantitative system was used 
for scoring tumour samples on whole tissue sections. This system basically used an 
ordinal score scale of 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = 
intense staining)
 
3.26  tumourigenesis study  
Cells were re"suspended, for in vivo administration, in sterile PBS, at pH 7.4 and 
1x10
6
 cells per mouse was administered by intrasplenic injection in a volume of 500Vl 
into male MF1 nude mice (Harlan"Olac). Three groups were used in this study: group 
1: HCT116 wild type, group 2: HCT116 GFP control and group 3: HCT116 GFP"Cten. 
The intra"splenic injections were performed by Dr Rajendra Kumari, Division of Pre"
Clinical Oncology, Nottingham University.  
 
Mice were maintained in sterile isolators within a barriered unit illuminated by 
fluorescent lights set to give a 12 hour light"dark cycle (on 07.00, off 19.00) at air 
temperature range of 23 ± 2ºC as recommended in the United Kingdom Home Office 
Animals (Scientific Procedures) Act 1986. Mice were housed in social groups during 
the procedure in plastic cages (Techniplast, UK) with irradiated bedding. Sterile 
irradiated 2019 rodent diet (Harlan Teckland, UK) and autoclaved water was offered 
ad libitum. An experienced technician checked the condition of the mice daily and 
weighed the mice weekly. The project was run under Home Office project PPL 
40/2962 which was awarded in November 2006 (Watson) following local ethical 
approval. The study also adhered to the UK Co"ordinating Committee for Cancer 
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Research (UKCCCR) guidelines.  
 
On day 42 mice were sacrificed by approved S1 method and the spleen, liver and lung 
were dissected and examined for orthotopic tumors and DM. All tissues were stained 
with hematoxylin and eosin and slides were scanned at x 20 using the NanoZoomer 2.0 
(Hamamatsu Corporation, Japan). The tumour volume was obtained usig the 
NanoZoomer Digital Pathology Image (NDPI) software (Hamamatsu Corporation, 
Japan).  
 
 
3.27 Statistical analysis 
Statistical analysis was performed using SPSS 16.0 statistical software (SPSS Inc. 
USA). All evaluations were done using the unpaired two"tailed Student’s t–test. 
Association between the Cten immunoreactivity expression and different 
clinicopathological parameters was evaluated using Chi"square test. Determination of 
the optimal Cten cut"off was performed using X"tile bioinformatics software, version 
3.6.1, 2003–2005, (Yale University, USA) (205). Survival curves were analysed by the 
Kaplan–Meier plot with a log rank test to assess significance. Multivariate Cox hazard 
analysis was used to test the statistical independence and significance of the variables. 
A p"value of <0.05 was considered significant. 
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Results 
 
Chapter 4. Evaluation of expression of Cten in benign colorectal 
diseases and CRC 
 
4.1 Introduction 
As described earlier in the first chapter, it appears that the function of Cten protein is 
tissue"specific. Cten is located on chromosome 17q21, a region often deleted in 
prostate cancer (8). In addition, previous studies have shown that cten is down"
regulated in prostate cancers, and it is cleaved by caspase"3 during apoptosis (8, 40). 
Moreover, Cten restores the tumour suppression activity of DLC"1 via recruiting it to 
focal adhesions, suggesting the tumour suppression function of Cten in certain tissues 
(55). However, it has been found that although cten is not normally expressed in some 
tissues, its expression is up"regulated when these tissues become cancerous. Recently, 
studies have shown that cten might possess an oncogenic activity in certain tissues. 
Cten is up"regulated in thymomas, lung and gastric cancers compared to normal tissues, 
and in general, its over"expression is associated with poor prognostic outcomes (56, 
57, 24). The role of Cten in CRC is uncertain and thus, we sought to investigate the 
Cten expression during the development of CRC and ascertain whether this expression 
has any prognostic implications in CRC. 
 
 
 
 
 
An investigation of the role of C"terminal tensin"like (Cten) gene in colorectal cancer   
Results 
 
67 
4.2 Evaluation of expression of Cten in non2neoplastic colorectal diseases (normal 
and IBDs) 
In order to evaluate the Cten protein expression in non"neoplastic colorectal diseases, 
ten cases of normal tissue (from tumour edges) and 15 cases of IBDs (7 cases of CD 
and 8 cases of UC) were analysed immunohistochemically using standard techniques 
(see chapter 2). Slides were designated positive if >10% cells showed expression of 
Cten. 
 
Evaluation of Cten protein expression on whole tissue sections containing both IBDs 
and normal mucosa revealed a complete lack of the Cten expression in normal colonic 
epithelium apart from weak cytoplasmic staining which was seen in occasional crypts 
(Figure 11). Similarly, 3/15 (30%) of IBDs cases showed negative Cten expression. In 
contrast, moderate apical cytoplasmic Cten immunoreactivity was seen in 12/15 (70%) 
of IBDs (Figure 12). No cell membrane, nuclear or stromal expression of Cten was 
detected in any of the examined cases.  
 
 
 
 
 
 
 
 
 
 
Figure 11. Cten immunostaining in normal colonic tissue. Immunohistochemical staining for Cten on 
normal colonic tissue (x200), demonstrating negative staining of Cten in normal crypts. 
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(a) 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
  
 
(c) 
 
 
 
 
 
 
 
 
 
Figure 12. Cten immunostaining in non2neoplastic colorectal diseases. (a, x200), Moderate Cten 
cytoplasmic staining in IBDs. (b, x100) Sections from normal kidney tissue representing an internal 
positive control for Cten. (c, x200) Negative control. 
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4.3 Evaluation of expression of Cten in benign colorectal diseases  
Cten expression was tested in whole tissue sections containing 20 cases of colorectal 
adenomas with low grade dysplasia using IHC. Moderate apical cytoplasmic Cten 
expression was seen in 19/20 (95%) of colorectal adenomas (Figure 13). In contrast, 
no cell membrane, nuclear or stromal expression of Cten was detected in any of the 
examined cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Cten immunostaining in colorectal adenomas.  Immunohistochemical staining for Cten on 
whole tissue sections of colorectal adenomas (x200), demonstrating moderate apical cytoplasmic Cten 
expression. 
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4.4 Evaluation of expression and role of Cten in CRC  
 
The up"regulation of Cten protein levels in colorectal adenomas and IBDs prompted us 
to investigate the level of Cten expression in CRC. We would also correlate that with 
the prognostic data in order to see if Cten has any prognostic implication in CRC. 
 
4.4.1 Cten expression in CRC 
After excluding the uninformative TMA cores (120) from the study, which were either 
lost, folded, fragmented or did not have invasive tumour tissue, 342 tumours were 
available for Cten immunostaining assessment. Of these, 25 cases were excluded due 
to unavailability of survival data for them. The staining pattern for Cten in tumour 
cells was homogenous cytoplasmic staining (Figure 14). In the whole series, 317/342 
(92.6%) of the tumours showed expression for Cten. Patchy focal nuclear staining was 
seen in 37/342 (10.8%) of cases (Figure 15). In contrast, no tumour cell membrane or 
stromal expression of Cten was noticed in any of the examined cases. The X"tile bio"
informatics software was used to define optimal cut"off points of Cten H"score values 
(<150, negative/low; ≥150, moderate/strong expression). This program basically 
divides the total patient cohort randomly into two separate equal training and 
validation sets ranked by patients’ follow"up time. The optimal cut"points were 
determined by locating the brightest pixel on the X"tile plot diagram of the training set. 
Statistical significance was tested by validating the obtained cut"point to the validation 
set. 
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Figure 14. Cten protein expression in CRC. Immunohistochemical staining for Cten on CRC (x200), 
demonstrating strong cytoplasmic Cten expression. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Cten immunostaining in CRC. Immunohistochemical staining for Cten on CRC (x200), 
demonstrating patchy focal Cten nuclear staining in some cases. 
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4.4.2 Association of Cten cytoplasmic expression with clinicopathological 
parameters 
 
The association between Cten cytoplasmic expression in CRC and clinicopathologic 
variables is summarised in Table 5. The difference was analysed by the chi"square test, 
revealing that tumours with high Cten expression were associated with advanced 
Dukes stage, more frequent LN metastasis, extra"mural VI and more prone to 
metastasis. Firstly, high Cten expression was significantly correlated with advanced 
Dukes stage (p=0.001; chi"square test). Three of 62 (4.8%) and 45 of 252 (17.9%) 
tumours in the high/low Cten expression groups had Dukes stage A respectively. In 
contrast, 15 of 62 (24.3%) in the high Cten expression group had Dukes stage D 
compared with 27 of 252 (10.7%) in low Cten expression group. Secondly, regarding 
LN involvement, the frequency LN metastasis was significantly higher (p<0.001; chi"
square test) in the high Cten expression group with an incidence rate of 35% (20 of 57) 
compared with a rate of 15.8% (38 of 241) for the low Cten expression group. 
Additionally, the incidence of VI was significantly higher (p=0.001; chi"square test) in 
the high Cten expression group (38 of 62 patients, 61.3%) than in the low Cten 
expression group (81 of 249, 32.5%). Finally, the incidence of of DM was also 
significantly higher (p=0.008; chi"square test) in the high Cten expression group (15 of 
62 patients, 24.2%) than in the low Cten expression group (26 of 250, 10.4%). There 
were no significant differences in patients’ age, gender, tumour histological type, 
tumour grade and tumour site between the high and low expression groups.  
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Table 5. Clinical and pathological correlates of Cten expression. High Cten expression was 
associated with advanced disease and poor prognostic features. 
 
'ote: The analysis has been done in a patient of cohort of 317 cases with CRC. If the total number of 
cases in a given parameter did not add up to 317, this indicates that there were no data available for the 
missed cases of each specific factor.  
 
 
        Parameter 
 
Low Cten 
 
High Cten 


2
 

pvalue 
 
Total 'O. 
 
Patient age (years) 
     
  < 65 33 (13%) 10 (16.1%) 0.312 0.593 314 
  65"80 
  > 80 
 
187 (74.3%) 
32 (12.7%) 
44 (70.9%) 
8 (13%) 
 
 
 
 
 
 
 
Gender 
     
  Female 107 (42%) 23 (37%) 0.488 0.485 317 
  Male 148 (58%) 39 (63%)    
 
Tumour histological type 
     
  Adenocarcinoma 224 (90%) 52 (85%) 2.450 0.291 310 
  Non"adenocarcinoma 25 (10%) 9 (15%)    
 
 
Tumour grade 
     
  Well differentiated 18 (7.2%) 3 (5%) 0.267 0.872 309 
  Moderately differentiated 196 (79%) 49 (80.3%)    
  Poorly differentiated 
 
Tumour site 
34 (13.8%) 9 (14.7%)    
  Colon 121 (53%) 33 (57.9%) 0.806 0.848 285 
  Rectum 107 (47%) 24 (42.1%)    
 
 
Dukes stage 
     
  A 45 (17.9%) 3 (4.8%) 16.318 0.001 314 
  B 100 (39.7%) 17 (27.4%)    
  C 80 (31.7%) 27 (43.5%)    
  D 
 
L' stage 
27 (10.7%) 15 (24.3%)    
  0 148 (61.4%) 18 (31.7%) 18.536 <0.001 298 
  1 55 (22.8%) 19 (33.3%)    
  2 
 
VI 
38 (15.8%) 20 (35%)    
  Negative 168 (67.5%) 24 (38.7%) 11.436 0.001 311 
  Positive 81 (32.5%) 38 (61.3%)    
 
DM 
     
  Negative 224 (89.6%) 47 (75.8%) 9.616 0.008 312 
  Positive 
 
26 (10.4%) 15 (24.2%)    
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4.4.3 Association of Cten cytoplasmic expression with patients’ outcome 
 
Kaplan"Meier survival analysis showed that patients with high Cten expression had a 
significantly poorer prognosis than patients with low Cten expression. High Cten 
expressing tumours had shorter DFS than those with low Cten expression (p<0.001; 
log"rank test, Figure 16). However, multivariate Cox proportional hazard analysis 
including tumour size, LN status and DM occurrence (TNM) stage, VI and Cten 
expression revealed that there was a trend towards Cten expression as an independent 
predictor of DFS in CRC (hazard ratio 1.559, 95% CI 0.963–2.526, p=0.071, Table 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Kaplan2Meier plot for DFS in relation to expression of cytoplasmic Cten. Patients with 
high Cten expression had a significantly shorter DFS than patients with low Cten expression (p<0.001; 
log"rank test). The data were right censored at 120 months and so all cases had 120 months follow 
up.  The two survival lines are not the same length because none of the high Cten cases lived beyond 
100 months. Only the StageIII tumours (Dukes' C) had chemotherapy and so this was not included in the 
analysis. 
+,-./"0 
1-./*"0 
Diseasefree survival (months) 
O
v
e
ra
ll
 s
u
rv
iv
a
l 
ra
te
 
2 
An investigation of the role of C"terminal tensin"like (Cten) gene in colorectal cancer   
Results 
 
75 
Table 6. Cox2proportional hazard analysis for predictors of DFS and Cten expression. Multivariate 
Cox hazard analysis including TNM, VI and Cten expression shows a trend towards Cten expression as 
an independent predictor of DFS in CRC (hazard ratio 1.559, 95% CI 0.963–2.526, p=0.071). 
 
 
Parameter 
 
Hazard ratio 
 
95% CI 

pvalue 
 
Disease2free survival 
   
   
  TNM 
 
0.061 
 
0.025–1.493 
 
<0.001 
 
  VI 
   
  Cten expression 
 
1.985 
 
1.559 
 
1.275–3.091 
 
0.963–2.526 
 
  0.002 
 
  0.071 
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4.4.4 Association of Cten nuclear expression with clinicopathological parameters 
and patient outcome 
 
On further analysis 37/342 (10.8%) of cases showed Cten nuclear staining. There was 
no significant association between any level of Cten nuclear expression and known 
clinicopathological parameters, including patients’ age (p=0.741; chi"square test), 
gender (p=0.411; chi"square test), tumour histological type (p=0.597; chi"square test), 
tumour grade (p=0.777; chi"square test), tumour site (p=0.761; chi"square test), Dukes 
stage (p=0.565; chi"square test), LN metastasis (p=0.997; chi"square test) and DM 
(p=0.437; chi"square test). Furthermore, on Kaplan"Meier analysis, no significant 
association was found between Cten nuclear expression and DFS (p=0.878; log"rank 
test, Figure 17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Kaplan2Meier plot for DFS in relation to expression of nuclear Cten. Kaplan"Meier 
graph showing no significant association between Cten nuclear expression and DFS (p=0.878; log"rank 
test) in CRC.   
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4.5 Evaluation of expression of Cten in metastatic tumours 
 
Tumours with high Cten expression were associated with poor prognostic features 
such as advanced Dukes stage, more frequent LN metastasis, and extra"mural VI. 
Multivariate analysis however showed that high Cten expression was an independent 
prognostic factor. There was also an association of high Cten expression with distant 
metastasis and to further investigate this, another independent series of 40 cases of 
paired primary CRC and corresponding hepatic metastasis deposits was tested for Cten 
expression by IHC. Cten cytoplasmic staining was scored using the H"score system. 
Samples were done in triplicate and the average score was taken to represent each 
patient’s tumour score. Both primary and metastatic tumours showed similar levels of 
cytoplasmic staining. However, metastatic deposits were significantly associated with 
a shift of Cten expression to the nucleus (p=0.002; Fisher’s exact test, Figure 18 a, b).   
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(a) 
        
Cten (Primary Tumour)                                  Cten (Liver metastasis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (b) 
 
Figure 18. Cten protein expression in primary tumour samples and their corresponding liver 
metastasis. A. Cten immunostaining showing cytoplasmic Cten expression in primary tumours (x100) 
and nuclear Cten expression in metastatic tumours (x200). B. Positively stained TMAs showed that 
there was no significant difference between the primary tumour samples and the liver metastases 
regarding cytoplasmic Cten levels (p=0.138; Fisher’s exact test), but interestingly, we found a highly 
significant difference in nuclear localisation of Cten between these TMA samples (p=0.002; Fisher’s 
exact test).  
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4.6 Discussion 
 
Our study involved evaluation of immunohistochemical staining of Cten in AP as well 
as in CRC. We detected a consistent up"regulation of Cten in 90% of colorectal 
adenoma with low grade dysplasia. Our findings are in agreement with previous 
studies reporting a 4.8"fold increase of Cten mRNA in colorectal adenomas compared 
with normal mucosa tissue (206). In addition, we have reported that normal colonic 
mucosa showed very low or almost negative Cten expression at protein levels. Taken 
together, this confirms that Cten is dramatically up"regulated in the early stages of 
colorectal tumour development.  
 
IBD, in the form of CD and UC, is generally characterised by repeated episodes of 
extensive intestinal ulcerations and in each episode the inflammation is succeeded, 
eventually, by tissue healing whereby there is repair of the damaged mucosa or 
remodeling of the epithelium with, in some cases, restitution to near"normal original 
architecture (182). In order to achieve this, certain cellular processes must be activated. 
These involve an increase in cell numbers to replace the lost tissue, restitution by 
migration of epithelial cells from the wound margins and eventual filling and 
remodeling of the damaged area by proliferating epithelial and connective tissue cells 
to restore normal appearances (182). In this study we provide the first report of Cten 
up"regulation in regenerative mucosa in 70% of IBDs, indicating that Cten may play a 
role in regulating the regenerative process in colorectal diseases. It is possible that up"
regulation of Cten in regenerating tissue is related to some of its other proposed 
functions, such as control of adhesion and migration. Our data from our forced 
expression and knock"down experiments concurred and showed that Cten appears to 
stimulate cell migration in both transwell migration assays and cell wounding assays 
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(see the next chapter for details). Enhanced cell migration may be important in wound 
healing by allowing epithelial cells to migrate to areas where epithelium has been lost 
(182).  
 
In this study, we have also evaluated the expression of Cten protein using IHC in a 
large well"characterised cohort of CRC cases. This is the largest study to date 
pertaining to Cten protein expression in CRC and we found that around 90% of 
tumours expressed some level of Cten in the cytoplasm. Our series could be 
dichotomised into those with low Cten expression (H score <150) and high Cten (H 
score >150). We found that high cytoplasmic Cten expression was significantly 
associated with poor prognostic clinico"pathologic variables, including advanced 
Duke’s stage, lymph node metastasis, extra"mural VI and DM. In addition, high Cten 
expressing tumours had shorter DFS than those with low Cten expression. However, 
multivariate Cox proportional hazard analysis including tumour size, LN status and 
DM occurrence (TNM) stage, VI and Cten expression showed that Cten expression 
was of borderline significance as an independent predictor of DFS in CRC. Recently 
published data have demonstrated that the C"terminal of the tensin family proteins 
contains an SH2 domain, allowing them to interact with certain tyrosine"
phosphorylated proteins, such as PI3K, FAK and P130Cas, thereby regulating cell 
motility and migration (3, 8, 209). As Cten shares extensive homology with other 
tensin members at its C"terminus, it has been suggested that Cten may possibly affect 
diverse biological activities including cell motility and migration in a manner similar 
to that of the other tensin proteins. The high frequency of expression of Cten in 
adenomas has showed that up"regulation is an early event in the development of 
colorectal tumours. Taken together with the biological data on Cten, we may 
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conjecture that Cten is a motility associated molecule and may be involved in driving 
tumour progression and metastasis and could therefore represent a therapeutic target as 
well as a prognostic factor in patients with CRC.   
 
Nuclear expression of Cten in CRC has been described in other studies and was 
confirmed in our study. However, the number of cases showing nuclear expression was 
small (10% of the total study group) and it was not associated with the known 
clinicopathological parameters of CRC. Only very small numbers of cases were 
available and thus it is likely that only strong effects will have been identified. The 
study was significantly underpowered to pick up moderate or weak associations. This 
study also revealed that nuclear Cten expression was significantly greater in the 
metastatic deposits than the primary tumours although there was no significant 
difference between the primary tumour samples and the liver metastases regarding 
cytoplasmic Cten levels. The functional implication of nuclear localisation of Cten has 
been investigated in a previous study (207). In this study Cten has been reported to 
interact with beta"catenin, a critical player in the canonical Wnt pathway. This 
interaction is critical for Cten"mediated effects on colony formation, anchorage"
independent growth, and invasiveness of colon cancer cells (207).  
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Chapter 5.  Evaluation of the function of Cten in CRC 
 
5.1 Introduction 
Our immunohsitochemical analysis showed that there is up"regulation of Cten in 
colorectal adenomas and IBD and high expression of Cten in the primary colorectal 
tumour. Its expression is associated with advanced disease and poor prognostic 
outcomes in CRC. Therefore, we decided to study the function of Cten in CRC through 
examination of a series of CRC cell lines for expression of Cten in order to identify 
cell lines with high and low expression of the gene. This was to be followed by 
functional analysis of Cten using a dual approach of forced Cten expression in cell 
lines with low expression and Cten knock"down in the cell lines with high expression. 
This approach would allow us to analyse if modulating levels of Cten expression can 
influence cellular processes such as cell proliferation, resistance to staurosporine 
induced apoptosis, cell migration and cell invasion using the appropriate assay. 
Finally, the effect of Cten on tumour cells was tested invivo by injecting cells stably 
transfected with GFP tagged Cten into mice and compared that with GFP"injected 
mice in order to test the role of Cten in inducing metastasis.   
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5.2 Quantification of  in CRC cell lines  
5.2.1 Cloning of HPRT into pCR2.1 vector  
 
Cloning of HPRT and Cten coding sequences into pCR2.1 vector was done in order to 
use pCR2.1"HPRT and pCR2.1"Cten plasmids as templates to monitor their levels 
quantitatively in CRC cell lines. This allows absolute quantification of Cten in CRC 
cell lines. In addition, it provides a tool to study the effects of exogenous Cten on cell 
signalling and cell behaviour.  
 
The cloning of HPRT into pCR2.1 vector requires a prior addition of adenosine (A) 
residue to the 3' ends of the double stranded PCR product through adding Taq 
polymerase enzyme to the PCR. This enabled the direct cloning into a linearised 
pCR2.1 vector which has single 3´"thymidine (T) overhangs within the vector tails.  
 
Conventional PCR using 10ng cDNA of SW480 CRC cell line as a template and the 
HPRT full length coding sequence primers amplified a product of the expected size 
(675bp) (Figure 19). After that, the PCR product was purified and ligated into pCR2.1 
vector using a ratio of 1:1 (vector: insert). The ligation mix was transformed into 
competent bacteria, colonies were picked, mini"preps grown and plasmid DNA 
(pCR2.1"HPRT) extracted. Real time PCR was performed using pCR2.1"HPRT as a 
template in combination with HPRT primers (see chapter 3 for primer sequences). This 
showed a single and specific peak comparable for all samples tested and corresponded 
to a positive control SW480 cell line’s HPRT peak (Figure 20). In"frame cloning of 
HPRT was confirmed by sequence analysis (Appendix 9.5). 
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Figure 19. HPRT PCR product amplification for cloning into pCR2.1 vector. Following 
amplification, the PCR product was purified on a 1% gel and sized according to the 100bp DNA ladder, 
NTC:negative control. 
 
 
 
 
 
 
  
 
 
 
 
Figure 20. Real time PCR dissociation curves of pCR2.12HPRT cloning samples. Real time PCR 
was performed using pCR2.1"HPRT cloning samples as templates in combination with HPRT primers 
showed a single and specific peak comparable for all samples tested and corresponded to a positive 
control SW480 cell line’s HPRT peak. 
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5.2.2 Cloning of Cten into pCR2.1 vector  
In order to clone Cten into pCR2.1 vector, a PCR was performed using the pEGFPC"1 
plasmid containing the complete coding sequence of Cten as a template and Cten 
primers which create BamH1 and HindIII overhangs at the 5’ and at the 3’ termini of 
the PCR product as described in chapter 3. Conventional PCR of the pEGFPC"1 
plasmid using the above primers amplified a product of the expected size (2,148bp) 
(Figure 21). This PCR product was then gel purified and cloned into pCR2.1 vector 
following the same TA cloning principle and conditions used in the previous section.  
 
 
 
 
 
                       
 
 
 
Figure 21. Cten PCR product amplification for cloning into pCR2.1 vector. Following 
amplification, the Cten PCR product (2,148bp) was purified on a 1% gel and sized according to the 1KB 
DNA ladder, NTC:negative control. 
 
An analytical digest of putative pCR2.1"Cten was carried out using EcoRI an enzyme 
which cuts twice in the pCR2.1 vector (Figure 22), but not in the Cten PCR insert as 
has been checked by using the Webcutter 2.0 software. The digestion results confirmed 
the presence of Cten insert within the pCR2.1 vector (Figure 23). 
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Figure 22. The map of the linearised vector, pCR2.1. Red boxes indicate EcoRI enzyme restriction 
sites. This enzyme cuts twice in the pCR2.1 vector, before and after the insert, thereby releasing the 
cloned PCR product from the pCR2.1 vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. EcoRI enzyme restriction digests of pCR2.12Cten plasmid in tested samples. Sample 4 
showed the presence of pCR2.1"Cten construct (the 2 bands are the right size bands for both the insert 
and the vector). S: Sample, U: Undigested, D: Digested.  
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For further evaluation pCR2.1"Cten plasmid, an ordinary PCR was undertaken using 
the Cten primers used in TA cloning. This showed a single and specific band for Cten 
coding sequence corresponded to pEGFPC1"Cten plasmid positive control (Figure 24). 
We sent 12Vl of pCR2.1"Cten plasmid for sequencing, and the results showed that 
Cten was inserted into pCR2.1 vector in reverse (HindIII to BamHI) orientation 
(Appendix 9.6, 9.7). This is because the TA vector cloning system allows the ligation 
of an insert in both 5’"3’ and 3’"5’ orientations. 
 
 
 
 
 
 
 
 
 
Figure 24.  Cten PCR product amplification using pCR2.12Cten plasmid. A PCR showed a band 
corresponded to Cten coding sequence and confirming the cloning of Cten into pCR2.1 vector. 1 
(pCR2.1"Cten sample), 2 (negative control), 3 (pEGFPC1"Cten plasmid positive control). 
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5.2.3 Evaluating the  mR'A expression in CRC cell lines 
Expression of HPRT mRNA was evaluated by Q"RT–PCR using HPRT primers in 29 
CRC cell lines (Figures 25"28, see chapter 3 for primer sequences). Data was analysed 
using the standard curve method (whereby a reference sample is serially diluted and 
the Ct values at each dilution are plotted on a graph) with cloned HPRT in pCR2.1 
used to generate the standard curve.  
  
 
 
 
 
 
 
 
 
Figure 25.  Q2RT2PCR standard curve of 29 human CRC cell lines. The Q"RT"PCR was 
carried out in triplicates and showed 98.6% efficiency.  
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Figure 26.  Q2RT2PCR amplification plots of 16 human CRC cell lines. Serial dilutions for 
HPRT standard curve were prepared in decreasing 10"fold increments starting from 10ng. As depicted 
above, HPRT message in CRC cell lines can be clearly detected all of the way down from 0.1ng 
standard curve dilution. NTC were came"up after 35 cycles. The Q"RT"PCR was carried out in 
triplicates.  
 
 
 
 
 
 
 
 
 
 
Figure 27.  Q2RT2PCR amplification plots of 13 human CRC cell lines. HPRT message in 
CRC cell lines can be clearly detected all of the way down from 0.1ng standard curve dilution. NTC 
were came"up after 36 cycles. The Q"RT"PCR was carried out in triplicates. 
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Figure 28.  Q2RT2PCR dissosciation curves of 29 human CRC cell lines. Dissosciation curves 
of HPRT in CRC cell lines showed a single and specific peak comparable for all samples. 
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5.2.4 Evaluating the  mR'A expression in CRC cell lines 
Expression of Cten mRNA was evaluated by Q"RT"PCR using Cten primers in 29 
CRC cell lines (Figures 29"32, see chapter 3 for primer sequences). Data was 
evaluated using the standard curve method with cloned Cten in pCR2.1 used to 
generate the standard curve. Analysis was performed in triplicate for each sample and 
data was normalised to cloned HPRT in pCR2.1 vector to obtain absolute Cten mRNA 
levels for the cell lines tested. 
 
 
 
 
 
 
 
 
 
 
 
Figure 29.  Q2RT2PCR standard curve of 29 human CRC cell lines. The Q"RT"PCR was 
carried out in triplicates and showed 87.1% efficiency. 
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Figure 30.  Q2RT2PCR amplification plots of 9 human CRC cell lines. Cten message in CRC 
cell lines can be clearly detected all of the way down from 0.001ng standard curve dilution. NTC were 
came"up after 38 cycles. The Q"RT"PCR was carried out in triplicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31.  Q2RT2PCR amplification plots of 20 human CRC cell lines. Cten  message in CRC 
cell lines can be clearly detected all of the way down from 0.1ng standard curve dilution. NTC were 
came"up after 38 cycles. The Q"RT"PCR was carried out in triplicates. 
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Figure 32. Q2RT2PCR dissosciation curves of 29 human CRC cell lines. Dissosciation curves 
of Cten  in CRC cell lines showed a single and specific peak comparable for all samples. 
 
 
Normalised Cten mRNA expression in CRC cell lines showed that 18/29 (62%) cell 
lines showed up"regulation of Cten mRNA levels and they differ in their level of 
expression up to 50 fold. The cell lines showing up"regulation appeared to fall into two 
groups, with 13 showing a two" to eight"fold increase and five showing over a 35"fold 
increase. These results are summarised in Table 7 and Figure 33.  
 
HCT116 and SW480 are both well"described cell lines which were found to have little 
expression of Cten at the mRNA level. These were thus chosen for Cten forced 
expression experiments. In contrast, following the Q"RT"PCR analysis, SW620 was 
found to have high expression of Cten at the mRNA level and thus was thus most 
suitable for gene knock"down experiments. 
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Table 7. Expression of  in CRC cell lines assessed by Q2RT2PCR. The normalised Cten mRNA 
was found to be over"expressed in several CRC cell lines at varying levels. 
 
    Cell line 
 
Fold difference 
  
     DLD1 57.1 
     COLO205 
     LOVO 
51.4 
48.6 
     SW620 48.6 
     COLO201 35.7 
     C80 7.1 
     GP2D 7.1 
     VACO10MS 
     C32 
7.1 
4.3 
     C84 
     HCA46 
4.3 
4.3 
     SW1116 4.3 
     VACO5 4.3 
     C125 
     LS1034 
3.6 
3.6 
     SW122 3.6 
     SW480 3.6 
     SW948 
     C106 
2.9 
0.7 
     COLO320DM 0.7 
     HT29 0.7 
     HT55 0.7 
     RKO 
     HCA7 
0.7 
0.6 
     HCT116 0.6 
     HUTU80 0.6 
     HRA19 
     CACO2 
0.3 
0.2 
     SW837 0.2 
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Figure 33. Bar chart of  levels in CRC cell lines as measured by Q2RT2PCR.  Cten values were normalised to the housekeeping gene HPRT and up"regulated in CRC 
cell lines at varying levels. 18/29 (62%) of CRC cell lines showed up"regulation of message expression (i.e. >2 fold) with a 5 fold increase seen in DLD1.  
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5.3 Establishment of stable Cten2stably expressing cell lines 
 
HCT116 and SW480 are both well described cell lines. Their identities were 
confirmed by mutation screening analysis done by our group using the high resolution 
melting curve analysis of DNA/cDNA (208). These cell lines were found to have little 
expression of Cten at the message level and no detectable Cten protein by Western 
blot. Thus, these were chosen for studies of Cten function. HCT116 was stably 
transfected with an expression vector containing GFP"tagged Cten or with empty GFP 
vector (as control) followed by prolonged growth in G418 selection media. Full"length 
protein expression in the stable cell lines obtained was confirmed by western blotting. 
Whole cell lysates were blotted with anti"Cten antibody and a band of 110 kDa 
(representing the GFP"Cten protein) was present in HCT116 cell line transfected with 
GFP"Cten plasmid whilst there was no evidence of Cten in HCT116 cell line 
transfected with GFP vector control. β"actin was used as a loading control (Figure 34). 
Evaluation of the Cten protein in the stably transfected cell lines showed levels which 
were equivalent to those present in the cell line SW620 (Figures 34). This is derived 
from a metastatic deposit and shows high endogenous Cten mRNA and protein levels. 
For SW480 a slightly different strategy was used and the transfected cells were FACS"
sorted 24 hours after transfection. Transfection efficiencies were unexpectedly low 
with only 11% efficiency in the GFP"Cten transfections versus 32% in the GFP vector 
controls (Figure 35). After sorting, cells were grown in G418 selection media to 
produce stably transfected colonies.  
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SW480 (GFP) SW480 (GFPCten) 
SW480 Untreated 
  
                                                                 
       Cten 
                 
 
                
      β2actin 
 
Figure 34. Immunoblotting for Cten using whole cell extracts from HCT1162GFP or HCT1162
GFP2Cten. HCT116 was stably transfected with GFP–Cten through prolonged growth in selection 
G418 selection. Evaluation of the Cten protein in thestably transfected cell lines showed levels which 
were equivalent to those present in the cell line SW620. β"actin is shown as a loading control. Please 
note that β"actin western is overexposed and this is true for most of the blots in this study. The reason 
for that is because we load a lot of protein (30 ug) to detect Cten protein and other proteins of interest 
and the loading control is tested on the same samples.   
 
 
 
 
 
 
Figure 35. SW480 cell line FACS sorting. Non"transfected cells were used to set the gating levels. 
Cells transfected with GFP"Cten or empty vector were then sorted on the basis of fluorescence.   
110 kDa 
GFP                        GFP2Cten                             SW480                  SW620 
79 kDa 
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5.4 Role of Cten in regulating cell proliferation  
The effects of Cten expression on proliferation were tested in both HCT116 and 
SW480 cells using a time course experiment conducted over a period of 7 days. This 
showed that when compared with empty vector controls; forced expression of Cten 
does not have an effect of proliferation in either cell line (Figure 36).  
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(a) 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
Figure 36.  Effect of Cten forced expression on cell proliferation. A time course analysis of cell 
proliferation over seven days in (a) HCT116 and (b) SW480 cell lines showed that forced expression of 
Cten had little effect on cell numbers compared to controls. Error bars show standard deviation. 
 
 
F
lu
o
re
sc
en
ce
 
 

)

)
"
")
 
 )

)
7 7 7 7!
Cell Line 
134*.<@
345	0
134*.<@
0
 

)

)
"
")
 
 )

)
7 7 7 7!
Cell Line 
:;#.<@
345	0
:;#.<@
0
F
lu
o
re
sc
en
ce
 
An investigation of the role of C"terminal tensin"like (Cten) gene in colorectal cancer   
Results 
 
100 
5.5 Role of Cten in resisting apoptotic stress 
Having shown that Cten forced expression dose not have an effect on cell number in 
CRC cell lines, we next tested whether Cten could cause resistance to staurosporine"
induced apoptotic stress. Staurosporine is commonly used to induce apoptosis in cells 
and was used to test the resistance to apoptosis conferred by Cten. After 24 hours 
incubation with 6VM staurosporine, more living (i.e. adherent.) cells and fewer dead 
cells (as determined by uptake of trypan"blue) were observed in wells containing Cten  
transfected cells than in wells containing GFP"transfected controls (p<0.001 for both; 
Student’s t"test, Figure 37).  
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Figure 37. Cten conferred resistance to staurosporine2induced apoptosis in both SW480 and 
HCT116 cells. Induction of apoptosis was quantified by two methods: number of adherent cells 
(measured by the methylene blue assay) (a,b) and number of floating cells taking up trypan blue 
(measured by manual counting) (c, d). For both methods of assessment and in both cell lines, there was 
a significant difference (p<0.005 for each condition; Student’s t"test).  
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5.6 Role of Cten in regulating cell motility 
5.6.1 Effects of Cten forced expression on cell migration and invasion  
Although forced expression of Cten had no effect on proliferation in HCT116 cells, it 
altered their cellular morphology. Examination by epifluorscence microscopy showed 
that cells transfected with GFP"Cten adopted an elongated spindle"like shape whilst 
those transfected with GFP control plasmid retained an epithelioid appearance (Figure 
38).  
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Figure 38. Epifluorescence microscopy to assess the localisation of GFP and Cten in transfected 
cells. Cells transfected with GFP empty vector had a rounded phenotype with GFP present both within 
the nucleus and the cytoplasm. Cells transfected with GFP"Cten showed a more spindle like morphology 
with fluorescence seen only in the cytoplasm. 
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Having shown that forced expression of Cten induced a change in appearance of the 
cells, manifested as an acquisition of an elongated spindle"like appearance, consistent 
with EMT, this was an unexpected observation and prompted us to evaluate the effect 
of Cten on cell migration and invasion. Transwell migration assays, using SW480 and 
HCT116 cell lines resulted in markedly increased cellular migration (p<0. 001 for each 
cell line; Student’s t"test, Figure 39) of cells containing Cten versus control cells. In 
order to validate the transwell migration assay, a cell wounding assay was performed 
using HCT116 GFP" and HCT116 GFP"Cten"transfectants. Cells expressing Cten 
showed a more rapid migration across the wound than controls (p=0.03; Student’s t"
test, Figure 40) and thereby confirmed our transwell migration assay findings. Cell 
invasion was tested using the Boyden chamber assay containing a thin layer of 
Matrigel (5mg/ml) on the upper side of the filter. In both HCT116 and SW480 cells, 
forced expression of Cten stimulated invasion compared to GFP control cells (p<0. 
001 for each cell line; Student’s t"test, Figure 41). 
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Figure 39. Effect of Cten forced expression on cell migration using a transwell migration assay. In 
both HCT116 and SW480 cell lines, transwell migration assays showed that greater numbers of cell 
migrated through the filter when transfected with GFP"Cten compared to control empty GFP vector 
(p<0.001 for both cell lines; Student’s t"test). Data shown are representative of experiments performed 
in triplicate (and replicated in independent experiments). Error bars show standard deviation.   
 
 
 
 
 
 
Figure 40. Effect of Cten forced expression on cell migration using a cell wounding assay.  The 
assay in HCT116 showed greater migration across the wound in cells transfected with GFP"Cten than 
empty vector controls. The area of the wound was measured using ImageJ and showed that the wound 
was significantly smaller in cells transfected with GFP"Cten than controls (p=0.03; Student’s t"test).   
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Figure 41. Effect of Cten forced expression on cell invasion. In both SW480 and HCT116 cell lines, 
invasion assays showed that Cten stimulated invasion through matrigel (p<0.001 for both cell lines; 
Student’s t"test). Data shown are representative of experiments performed in triplicate (and replicated in 
independent experiments). Error bars show standard deviation.   
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5.6.2 Effects of Cten knock2down on cell migration and invasion 
Having shown that forced expression of Cten in HCT116 and SW480 CRC cell lines 
promotes cell motility, we used the reciprocal approach of knock"down of 
endogenously over"expressed Cten in order to validate our findings. SW620 cells, 
which endogenously express high levels of Cten, underwent gene knock"down by 
RNAi.  Cells were transfected with specific Cten siRNA or non"targeting scrambled 
control. First, we confirmed the efficacy of Cten siRNA knock"down by q"RT"PCR 
and western blotting. We detected a 70% decrease in Cten mRNA levels, which was 
reflected also at protein levels (Figure 42 a, b).  
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Figure 42. Cten knock2down in SW620 cells. Cten knock"down using Cten siRNA was confirmed by 
Q"RT"PCR (a) and western blotting (b). A 70% decrease in Cten mRNA levels (a), was also reflected at 
protein levels (b). β"actin was used as a loading control. Error bars show standard deviation.   
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Experiments were repeated following Cten knock"down. Cell migration assays using 
the Boyden chamber showed a marked decrease in cellular migration when Cten levels 
were depleted compared with siRNA control transfected cells (p<0.001; Student’s t"
test, Figure 43). Effect of Cten knock"down on cell invasion showed a statistically 
significant decrease in cellular invasion capability, when high endogenous Cten levels 
were decreased (p<0. 001; Student’s t"test, Figure 44).  
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Figure 43. Effect of Cten knock2down on cell migration. Transwell migration assay showed a 
significant decrease in cellular migration of cells transfected with Cten siRNA compared with siRNA 
control transfected cells (p<0.001; Student’s t"test). Data shown are representative of experiments 
performed in triplicate (and replicated in independent experiments). Error bars show standard deviation.   
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. Effect of Cten knock2down on cell invasion. Invasion assay showed a significant decrease 
in cellular invasion of cells transfected with Cten siRNA compared with siRNA control transfected cells 
(p<0.001; Student’s t"test). Data shown are representative of experiments performed in triplicate (and 
replicated in independent experiments). Error bars show standard deviation.   
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5.7 Role of Cten in metastasis  
Our current data show unequivocally that Cten plays a role in stimulating cell motility 
in CRC. Acquisition of cell motility may be important in tumour metastasis and thus 
we tested whether Cten could enhance the metastatic properties of HCT116. For this 
purpose invivo models of tumour metastasis in mice were used. Cells were stably 
transfected with either GFP"Cten or GFP alone (as controls) and injected into the 
spleens of nude mice. Compared to the controls, mice injected with cells expression 
GFP"Cten developed a significantly greater total tumour burden in the spleen (average 
intra"splenic tumour volume for mice injected with cells expression HCT116 GFP"
Cten and HCT116 GFP were 4.3mm
3
 and 1.2mm
3
 respectively, p=0.03; Mann"
Whitney U test, Figure 45). The number of discrete tumour deposits in the liver was 
similar in both groups but the size of the deposits was greater in mice injected with 
cells expression HCT116 GFP"Cten leading to a greater tumour burden (average intra"
hepatic tumour volume for mice injected with cells expression HCT116 GFP"Cten and 
HCT116 GFP were 3.5mm
3
 and 1.4mm
3
 respectively (p=0.05; Mann Whitney U test, 
Figure 46). There were no significant differences in overall survival between the mice 
injected with cells expression HCT116 GFP"Cten and HCT116 GFP (p=0.214; log"
rank test, Figure 47). 
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Figure 45. Average intra2splenic tumour volume from the mice injected with HCT1162GFP or 
HCT1162GFP2Cten cells. Compared to the controls, mice injected with cells expression GFP"Cten 
developed a significantly greater total tumour burden in the spleen (p=0.03; Mann Whitney U test). The 
tumour volume was measured using the NDPI software. Arrows show intra"splenic tumour. Error bars 
represented standard deviations. 
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Figure 46. Average liver tumour volume from the mice injected with HCT1162GFP or HCT1162
GFP2Cten cells. Compared to the controls, mice injected with cells expression GFP"Cten developed a 
significantly greater total tumour burden in the liver (p=0.05; Mann Whitney U test). Arrows show liver 
tumour. Error bars represented standard deviations 
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Figure 47. Kaplan–Meier plot for survival in mice injected with HCT1162GFP or HCT1162GFP2
Cten cells. Analysis of the Kaplan–Meier showed  no significant differences in overall survival between 
the mice injected with cells expression HCT116 GFP"Cten and HCT116 GFP (p=0.214; log"rank test). 
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5.8 Discussion  
The Q"RT"PCR for Cten showed high efficiency and a wide dynamic range (i.e. the 
standard curve performed for the Cten PCR was able to detect Cten cDNA template at 
concentrations ranging over 5 orders of magnitude. Cten mRNA was detectd in 62% 
cell lines although they differed in their level of expression up to 57 fold " well within 
the dynamic range of the PCR thus confirming the reliability of the quantification). 
The wide range of expression of Cten in the cell lines reflects the heterogeneity in the 
cell lines in the same way that tumours are heterogeneous for expression of many 
different types of genes. Given the small numbers of cell lines, the interpretation has to 
be cautious, although it is of interest that three of five cell lines with very high 
expression (COLO205, SW620 and COLO201) were derived from metastatic deposits, 
suggesting the close association between Cten expression and cancer metastasis in 
CRC. The Q"RT"PCR was only done once – this was because it was about identifying 
cell lines with high and low expression and then confirming this with Westerns. 
HCT116 and SW480 are both well"described cell lines which were found to have little 
expression of Cten at the mRNA level and little detectable Cten protein by western 
blot. These were thus chosen for studies of Cten forced expression experiments. In 
comparison, SW620 cell line was found to have high Cten expression at both mRNA 
and protein levels. Therefore, it was chosen for Cten gene knock"down experiments. 
 
The C"terminal of tensin protein contains a SH2 domain, allowing tensin to interact 
with certain tyrosine"phosphorylated proteins, such as PI3K, FAK and P130Cas. This 
binding is critical for tensin"mediated effects on cell motility, migration and cell 
survival, suggesting that tensin is not only a structural protein but also plays a key role 
in mediating signalling transduction at focal adhesions (3, 8, 209). As Cten shares 
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extensive homology with other tensin members at its C"terminus, it has been proposed 
that Cten may possibly affect diverse biological activities including cell motility, 
migration and cell survival in a manner similar to that of the other tensin proteins. In 
addition, studies in breast cell lines show that Cten protein stimulates cell motility 
through displacement of TNS3 at focal adhesions and consequent dissociation between 
the cytoplasmic tails of integrin molecules and actin fibres (30). Our data showed that 
forced expression of Cten in CRC cell lines could induce EMT and this would be 
suggestive of a role in controlling cell motility in CRC. This was confirmed by 
experiments showing that Cten could stimulate cell migration and cell invasion in both 
HCT116 and SW480 cell lines. In order to further evaluate the role of Cten in 
modulating cell motility, we used RNAi to knock"down Cten in the CRC cell line 
SW620. This cell line expresses high levels of endogenous Cten and knock"down of 
Cten resulted in inhibition of cell migration and invasion. Our data are in agreement 
with those of Liao et al, who reported that forced Cten expression and knock"down in 
CRC cell lines expressing low and high levels of Cten protein is associated with 
enhanced and suppressed transwell migration and invasion abilities respectively (207). 
 
This implies that Cten may be a gene that promotes tumour metastasis. We can 
speculate further that the observed resistance to staurosporine"induced apoptosis may 
reflect an ability to survive in hostile environments such as sites of metastasis. Our 
data support Cten’s role as an oncogene and, furthermore, suggest that its role may be 
in supporting tumour metastasis rather than tumour growth.  
 
Our current data show that compared with control mice (injected with cells transfected 
with GFP empty vector), mice injected with cell expressing Cten developed a greater 
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tumour burden both locally within the spleen and within the liver metastases. These 
data clearly demonstrate the significant association of Cten with cancer metastasis in 
both invitro and invivo models and would support our own data and other published 
data showing the association between high Cten expression and advanced disease stage 
in lung, thymic and gastric tumours (56, 57, 24). Our data also show no significant 
differences in overall survival between the mice injected with cells expression 
HCT116 GFP"Cten and HCT116 GFP. This is not unexpected, due to small numbers 
of mice used in the study. Given this, any attempt to identify assosciations was 
underpowered significantly. 
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Chapter 6. Evaluation of Cten targets in CRC  
 
6.1 Introduction 
Previous studies had shown that ectopic expression of Cten protein in CRC cell lines 
caused changes in cell morphology and increased cell motility (both migration and 
invasion). These data were validated in another testing system. RNAi was used to 
knock down Cten in the CRC cell line SW620 which resulted in inhibition of both cell 
migration and invasion. Furthermore, high levels of Cten expression were significantly 
associated with advanced disease/metastasis in human CRC. In addition, Cten 
expression was capable of enhancing metastasis in an invivo model. Therefore, we 
sought to clarify the mechanistic basis of Cten"mediated changes in cell motility in 
CRC.  
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6.2 Cloning of Cten into an expression vector 
In order to validate our previous Cten functional results using the GFP tagged Cten 
plasmid and to test whether the GFP would cause a functional problem, it was 
necessary to shuttle the Cten coding sequence into a Myc tagged vector and to 
engineer a pCMVTag3B"Cten expression construct. To achieve that, sequential 
BamHI and HindIII restriction digests were employed for both pCR2.1"Cten plasmid 
and pCMVTag3B vector in order to isolate the Cten insert from pCR2.1 vector and 
shuttle into pCMVTag3B expression vector. 
 
The pCR2.1"Cten plasmid BamHI and HindIII restriction digests confirmed the 
sequencing results and showed that Cten was inserted into pCR2.1 vector in reverse 
(HindIII to BamHI) orientation. The digestion results showed the linearisation of 
pCR2.1"Cten plasmid after HindIII digestion and releasing the Cten insert from the 
pCR2.1 vector after BamHI digestion (Figure 48, 49).  
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Figure 48. pCR2.1 vector map. Red boxes show BamHI and HindIII enzymes restriction sites. 
 
(a) 
 
 
 
 
 
 
 
(b) 
 
 
 
  
 
 
 
Figure 49. Gel purification and sequential digestion of pCR2.12Cten plasmid. The sequential 
digestion was done with one enzyme (a) then with both enzymes (b). The digestion results showed the 
linearisation of pCR2.1"Cten plasmid (6 KB) after HindIII digestion and releasing the Cten insert (2.1 
KB) from the pCR2.1 vector (3.9 KB) after BamHI digestion. There are two BamH1 site: in the vector 
upstream of the multiple cloning site and in the upstream primer of Cten.  If the insert goes in reverse 
orientation, even a single BamH1 digest will release the insert thus giving two bands.  
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The gel purified BamHI/HindIII Cten insert was then ligated into a BamHI/HindIII 
digested pCMVTag3B vector (Figure 50, 51) at ratio of 1:1. Another 2 ligation 
reactions were also set up as negative controls. These contained all the reaction 
components except the purified insert in the first one and the vector in the second one 
(no colonies were seen in the negative control plates). The ligation mix was 
transformed into competent bacteria, colonies were picked, mini"preps grown and 
plasmid DNA extracted. 
 
 
 
Figure 50. pCMV2Tag3B expression vector map. Red boxes show BamHI and HindIII enzymes 
restriction sites. 
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       (a)                                                                          (b) 
 
 
 
 
 
 
Figure 51. Gel purification and sequential digestion of pCMV2Tag3B vector. The vector was 
digested with BamHI restriction enzyme, tube purified and sequentialy digested with HindIII restriction 
enzyme (a). Electrophoresed DNA was visualised under ultraviolet light and appropriate band (4.3 KB) 
was excised from the gel with clean scalpel in order to isolate the DNA from agarose gel using the Gel 
Extraction system, following the manufacturer’s standard protocol. Figure (b) shows that the band has 
been correctly excised. U: Undigested. 
 
Analytical digestion using XhoI and SacI of potential pCMVTag3B"Cten plasmid from 
positive colonies were performed to verify the presence of the insert within the vector. 
XhoI enzyme cuts once in both the Cten insert as well as in the pCMVTag3B vector, 
releasing two bands of expected size of 1,428bp and 5,020bp respectively. In 
comparison, SacI enzyme cuts once in the Cten insert, linearising the pCMVTag3B"
Cten plasmid with a band of expected size of 6,448bp (Figure 52). However, none of 
the analytical digestion results showed bands specific for pCMVTag3B"Cten plasmid. 
We only found empty pCMVTag3B vectors (Figure 53). This means that either 
pCMVTag3B vector was re"ligated and not completely double digested, or the ligation 
reaction was not efficient.  
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Figure 52. Diagram shows XhoI and SacI enzymes restriction sites in pCMVTag3B2Cten plasmid. 
XhoI enzyme cuts once in both the Cten insert at 720bp away from the 5' end and in the pCMVTag3B 
vector just 18bp after the Cten insert 3' end, releasing two bands of expected size of 1,428bp and 
5,020bp. In comparison, SacI enzyme cuts once in the Cten insert at 1761bp away from the 3' end, 
linearising the pCMVTag3B"Cten plasmid with a band of expected size of 6,448bp. 
 
 
(a)                                                                                     (b) 
 
 
 
 
 
 
 
 
 
Figure 53. Agarose gel of potential pCMVTag3B2Cten clones after analytical enzyme digestions. 
The digestion with (a) SacI and (b) XhoI enzymes show empty vectors (4.3 KB) in most of the test 
samples. Samples 4 and 5 digested with XhoI enzyme show additional non"specific bands (300bp), 
suggesting a partially digested samples. S: Sample, U: Undigested, D: Digested. 
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To overcome these problems, a new sequential digestion and gel purification of 
pCR2.1"Cten plasmid and pCMVTag3B vector were done, and at this time an 
additional washing step, during gel purification using QG buffer (750Vl) according to 
the manufacturer’s protocol, was performed to avoid vector self"ligation. This was 
followed by ligation reactions at ratio of 3:1 and 5:1 (vector: insert) to achieve a better 
ligation efficiency. Again, no colonies were seen in the negative control plates. 
Analytical digest using XhoI and SacI of potential pCMVTag3B"Cten plasmids were 
carried out, only empty pCMVTag3B vectors were detected (Figure 54 a, b). 
 
All attempts to shuttle the Cten gene from pCR2.1"Cten vector into a mammalian 
expression plasmid pCMVTag3B failed. Therefore, all transfections and functional 
analyses of Cten were carried out using GFP"Cten plasmid, which was kindly provided 
from (Dr Su Hao Lo, Department of Biochemistry and Molecular Medicine, University 
of California" Davis, USA) 
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Figure 54. Agarose gel of potential pCMVTag3B2Cten clones after analytical digestion with (a) 
SacI and (b) XhoI enzymes. The digestion results show empty vectors (4.3 KB) in most of the test 
samples. S: Sample, U: Undigested, D: Digested. 
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6.3 Cten and E2cadherin expression 
Given the effects of forced Cten expression on cell morphology and cell motility, we 
next sought to investigate possible mechanisms for these effects. Cten localises at focal 
adhesions and has been shown to disrupt integrin function. However, epithelial cells 
also have intercellular adhesion which is mediated via adherens junctions and, in 
particular, through the adhesion molecule E"cadherin. Disruption of adherens 
junctions through loss of E"cadherin function can stimulate cell motility (210). 
Western blot analysis of cells transfected with GFP"Cten showed decreased levels of 
E"cadherin protein " when compared with empty vector control cells in both HCT116 
and SW480 (Figure 55). This suggests that the effects of Cten are mediated via an E"
cadherin"dependent mechanism. In order to investigate whether reduction of E"
cadherin protein was due to reduced gene transcription or enhanced protein 
degradation, Q"RT"PCR analysis of CDH1 mRNA levels was performed. In both cell 
lines there was no change in message in cell lines transfected with Cten as compared to 
controls (Figure 56). This suggests that Cten causes reduction of E"cadherin protein at 
the posttranslational level. 
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Figure 55. Cten and E2cadherin protein expression. Western Blot for E"cadherin shows that, in both 
HCT116 and SW480 cell lines, the E"cadherin protein is markedly decreased in cells transfected with 
GFP"Cten compared with empty vector control. The β"actin control is performed from the same sample 
used for E"cadherin Western blotting. The bands may seem overexposed due to the high quantity of 
protein loaded in order to detect E"cadherin (see materials and methods) 
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Figure 56. Cten and  mR'A expression. Analysis of CDH1 expression levels by Q"RT"PCR 
showed that there is no change in mRNA levels following forced Cten expression. 
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Having shown that forced expression of Cten in HCT116 and SW480 CRC cell lines 
correlates with decreased E"Cadherin protein levels, we used the reciprocal approach 
of knock"down of endogenously over"expressed Cten in order to validate our previous 
findings. SW620 cells, which endogenously express high levels of Cten, were 
transfected with specific Cten siRNA or non"targeting scrambled control. The knock"
down of Cten in SW620 cells lead to increased E"cadherin levels (Figure 57), 
confirming our previous findings of an inverse relationship between Cten and E"
cadherin levels in CRC.  
 
 
 
 
                                                   
             E2cadherin 
 
                                      
                        
 
                         β2actin 
 
 
 
Figure 57. Effect of Cten knock2down on E2cadherin protein expression. Immunoblotting showed 
that Cten knock"down in SW620 cells leads to increased E"cadherin levels. β"actin was used as a 
loading control. Overexposure of the β"actin control is due to the same reason highlighted in the 
previous figure. Data shown are representative of experiments performed in duplicate (and replicated in 
independent experiments). 
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6.4 Cten and ILK expression 
The close localisation of ILK with Cten at cytoplasmic site of integrin molecules 
together with the reports that ILK can cause down"regulation of E"cadherin raises the 
possibility of that part of the Cten"mediated effect on cell migration and E"cadherin 
expression may occur via ILK. We tested this hypothesis using a dual approach of 
forced Cten expression and Cten knock"down in cell lines respectively expressing low 
and high levels of Cten protein. Forced expression of GFP"Cten in the CRC cell line 
HT116 cells resulted in up"regulation of ILK (Figure 58 a). In agreement with these 
results, the reciprocal Cten knock"down experiments in SW620 cells resulted in down"
regulation of ILK (Figure 58 b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An investigation of the role of C"terminal tensin"like (Cten) gene in colorectal cancer   
Results 
 
130 
 
(a) 
 
 
                                        HCT116 GFP             HCT116 GFP 2Cten         
 
                 ILK 
 
                     
 
 
           
         β−actin 
 
 
 
 
 
 
(b) 
 
                                      SW620 siR'A Cont.    SW620 siR'A Cten               
 
                    ILK 
 
                          
 
 
             
                     
                  β−actin 
 
 
 
 
 
Figure 58. Effect of Cten forced expression and knock2down on ILK protein expression. Western 
blots showed that forced expression and knock"down of Cten in HCT116 (a) and SW620 (b) cells, 
resulted in up"regulation and down"regulation of ILK protein level respectively. β"actin was used as a 
loading control. The reason for β"actin control being overexposed is because we load a lot of protein (30 
ug) to detect ILK protein and the loading control is tested on the same samples. Data shown are 
representative of experiments performed in duplicate (and replicated in independent experiments). 
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6.5 Cten and FAK expression 
6.5.1 Evaluation of expression and role of FAK in CRC 
FAK is a 125"kDa non"receptor and non"membrane associated PTK which localises to 
focal adhesions. These are sites where integrin molecules mediate attachment between 
the cell and the ECM (87, 88, 211). FAK has been shown to act as an early modulator 
in the integrin signalling cascade and facilitates ”outside"in” signalling to downstream 
targets such as extracellular signal–regulated kinase 2 or c"Jun"N"terminal kinase 
(212). FAK has been found to be highly expressed in a variety of tumours, including 
head and neck, ovarian, thyroid, and colon carcinomas (213"217). Forced FAK 
expression in ovarian cells has been reported to enhance G1 to S phase transition, 
suggesting a role for FAK in the promotion of cell proliferation (218). Conversely, 
knock"down of FAK protein or treatment of cancer cells with anti"FAK antibodies can 
induce apoptosis (219, 220). In addition, isolated fibroblasts from FAK"KO mice have 
been shown to migrate significantly more slowly than their normal counterparts (221) 
suggesting that FAK also promotes cell migration.  
 
For full activation, FAK requires phosphorylation of the amino acid residue Tyrosine 
397. This creates binding sites for SH2 domain"containing proteins thereby triggering 
multiple signalling pathways (222). The binding of Src to FAK can also phosphorylate 
FAK at Y925, an additional amino acid residue known to be associated with integrin 
adhesion dynamics and E"cadherin de"regulation during Src"induced EMT (223, 224). 
 
In the present study, we evaluated P"FAK protein expression in a large well"
characterised series CRC cases (n=462) with a long term follow"up using IHC and 
TMA to test if P"FAK has a prognostic significance in patients with CRC.   
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6.5.1.1 P2FAK expression in CRC cases 
After excluding the uninformative TMA cores (109) from the study, which were either 
lost, folded, fragmented or did not have invasive tumour tissue, 353 tumours were 
available for P"FAK immunostaining assessment by the H"score method. Expression 
of P"FAK was predominantly nuclear and was seen in 155/353 (44%) of cases (Figure 
59 a). Cytoplasmic expression of P"FAK was inversely correlated with nuclear 
expression of P"FAK and noticed in 79/353 (22%) of cases (Figure 59 b). In contrast, 
no tumour cell membrane or stromal expression of P"FAK was noticed in any of the 
examined cases. The X"tile bio"informatics software (Yale University, USA) was used 
to define optimal cut"off points of P"FAK H"score. This program basically divides the 
total patient cohort randomly into two separate equal training and validation sets 
ranked by patients' follow"up time. The optimal cut"points were determined by 
locating the brightest pixel on the X"tile plot diagram of the training set and 
dichotomised the scoring into "low P"FAK" (H score <30) and "high P"FAK" (H score 
>30). Statistical significance was tested, using the chi"square test, by validating the 
obtained cut"point to the validation set. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
 
 
 
 
 
 
 
 
 
 
Figure 59. P2FAK protein expression in CRC.  Immunohistochemical staining for P"FAK on TMA 
sections of CRC (x200), demonstrating (a) moderate P"FAK nuclear staining and (b) moderate 
cytoplasmic and nuclear staining. (c) Negative control. 
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6.5.1.2 Association of P2FAK expression with clinicopathological parameters 
Analysis of positively stained P"FAK cases revealed that there was no significant 
association between the level of P"FAK nuclear expression and known 
clinicopathological variables, including tumour histological type, tumour grade, 
tumour site, TNM staging, LN metastasis, VI and DM (Table 8). In contrast, P"FAK 
cytoplasmic expression within the malignant tumours, was significantly associated 
with DM (p=0.02; chi"square test) and showed an inverse association with a trend 
toward TNM staging (p=0.05; chi"square test), LN metastasis (p=0.07; chi"square test) 
and VI (p=0.09; chi"square test). However, no significant association was noticed 
between P"FAK cytoplasmic expression and tumour histological type, tumour grade 
and tumour site (Table 8).  
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Table 8. Association of P2FAK cytoplasmic and nuclear expressions with clinicopathological features. No significant association was found between P"FAK nuclear 
expression and known clinicopathological variables. In contrast, high P"FAK cytoplasmic expression was significantly associated with DM and showed an inverse association 
with a trend toward TNM, LN metastasis and VI. 
'ote: If the total number of cases in a given parameter did not add up to 155 (nuclear P"FAK) or 79 (cytoplasmic P"FAK), this indicates that there were no data available for 
the missed cases of each specific factor. 
 
Parameter 
 
Low P2FAK  
'uclear 
 
High P2FAK  
'uclear 


2
 

p 

Total 
'o. 
 
Low P2FAK  
Cytoplasmic 
 
High P2FAK  
Cytoplasmic 
 

2
 
 
p 

Total 
'o. 
 
Tumour histological type 
          
  Adenocarcinoma 74 (86%) 57 (88%) 2.450 0.351 151 14 (82.4%) 48 (84.2%) 4.540 0.102 74 
  Non"adenocarcinoma 12 (14%) 8 (12%)    3 (17.6%) 9 (15.8%)    
Tumour grade           
  Well differentiated 4 (4.9%) 6 (9%) 3.867 0.137 148 1 (5.8%) 7 (12.3%) 3.874 0.126 74 
  Moderately differentiated 65 (79.3%) 51 (77.3%)    14 (82.4%) 43 (75.4%)    
  Poorly differentiated 
Tumour site 
13 (15.8%) 9 (13.7%)    2 (11.8%) 7 (12.3%)    
  Colon 41 (52.5%) 34 (55%) 0.806 0.852 140 11 (65%) 27 (50%) 2.463 0.348 71 
  Rectum 37 (47.5%) 28 (45%)    6 (35%) 27 (50%)    
T'M stage           
  0 (Tis) 1 (1.2%) 0 (0%) 1.318 0.574 148 2 (10%) 13 (22%) 7.847 0.057 78 
  1 13 (15.8%) 10 (15%)    6 (30%) 25 (43.7%)    
  2 34 (41.5%) 23 (35%)    6 (30%) 15 (25.8%)    
  3 
  4 
L' stage 
26 (31.7%) 
8 (9.8%) 
23 (35%) 
10 (15%) 
   4 (20%) 
2 (10%) 
4 (6.8%) 
1 (1.7%) 
   
  0 49 (63%) 34 (53.2%) 4.536 0.104 142 8 (47%) 39 (71%) 6.819 0.071 72 
  1 17 (21.7%) 15 (23.4%)    4 (23.5%) 8 (14.5%)    
  2 
VI 
12 (15.3%) 15 (23.4%)    5 (29.5%) 8 (14.5%)    
  Negative 55 (65%) 43 (65.2%) 0.730 0.871 151 11 (58%) 44 (73.3%) 5.382 0.096 79 
  Positive 30 (35%) 23 (34.8%)    8 (42%) 16 (26.7%)    
DM           
  Negative 77 (90.6%) 56 (85%) 2.936 0.235 151 18 (69.3%) 27 (51%) 9.165 0.021 79 
  Positive 8 (9.4%) 10 (15%)    8 (30.7%) 26 (49%)    
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6.5.1.3 Association of P2FAK expression with patients’ outcome 
Univariate survival analyses showed that patients with high P"FAK nuclear expression 
had shorter DFS than those with low P"FAK nuclear expression (p=0.005; log"rank 
test, Figure 60 a). In addition, multivariate Cox proportional hazard analysis revealed 
that P"FAK nuclear positivity was a predictor of shorter DFS (p=0.016; log"rank test, 
Table 9) independent of TNM staging and vascular invasion. Unexpectedly, Kaplan"
Meier analyses showed that patients with high P"FAK cytoplasmic expression had 
better survival than those with low P"FAK cytoplasmic expression (p=0.001; log"rank 
test, Figure 60 b). 
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Figure 60. Kaplan2Meier plot for DFS in relation to expression of nuclear and cytoplasmic P2
FAK. (a) Patients with high nuclear P"FAK have a significantly shorter DFS than patients with low 
nuclear P"FAK (p=0.005, log"rank test). In contrast, (b) patients with high P"FAK cytoplasmic 
expression had better survival than those with low P"FAK cytoplasmic expression (p=0.001, log"rank 
test). 
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Table 9. Cox2proportional hazard analysis for predictors of DFS and P2FAK cytoplasmic and 
nuclear expression. Multivariate Cox hazard analysis including TNM, VI and P"FAK cytoplasmic and 
nuclear expressions shows that P"FAK nuclear expression was an independent predictor of DFS in CRC 
(hazard ratio 1.129, 95% CI 0.763–2.126, p=0.016). 
 
 
Parameter 
 
Hazard ratio 
 
95% CI 

pvalue 
 
Disease free Survival 
   
   
  TNM stage 
 
1.839 
 
1.582–2.251 
 
<0.001 
 
  VI 
   
  P"FAK nuclear expression 
 
  P"FAK cytoplasmic expression 
 
1.431 
 
1.129 
 
1.024 
 
1.043–2.152 
 
0.763–2.126 
 
0.524–2.011 
 
  0.002 
 
  0.016 
 
  0.804 
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6.5.2 Cten and FAK interaction 
Since tensin family proteins interact with FAK, we focused on FAK as another 
potential downstream signalling molecule for Cten in CRC. Therefore, the effect of 
Cten on FAK level was examined. Forced expression of Cten in HCT116 cells resulted 
in an increase of FAK and P"FAK levels (Figure 61). Knock"down of Cten in SW620 
cells confirmed the results obtained by over"expression studies. Western blot analysis 
from SW620 cells transfected with control siRNA showed high FAK and P"FAK 
levels in comparisons to cells transfected with Cten siRNA (Figure 62).  
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Figure 61. Effect of Cten forced expression on FAK and P2FAK protein expression levels. Western 
blots showed that forced expression of Cten in HCT116 cells resulted in an increase expression of FAK 
and P"FAK proteins. β"actin was used as a loading control. 
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Figure 62. Effect of Cten knock2down on FAK and P2FAK protein expression levels. Knock"down 
of Cten in SW620 cells, showed high FAK and P"FAK levels in control SW620 cells compared to cells 
transfected with Cten siRNA. β"actin was used as a loading control. 
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6.6 Cten and CD24 expression 
CD24 is a small 80 amino acids"spanning heavily glycosylated mucin"like glycosyl"
phosphatidylinositol (GPI)"linked cell surface protein. Previous studies have been 
reported CD24 to be over"expressed in a wide variety of tumours, including non"small 
cell lung cancers, pancreatic and gastric adenocarcinomas, ovarian cancer, CRC and 
BC and, in general, its over"expression has been associated with poor prognostic 
outcomes (174"178). It has been reported that CD24 has regulatory and recruitment 
effects on β1 integrin proteins, as it induces the lateral localisation of β1 integrins into 
lipid raft domains (225), hinting that CD24"mediated effects on cell motility may 
depend on the β1 integrin subunit. The close localisation of Cten at the cytoplasmic tail 
of β1 integrin prompted us to investigate the relationship between CD24 and Cten. 
Western blot analysis of the HCT116 cell line (expressing low levels of both CD24 
and Cten) stably transfected with pCDN6"CD24 (182) showed no effect on Cten 
expression in comparison to HCT116 cells (Figure 63 a). However, western blot 
analysis of HCT116 cells stably transfected with GFP"Cten, showed increased levels 
of CD24 compared to GFP vector control cells (Figure 63 b). Moreover, SW620 cells 
transfected with Cten siRNA contained lower CD24 levels than siRNA scrambled 
control cells (Figure 63 b).  
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Figure 63. Cten and CD24 protein expression. Western Blot for Cten and CD24 proteins shows that, 
in the same cell lines, forced expression of Cten was associated with up"regulation of CD24 
(glycosylated pattern) but not the vice versa. In addition, Cten knocked"down in SW620 cell line 
resulted in down"regulation of CD24 compared to siRNA scramble control. Positive controls shown in 
the top panel represent HCT116 and SW480 cells transfected with GFP"Cten. β"actin was used as a 
loading control. The bands may seem overexposed due to the high quantity of protein loaded in order to 
detect CD24 (see materials and methods) 
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Given the CD24"regulatory effect on the β1 integrin subunit where ILK and FAK are 
localised as well as the induction effect of Cten on CD24 levels, we hypothesised that 
Cten may function through CD24 signalling. To test this hypothesis, knock"down of 
CD24 in HCT116 cell line stably transfected with GFP"Cten was carried out and a 
significant decrease regarding both cell migration and invasion was observed in the 
absence of Cten in comparison to control cells (p<0.001 for both; Student’s t"test, 
Figure 64 a, b). Furthermore, Western Blot analysis showed that CD24 knock"down 
was associated with up"regulation of E"cadherin and down"regulation of ILK and FAK 
proteins, indicating that CD24 lies downstream of Cten in CRC and that Cten"
mediated effects on cell motility and E"cadherin, ILK and FAK levels may be CD24"
dependent (Figure 65). 
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(a) 
 
 
 
 
 
 
 
 
 
(b) 
 
Figure 64. Cten functional relationship with CD24 protein. Knock"down of CD24 in HCT116 cell 
line stably transfected with GFP"Cten showed a significant decrease in both (a) cell migration and (b) 
invasion assays (p< 0.001; Student’s t"test). 
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Figure 65. CD24 involovment in Cten signalling pathway. Western Blot analysis showed that CD24 
knock"down in Cten stably transfected HCT116 cells was associated with up"regulation of E"cadherin 
and down"regulation of ILK and FAK proteins. β"actin was used as a loading control. The bands may 
seem overexposed due to the high quantity of protein loaded in order to detect FAK, ILK and E"
cadherin proteins (see materials and methods) 
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6.7 Analysis of Cten and P2FAK expression in metastatic CRC  
The data from the invitro experiments led us believe that ILK and P"FAK were 
downstream targets of Cten. We sought to validate this by examining the expression 
levels of these proteins in tissue samples by IHC. Attempts of IHC with the 
commercially available antibodies for ILK were unsuccessful. Immunohistochemical 
expression of Cten and P"FAK was examined in a series of 40 matched samples of 
primary colorectal adenocarcinomas and corresponding liver metastases arrayed as 
tissue microarrays  (provided by our group). The level of staining was evaluated using 
the H"score system. The tissue microarrays showing no or weak staining (H"score <30) 
were classed as negative, those showing moderate or strong staining (H"score >30) 
were counted as positive. Evaluation of all the cases (i.e. both primary tumours and 
metastases) revealed a highly significant difference between levels of P"FAK 
expression in the primary and metastatic cases (p=0.001; chi"square test). There was 
no significant association between Cten expression and P"FAK expression in primary 
tumours (p=0.491; chi"square test), but interestingly, we found a highly significant 
association between nuclear Cten expression and P"FAK expression in hepatic 
metastases cases (p<0.001; chi"square test). One of 14 (2%) in the negative P"FAK 
expression group showed Cten positive immunoreactivity. In comparision, 14 of 26 
(98%) in the positive P"FAK expression group had Cten positive immunoreactivity 
(Figure 66, Table 10).  
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Figure 66. P2FAK protein expression in primary tumour samples and their corresponding liver 
metastasis. Positively stained tissue microarrays from the same sections showed a positive correlation 
between Cten expression and P"FAK expression in hepatic metastases cases. 
 
 
 
Table 10. Association between Cten expression and P2FAK expression in hepatic metastases cases. 
Positive significant association was found between nuclear Cten expression and P"FAK expression in 
hepatic metastases cases (p<0.001; chi"square test). 
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6.8 Discussion 
The molecular basis of Cten"mediated effects on cell migration and EMT is still under 
investigation. In the current study, we have shown that, in both CRC cell lines, Cten 
forced expression and knock"down was associated with down"regulation and up"
regulation of E"cadherin protein expression, respectively. This suggests that Cten is 
important in the regulation of cell motility through E"cadherin"dependent mechanisms. 
A growing body of evidence has reported loss of E"cadherin expression in advanced 
CRC (226) and interestingly, experiments used to silence the expression of E"cadherin 
not only showed a morphological shift from an epithelial to mesenchymal phenotype, 
characteristic of EMT, but also a concomitant increase in invasive cell behaviour 
(227). 
 
The close localisation of ILK with Cten at the cytoplasmic site of integrin molecules 
raises the possibility that the Cten"mediated effect on cell migration and E"cadherin 
expression signals via this molecule. It has been shown that ILK expression is elevated 
in a variety of cancers including CRC and the levels of expression were significantly 
higher in invasive than non"invasive lesions (228). Over"expression of ILK in normal 
breast epithelial cells results in down"regulation of E"cadherin expression, possibly 
through activation of the E"cadherin repressor Snail. In correlation with that, the ILK"
over"expressing cells also become invasive, reorganise cortical actin into cytoplasmic 
stress fibers, and switch from an epithelial cytokeratin positive to a mesenchymal 
vimentin intermediate filament phenotype, suggestive of a role for ILK in EMT, which 
is a hallmark of cancer progression to an increasingly malignant phenotype (163). The 
present study has shown that Cten"forced expression and knock"down in CRC cell 
lines resulted in up"regulation and down"regulation of ILK respectively, indicating that 
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Cten"mediated effect on cell migration and E"cadherin expression may signal directly 
or indirectly via ILK. Attempts of IHC with the commercially available antibody for 
ILK (ab2283, Abcam, UK) were unsuccessful. Two different immunohistochemical 
antibody detection Kits (ABC and EnVision kits, kindly provided by Prof. Ian Ellis, 
Division of Pathology, University of Nottingham, UK) were used and in each one we 
tried different dilutions of ILK antibody in order to optimise the optimal condition for 
ILK antibody to work. However, each time we found non"spescific background 
staining masking the ILK cytoplasmic staining.  
 
The expression and phosphorylation of the non"receptor tyrosine kinase FAK has been 
shown to correlate with epithelial to mesenchymal changes occurring in tumours 
during their progression to an invasive phenotype (229). In addition, FAK influences 
the sensitivity of tumour cells to chemotherapy, and combination of antisense 
oligonucleotide inhibitors of FAK with cytotoxic agents might be a promising anti"
cancer therapy (230). Given that, we sought to investigate the utility of P"FAK as a 
prognostic marker in CRC in a large and well"characterised cohort of CRC cases. 
Using IHC we were able to detect the expression of P"FAK protein in the nucleus in 
44% of tumours. This is similar to published data which have found 45% CRCs 
showing positive P"FAK expression (231). In the current study population nuclear P"
FAK expression was not related to any of the clinicopathological parameters 
examined. However, univariate and multivariate analysis of our population showed 
that high expression of nuclear P"FAK in CRC had a poor prognostic impact on 
patients’ outcome. Nuclear expression of P"FAK has also been reported in other 
studies and Ssang"Taek et al found that FAK may limit p53 activity through the FAK 
N"terminal FERM domain through directly interacting and suppressing transcriptional 
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activation of a number of p53 target genes including p21, Mdm2 and Bax. The latter 
molecules are important mediators of p53"induced apoptosis, which would propose an 
anti"apoptotic effect of nuclear FAK through a FERM"domain"initiated pathway (114). 
 
Cten co"localises with paxillin in focal adhesions and is involved in mediating the 
metastatic potential of mammary tumours (30). Cten contains a SH2 and PTB 
domains, both of which have been shown to be involved in protein"protein interactions 
(5, 11, 14). FAK has also been reported to localise to focal adhesions via its interaction 
with paxillin (91) thus some interaction between Cten and P"FAK may be expected. 
We have shown earlier that Cten regulates cell migration and invasion and our data 
here show that Cten also appears to regulate FAK and P"FAK in CRC cell lines. This 
suggests that Cten may mediate cell motility through FAK. In order to test whether this 
may occur in tumour tissue, we evaluated Cten and P"FAK proteins expression in a 
series of paired primary CRC and hepatic metastases. In agreement with previous 
studies we found similar levels of P"FAK in primary and metastatic deposits (232, 
233). Comparison of the Cten and P"FAK immunostaining showed that they were 
highly correlated thereby supporting the observations we have made in the cell lines.  
 
It has been shown in a previous study that CD24 promotes cell motility in a β1 
integrin"dependent manner. Analysis of the results of cell migration and invasion 
assays in A125 and MDA"MB"435S cells, stably transfected with CD24 or an empty 
pcDNA3.1 vector demonstrated that cells expressing CD24 migrated and invaded 
across an endothelial monolayer significantly faster than the control cells. In addition 
antibody"mediated blocking of β1 integrin interaction significantly reduced the 
migration of the CD24"transfectants, while it had no effect on the motility of the 
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CD24"negative control cells (225). Given that and the finding that CD24 can induce 
the lateral localisation of β1 integrins into lipid raft domains where it regulates its 
function and activity, we hypothesised that CD24 may be involved in the Cten 
signalling pathway and Cten"mediated effects on cell motility may rely on CD24. The 
present study has shown that Cten"forced expression and knock"down in CRC cell 
lines resulted in up"regulation and down"regulation of CD24 respectively and 
inhibition of CD24 abrogated the effects of Cten on cell motility indicating a 
functional relationship between these two proteins. In agreement with this, knock"
down of CD24 was associated with up"regulation of E"cadherin and down"regulation 
of ILK and FAK proteins, again indicating that CD24 lies downstream of Cten and the 
Cten"mediated effects on cell motility and E"cadherin, ILK, and FAK levels depend on 
CD24. These data are summarised in Figure 69.  
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Figure 67. A model representing the role of Cten in cancer metastasis. Having shown that 
manipulation of Cten protein in CRC cell lines was mirrored by similar changes in CD24 protein 
expression and inhibition of CD24 abrogated the effects of Cten on cell motility and E"cadherin, ILK, 
and FAK protein levels, we designed the following model suggesting the functional interaction between 
Cten and CD24 at focal adhesion and their role in cancer metastasis. In steady state, focal adhesion 
complex is stabilised and cells are attached to actin cytoskeleton through tensin. Following EGF 
stimulation, Cten is up"regulated, leads to induction of CD24 protein. Upon up"regulation, CD24 will 
lead to initiation of cell migration and colony formation by it self or it will activate ILK and FAK which 
lead to repression of E"cadherin and consequently EMT and cell migration. 
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Chapter 7. Cten expression in other tumour types 
 
7.1 Introduction 
The studies so far have shown the oncogenic role of Cten in CRC. It has been 
demonstrated that in CRC cell lines, Cten confers resistance to staurosporine"induced 
apoptosis, stimulates EMT together with migration and invasion. In addition, Cten up"
regulation in CRC patients is associated with advanced disease and poor prognosis. 
However, since Cten is a recently described gene, data about its regulation are sparse.  
In BC, Cten is positively regulated by c"Erb"B2 protein (30) – this is over"expressed in 
a specific subset of breast cancers due to gene amplification and is a part of the EGFR 
signalling pathway. The EGFR pathway signals through Kirsten rat sarcoma viral 
oncogene homolog (K"Ras) and although EGFR/c"Erb"B2 amplifications are rare in 
CRC, gain"of"function mutations in K"Ras are extremely common and are seen in up 
to 60% of tumours (208, 234). The K"Ras gene encodes a 21"kDa small protein that is 
activated in response to several factors, such as extracellular hormones, growth factors 
and cytokines and serves as a molecular switch converting signals from receptor and 
non"receptor tyrosine kinases to downstream cytoplasmic or nuclear events. These 
chemical signals lead to protein synthesis and regulation of variuos cellular processes, 
such as cell adhesion, survival, proliferation, apoptosis and differentiation (235). This 
prompted investigation of Cten expression in BC and correlation of that with the 
prognostic criteria. Since pancreatic cancer is characterised by a K"Ras mutation 
frequency of around 80% (236), it was decided to investigate this tumour too.    
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7.2 Evaluating the expression and the role of Cten in BC 
7.2.1 Cten expression in BC 
After excluding the uninformative TMA cores (220) from the study, which were either 
lost, folded, fragmented or did not have invasive tumour tissue, 1,500 tumours were 
available for Cten immunostaining assessment. The staining pattern for Cten in breast 
tumour cells was homogenous cytoplasmic staining (Figure 68). In the whole series, 
1,409/1,500 (93%) of the tumours showed expression for Cten. In contrast, no nuclear, 
cell membrane or stromal expression of Cten was detected in any tumour specimen. 
Normal breast epithelium entrapped in some cores did not show any Cten staining 
(Figure 68). The X"tile bio"informatics software was used to define optimal cut"off 
points of Cten H"score values (<85, negative/low; ≥85, moderate/strong expression) as 
described earlier in chapter 4. 
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Figure 68. Cten protein expression in normal and BC TMA cores:  (A, x100 and B, x200) normal 
breast showing negative Cten expression. (C, x100 and D, x200) low grade invasive ductal carcinoma 
with moderate Cten expression. (E, x100 and F, x200) high grade invasive ductal carcinoma showing 
strong Cten expression.   
A B 
C D 
E F 
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7.2.2 Correlation between Cten expression and clinicopathological parameters 
 
Table 11 summarises the associations between Cten expression and clinicopathological 
parameters. Cten expression was significantly associated with larger tumour size 
(p=0.035; chi"square test), higher tumour grade (p=0.023; chi"square test), axillary LN 
metastasis (p=0.016; chi"square test) and higher NPI (p=0.023; chi"square test). A 
significant association (p=0.017; chi"square test) was found between Cten expression 
and the histological tumour type with frequent expression in invasive ductal carcinoma 
of no special type, and lobular carcinoma showing high levels of Cten expression (98% 
and 100%, respectively). Furthermore, there was a significant association between 
increased Cten expression and phosphorylated"Akt (P"Akt), PIK3CA and N"cadherin 
(p<0.001; chi"square test). However, Cten expression was not significantly associated 
with patients’ age, menopausal status, VI, p53, human epidermal growth factor 
receptor 2 (HER2), EGFR, ER, Mindbomb homolog 1 (MIB1) and breast cancer1, 
early onset (BRCA1) expression or any of Nielson’s group subtypes (Table 12). 
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Table 11. Correlations between Cten expression and clinicopathological parameters. High Cten 
expression was associated with advanced disease and poor prognostic features. 
 
 
 
Parameter 
 
Low Cten 'o.(%) 
 
High Cten 'o. (%) 


2
 

p value 
 
Age 
    
  <50 47 (9.4%) 451 (90.6%) 2.047 0.152 
  >50 66 (7.3%) 842 (92.7%)   
 
Menopausal status 
    
   Premenopausal 52 (9.9%) 475 (90.1%) 3.820 0.064 
   Postmenopausal 61 (6.9%) 
 
818 (93.1%)   
Tumour size     
  <1.5 cm 80 (9.2%) 791 (90.8%) 4.254 0.044 
  >1.5 cm 29 (5.1%) 501 (94.9%)   
 
Lymph 'ode stage 
    
  1 ( Negative) 82 (9.8%) 787 (90.2%) 5.842 0.035 
  2/3 (Definite) 21 (4.6%) 602 (96.4%)   
 
Grade 
    
  1   30 (12.2%) 215 (87.8%) 7.555 0.019 
  2 38 (7.9%) 445 (92.1%)   
  3 45 (6.7%) 629 (93.3%)   
 
'PI 
    
 Good (<3.4)   45 (10.1%) 402 (89.9%) 7.578 0.016 
 Moderate (3.41–5.4) 59 (8.1%) 671 (91.9%)   
 Poor (4.41–5) 9 (4%)               218 (96%)   
 
VI 
    
  Negative 81 (10%) 722 (90%) 1.185 0.286 
  Definite  42 (9.2%)     411 (90.8%)   
 
Local recurrence  
    
  Negative   49 (12.1%) 381 (87.9%) 5.211 0.039 
  Positive 75 (9.1%) 822 (90.9%)   
 
Regional recurrence 
    
  Negative   45 (10.1%) 442 (90.8%) 4.778 0.042 
  Positive 35 (6.7%) 769 (93.3%)   
 
DM 
    
  Negative 80 (9.4%) 791 (90.6%) 4.780 0.041 
  Positive 36 (5.2%) 499 (94.8%)   
 
Histological type  
    
  Ductal/NST               55 (7%)               735 (93%) 7.634 0.012 
  Lobular 10 (7.4%) 148(92.6%)   
  Tubular  mixed 21 (11.3%) 229 (88.7%)   
  Medullary     5 (13.2%)    33 (86.8%)   
  Other special types               14 (20%) 56 (80%)   
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Table 12. Correlations between Cten expression and other biomarkers. High Cten expression was 
significantly associated with PR (p=0.016; chi"square test), P"Akt, PIK3CA and N"cadherin proteins 
(p<0.001; chi"square test) and showed a trend toward P"cadherin (p=0.085; chi"square test). 
 
Parameter 
 
Low Cten 'o.(%) 
 
High Cten 'o. (%) 


2
 

pvalue 
 
ER 
    
  Negative 24 (7.0%) 319 (93.0%) 0.650 0.477 
  Positive 68 (8.4%) 
 
741 (91.6%)   
PR     
  Negative 32 (5.7%) 525 (94.3%) 6.119 0.016 
  Positive 70 (9.5%) 668 (90.5%)   
 
AR 
    
  Negative 27 (8.0%) 315 (91.0%) 0.669 0.457 
  Positive 58 (7.4%) 731 (93.6%)   
 
HER2 
    
  Negative 99 (8.4%)             1,084 (91.6%) 1.623 0.654 
  Positive 11 (5.9%) 174 (94.1%)   
 
EGFR 
    
  Negative 70 (7.6%) 855 (92.4%) 0.022 0.890 
  Positive 18 (7.9%) 211 (92.1%)   
 
P53 
    
  Negative 74 (7.7%) 889 (92.3%) 0.092 0.814 
  Positive 25 (7.2%) 323 (92.8%)   
 
E2cadherin              
    
  Negative 35 (6.9%) 471 (93.1%) 0.124 0.345 
  Positive 69 (8.5%) 739 (91.5%)   
 
P2cadherin              
    
  Negative 47 (9.2%) 465 (90.8%) 5.147 0.058 
  Positive 37 (6.3%)          548 (93.7%)   
 
'2cadherin              
    
  Negative   72 (11.1%) 578 (88.9%) 26.91 <0.001 
  Positive 11 (2.5%) 424 (97.5%)   
 
PIK3 
    
  Negative    46 (14.2 %)  278 (85.8%) 37.22 <0.001 
  Positive   41 (4.3 %)   911 (95.7 %)   
 
P2Akt 
    
  Negative                55 (10.2%)              551 (87%) 27.23 <0.001 
  Positive 14 (2.5%)  427 (97.5%)   
       
MIB1     
  Low proliferative      38 (9.8%) 348 (90.2%) 2.567 0.131 
  High proliferative   51 (7.1%) 668 (92.9%)   
       
'ielsen groups     
  Luminal 74 (8.4%) 804 (91.6%) 2.053 0.562 
  HER2   12 (6.2%) 183 (93.8%)   
  Basle"like                  3 (4.8%)    60 (95.2%)   
 
An investigation of the role of C"terminal tensin"like (Cten) gene in colorectal cancer   
Results 
 
160 
7.2.3 Correlation between Cten expression and patients’ outcome 
Kaplan"Meier plotting demonstrated that patients with high Cten expression had 
significantly poorer prognosis than those with low Cten expression. Moreover, Cten 
expression was associated with an increased likelihood to develop DM (p=0.041; chi"
square test), but this was not significantly associated with any particular metastatic 
site. Univariate survival analyses showed that patients with tumours positive for Cten 
had shorter BCSS (p=0.004; log"rank test, Figure 69). Positive expression of Cten also 
showed association with a shorter DFI (p=0.041; log"rank test, Figure 69). However, 
multivariate Cox proportional hazard analysis including tumour size, histological 
grade, LN stage, adjuvant hormonal, chemotherapy and Cten expression showed that 
Cten expression was not an independent predictor of BCSS and DFI (p=0.213, 
p=0.874 respectively) (Table 13). 
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(a) 
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(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69. Kaplan2Meier plot for BCSS and DFI in relation to expression of cytoplasmic Cten. 
Kaplan–Meier plots showed that patients with tumours positive for Cten had shorter (a) BCSS (p=0.004) 
and (b) shorter DFI (p=0.041). All surviving patients were censored after 250 months follow"up 
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Table 13. Cox2proportional hazard analysis for predictors of BCSS, DFI and Cten expression. 
Multivariate Cox hazard analysis including tumour grade, size, LN stage and Cten expression shows that 
Cten expression was not an independent predictor of BCSS and DFI in BC (p=0.213; hazard ratio 1.379, 
95% CI 0.832–2.287, p=0.874; hazard ratio 1.034, 95% CI 0.681–1.571, respectively). 
 
 
 
Parameter 
 
Hazard ratio 
 
95% CI 

pvalue 
 
BCSS 
   
   
  Tumour size 
 
1.328 
 
1.181–1.493 
 
<0.001 
   
  Nodal stage 
 
  Tumour grade 
 
1.874 
 
2.106 
 
1.600–2.196 
 
1.745–2.542 
 
<0.001 
 
<0.001 
 
  Chemotherapy 
 
  Endocrine therapy  
 
0.679 
 
0.924 
 
0.511–0.901 
 
0.845–1.011 
 
  0.007 
 
  0.084 
 
  Cten expression 
 
1.379 
 
0.832–2.287 
 
  0.213 
 
 
DM2free interval 
   
   
  Tumour size 
 
1.408 
 
1.254–1.581 
 
<0.001 
 
  Nodal stage 
 
  Tumour grade 
 
1.899 
 
1.682 
 
1.633–2.208 
 
1.425–1.987 
 
<0.001 
 
<0.001 
 
  Chemotherapy 
 
  Endocrine therapy  
 
0.673 
 
0.931 
 
0.513–0.883 
 
0.856–1.012 
 
  0.004 
 
  0.093 
 
  Cten expression 
 
1.034 
 
0.681–1.571 
 
  0.874 
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7.3 Evaluating the expression of Cten in pancreatic cancer  
It has been shown that in BC, Cten is a downstream target of EGFR signalling and 
these studies shown that other EGFR downstream targets, P"Akt and PIK3CA, are 
significantly associated with increased Cten expression.  Since these molecules are up"
regulated in pancreatic cancer (237, 238), this prompted us to evaluate the expression 
of Cten using IHC in a large well"characterised pancreatic cancer series, containing 
normal, benign and malignant pancreatic tissues in order to explore Cten’s biological 
significance in pancreatic cancer. 
 
Our study showed that 31/44 (65%) of tumours expressed moderate"stong levels of 
Cten in the cytoplasm (Figure 70 a). In contrast, no tumour cell membrane, nuclear or 
stromal expression of Cten was noticed in any of the examined cases. Similarly, 
chronic pancreatitis and normal pancreatic tissues were also showed complete lack of 
the Cten expression (Figure 70 b, c). These data clearly suggested that Cten may play a 
role during pancreatic carcinogenesis. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 70. Cten immunostaining non2neoplastic pancreatic diseases and pancreatic cancer. 
Immunohistochemical staining for Cten on TMA sections demonstrating a strong expression in (a, x100) 
pancreatic ductal adenocarcinoma and a complete lack of staining in chronic pancreatitis (b, x100) and 
normal pancreatic epithelium (c, x100).  
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7.4 Discussion 
In breast tissue, Cten is regulated by the EGFR and appears to exist in a relationship of 
mutual exclusivity with TNS3 at focal adhesions. Treatment of the normal human 
mammary cell line MCF10A with EGF appears to induce expression of Cten, thereby 
causing a switch from TNS3 to Cten at focal adhesions. This stimulates migration 
through disruption of the link between integrins and cortical actin fibres (30). As an 
increase in motility and migration are indispensable components of tumour growth and 
metastatic spread (239), this prompted us to investigate the level of Cten expression in 
BC and correlate that with the prognostic criteria, in order to evaluate if Cten has any 
prognostic implication in BC. 
 
In this study, the expression of Cten protein was assessed using IHC in a large, well"
characterised cohort of BC cases, to evaluate its potential biological and prognostic 
relevance. We found that Cten expression was significantly associated with poor 
prognostic clinicopathologic parameters, including larger tumour size, higher tumour 
grade, axillary LN metastasis and poor NPI. Moreover, our data showed that Cten was 
more frequently over"expressed in invasive duct carcinoma NST and invasive lobular 
carcinoma, histological types known to be associated with poor prognosis (240).  
 
In agreement with our findings in CRC that Cten changed cell morphology and 
increased cell motility through repression of E"cadherin protein, we have found a 
significant association, in the BC study, between Cten expression and lobular 
carcinoma that is known to be associated with loss of E"cadherin expression (241). 
Although, Cten expression did not show a significant association with E"cadherin 
protein expression in this series, there was a significant association with N"cadherin 
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and a trend of positive association with P"cadherin expression; markers which have 
been reported to be frequently over"expressed in high"grade invasive breast 
carcinomas, conferring an increased motility of BC cells and being associated with 
tumour aggressiveness (242, 243). A growing body of evidence has shown that 
decreased expression of E"cadherin does not necessarily lead to induced cell motility 
in BC cells. In addition, forced expression of E"cadherin in invasive, N"cadherin"
expressing MDA"MB"435 cells does not reduce their motility or invasive capacity. 
However, forced expression of N"cadherin in non"invasive, E"cadherin"positive BT"20 
cells confers the capacity to invade, even though they continued to express high levels 
of E"cadherin (244). Taken together, these data demonstrate that BC invasiveness 
might be correlated with N"cadherin expression rather than lack of E"cadherin 
expression as reported in CRC (244).  
 
Our findings are in agreement with previous studies showing association between Cten 
and both high tumour grade and the ability to metastasise to axillary LN (30). 
Moreover, we showed that patients with Cten over"expressing tumours had shorter 
BCSS and distant metastasis"free interval, supporting the oncogenic role of Cten in 
BC. However, our data showed that Cten expression was not significantly associated 
with increased expression of HER2, EGFR and ER as shown previously (30). This 
discrepancy may be due to the variations in the number of cases involved in both 
studies. They investigated a relatively small cohort (n=272) of primary breast tumours 
compared to the number of cases (n=1,409) assessed in this study.  
 
Having shown that Cten is a downstream target of EGFR signalling in BC and, since 
the EGFR and its downstream targets P"Akt and PIK3CA and up"regulated in 
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pancreatic cancer (237, 238), we hypothesised that Cten may have a role in pancreatic 
cancer. To test this hypothesis, Cten protein expression was evaluated using IHC in a 
large well"characterised pancreatic cancer TMA series, containing normal, benign and 
malignant pancreatic tissues in order to evaluate Cten’s biological significance in 
pancreatic cancer. 
 
Our study showed that 65% of tumours showed positive Cten cytoplasmic expression. 
In contrast, no tumour cell membrane, nuclear or stromal expression of Cten was 
noticed in any of the examined cases. Similarly, chronic pancreatitis and normal 
pancreatic tissues were also showed complete lack of the Cten expression. These data 
clearly suggest that Cten may play a role during pancreatic carcinogenesis. Recently, 
we have reported that Cten is expressed in certain pancreatic cell lines. Forced 
expression of Cten in Panc"1 (a pancreatic cancer cell line with low Cten expression) 
and knockdown in PSN"1 (a pancreatic cancer cell line showing high Cten expression) 
did not alter cell proliferation but were associated with enhanced and suppressed 
colony forming, transwell migration and invasion abilities respectively. Both of these 
observations were consistent with findings in CRC (data submitted for publication). 
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Chapter 8. General discussion and future outlook 
In this thesis, we have characterised the expression and biological role of Cten in the 
colon, especially during the development of CRC. Expression of Cten was tested by 
IHC whilst the biological role of Cten was tested in CRC using both invivo and in
vitro models. For functional studies, a dual approach was used in order to avoid 
inaccurate conclusions from “off target” effects of gene knock"down and non"specific 
effects of forced expression. Concordance of the data using these two different 
methodologies was taken to signify a credible result. The potential downstream 
signalling targets for Cten were explored through evaluating the relationships between 
Cten expression and other secondary molecules associated with cancer metastasis, 
such as CD24, ILK, FAK and P"FAK in both CRC cell lines and tissue samples. 
Finally, having found it to be functionally important in CRC, we were prompted to 
look in other organs. We investigated the level of Cten expression in BC and 
pancreatic cancer and correlated that with the prognostic criteria in order to explore the 
biological and signalling implications of Cten expression in those organs. 
 
Published data would suggest that the activity of Cten is probably context"dependent 
and may vary in tumours of different origin. The role of Cten in CRC is currently 
unknown. Tumours usually follow a well established pattern of early non"invasive 
adenomatous growth, succeeded by the ability to invade locally into the adjacent 
tissues and ultimately by acquisition of metastatic features. The mechanisms by which 
tumour cells acquire the ability to invade and metastasize are unclear, although many 
consider that these processes require disruption of cell–cell and cell–matrix adhesion 
and EMT.  
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Cten has no actin binding domain and thus when it is present it breaks the connection 
between the integrins and the actin cytoskeleton. It could therefore be expected to 
increase motility and this is what we found. Our data showed that in HCT116 and 
SW480 (cell lines shown to have low Cten expression), Cten ectopic expression 
significantly promotes both cell migration and invasion. The Cten"mediated effects on 
cell motility were further tested using RNA interference to knock down Cten in the 
CRC cell line SW620. This cell line expresses high levels of endogenous Cten and 
knock"down of Cten resulted in inhibition of cell migration. Since Cten has no effect 
on tumour growth, these data clearly suggest that, when acting as an oncogene in CRC, 
Cten
’
s role may lie more in positively regulating both cell migration and invasion 
rather than tumour growth. Our data are in agreement with studies by Liao et al, who 
found that MDA"MB"468 human mammary cells stably transfected with GFP and 
GFP"Cten plasmids grew at the same rate, suggesting that forced expression of Cten 
did not appear to alter cell proliferation (40). In addition, he reported that, in CRC cell 
lines, forced Cten expression and knock"down was associated with enhanced and 
suppressed transwell cell migration and invasion abilities respectively (207). Thus 
Cten is a motility associated molecule, its up"regulation in IBDs may aid the gut 
healing process and epithelial restitution. 
 
Physiologically perhaps Cten helps to integrate events in integrin and cadherin 
mediated adhesion to allow cell motility to occur. It certainly connects the two 
different types of adhesion molecules and both types of junctions (focal adhesions and 
adherens junctions) need to be broken down for motility. In cancer, Cten gives these 
properties to facilitate invasion and metastasis as our experiments have shown. In fact, 
the current study, evaluating the immunohistochemical expression of Cten in CRC, 
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indicated that high Cten expression was significantly associated with biological 
aggressiveness observed, including advanced Duke’s stage, LN metastasis, extra"mural 
VI and DM. Kaplan–Meier survival analysis demonstrated that patients with high Cten 
expression had significantly shorter DFS than those with low"Cten expression. In 
addition, we also have shown that high Cten expression in BC was significantly 
associated with poor prognostic variables including larger tumour size, higher 
histological grade, axillary nodal involvement and poor NPI. Our data showed that 
Cten was more frequently over"expressed in invasive duct carcinoma and invasive 
lobular carcinoma, histologic types known to be associated with aggressiveness and 
poor prognosis. Furthermore, Cten expression was significantly associated with up"
regulation of N"cadherin and there was a trend of positive association with P"cadherin 
expression; markers which have been reported to over"express frequently in high"grade 
invasive breast carcinomas, conferring an increased motility of BC cells and being 
associated with tumour aggressiveness. Kaplan"Meier survival analysis demonstrated 
that patients with high Cten expression had significantly shorter BCSS and metastasis"
free survival than those with low"Cten expression. Given the very low levels of Cten 
protein we reported in normal colonic and breast tissue epithelia, these data clearly 
confirm the dramatic up"regulation of Cten in cancer and this is associated with 
biological aggressiveness and poor prognostic outcomes. Our data showed that Cten 
expression in BC was not significantly associated with increased expression of HER2, 
EGFR and ER. These, however, contradict those of Katz et al, who reported a 
significant association between increased Cten expression and up"regulation of HER2, 
EGFR and ER proteins (30). We are uncertain of the cause for this discrepancy 
although this may be due to the variations in the number of cases involved in both 
studies (they investigated a relatively small cohort (n=272) of primary breast tumours 
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compared to our number of cases (n=1,409)) and it is of interest that, in agreement 
with our study, they found a significant association between Cten expression and both 
high tumour grade and the ability to metastasise to axillary LN (30).  
 
The data from the invitro were further confirmed by invivo experiment. Our results 
showed that compared to the controls, mice injected with cells expression GFP"Cten 
developed a significantly greater total tumour burden in the spleen. The number of 
discrete tumour deposits in the liver was similar in both groups but the size of the 
deposits was greater in mice injected with cells expression HCT116 GFP"Cten leading 
to a greater tumour burden. The data from the invitro and invivo experiments suggest 
that the motility inducing effects of Cten may contribute to tumour metastasis.  
 
The data from the invitro and invivo experiments led us to further investigate this 
association of Cten with tumour metastasis, through evaluating the Cten expression in 
a series of 40 cases of paired primary CRC and corresponding hepatic metastasis by 
IHC. Both primary and metastatic tumours showed similar levels of cytoplasmic 
staining. However, metastatic deposits were significantly associated with a shift of 
Cten expression to the nucleus, suggesting the functional implication of nuclear 
localisation of Cten and its association with tumour metastasis. The significance of 
nuclear localisation of Cten to the metastatic process is uncertain. Within the nucleus, 
it can be found in complex with β−catenin and it may thus be a modulator of Wnt 
signalling or regulate the β−catenin/T"cell factor transcriptional activity (207). Others 
have reported that Cten enhances colony formation in CRC cell lines (207) and thus 
we can conjecture that Cten mediated Wnt signalling may support stem cells in a 
foreign environment during tumour metastasis. 
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Although the above data suggest that Cten plays a role in advanced CRC, it wasn’t 
clear when Cten was up"regulated in the adenoma"carcinoma sequence. Thus we 
investigated Cten expression in tissue sections containing colorectal adenoma. Our 
data showed a consistent up"regulation of Cten in 90% of colorectal adenoma with low 
grade dysplasia, and this confirms that Cten is dramatically up"regulated in the early 
stages of colorectal tumour development. Up"regulated Cten in adenomas may seem 
bizarre at first glance since adenomas are not invasive and thus is no obvious selective 
advantage. However, adenomas can frequently be seen migrating into non"neoplastic 
crypts and this probably represents a method of adenoma growth. It may be the 
selective advantage of Cten up"regulation in the early stages of tumourigenesis. 
 
In agreement with our data, it has been reported that in thymomas and lung tumours, 
Cten functions as an oncogene with progressive up"regulation correlating with 
advanced tumour stage (56, 57). Moreover, evaluation of the expression of Cten in 
gastric cancer cases using IHC revealed that high Cten expression was significantly 
associated with poorer tumour grade, deeper invasion into the serosal layer, peritoneal 
dissemination and LN metastasis. Kaplan–Meier survival analysis demonstrated that 
patients with high Cten expression tended to show shorter survival than those with 
low"Cten expression (24).  
 
Our data show that Cten has an oncogenic behaviour in CRC, BC and pancreas whilst 
others have shown a similar role in thymomas, lung and gastric cancers. This is 
however contradictory to data published by other groups showing that Cten may have 
tumour suppressor activity in certain types of tumours. The Cten gene is localised at 
chromosome 17q21, a region frequently deleted in prostate cancer and its expression is 
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down"regulated in prostate cancer compared to normal prostate (8). In addition, 
previous studies using coimmunoprecipitation assay, show that Cten is able to interact, 
via its SH2 domain, with DLC1 protein, and may therefore enable its appropriate focal 
adhesion localisation, that is essential for DLC1's tumour suppression activity. DLC1 
is identified as a candidate tumour suppressor, that regulates actin stress fibers and cell 
adhesion and inhibits tumour cell growth and migration (55). Its expression is down"
regulated in various cancers, including liver, breast, lung, brain, stomach, colon, and 
prostate cancers. Therefore, these data indicate that down"regulation or loss of Cten 
expression may be advantageous to the development or spread of certain types of 
tumours (55). On the other hand, recruiting DLC1 to focal adhesions may not be the 
only function for cten. It is known that caspase"3 is able to cleave Cten at the 
DSTD
570
S sequence, thereby releasing a fragment, Cten 571–715, which contains the 
PTB domain and is able to reduce cell growth by inducing apoptosis through binding 
to the β
 
integrin tails and disruption of the link between integrins and cortical actin 
fibres. In this case, the loss of cten expression may lead to uncontrolled cell growth 
and result in cell transformation (40). Thus, all together these findings strongly support 
the idea that the activity of Cten is probably context"dependent and may vary in 
tumours of different origin. 
 
The observed EMT and the altered cell motility following forced Cten expression 
prompted us to examine whether these changes could be caused through alteration of 
CDH1 expression. Western blot analysis of proteins extracted from HCT116 and 
SW480 cells transfected with GFP"Cten plasmid and SW620 cells transfected with 
Cten siRNA showed that forced Cten expression and knock"down were associated 
with down"regulation and up"regulation of E"cadherin protein levels respectively, 
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suggesting that Cten"mediated effects on cell motility and EMT in an E"cadherin"
dependent manner. 
 
The mechanism by which Cten may cause down"regulation of E"cadherin protein is 
uncertain. The association of Cten with integrin molecules raises the possibility of an 
effect via ILK. Forced expression of Cten in the CRC cell line HT116 cells resulted in 
up"regulation of ILK. In agreement with these results, the reciprocal Cten knock"down 
experiments in SW620 cells resulted in down"regulation of ILK. Activation of ILK has 
been reported to inhibit transcription of CDH1 through induction of the repressor 
SAIL. However, we found that there was no change in CDH1 mRNA levels 
following Cten expression, suggesting that reduction in E"cadherin protein was 
probably due to post"transcriptional regulation. Thus if Cten is responsible for down"
regulation of E"cadherin through ILK, it is probably not through the SAIL pathway. 
 
It is likely that Cten activates other downstream targets in addition to ILK. FAK is a 
125 kDa non"receptor and non"membrane associated PTK, which also localises at 
focal adhesions and is involved in many critical cellular events including adhesion, 
migration, proliferation and survival. Upon clustering of integrins, FAK is recruited to 
focal adhesions and this leads to phosphorylation of FAK at Tyr397, which creates a 
high"affinity binding site recognised by the SH2 domain of PI3K triggering the 
PI3K/Akt signalling pathway, which in turn controls cell spreading, cell movement 
and cell survival. The binding of Src to FAK can also phosphorylate FAK at Y925, an 
amino acid residue known to be associated with integrin adhesion dynamics and E"
cadherin de"regulation during Src"induced EMT (223, 224). 
 
An investigation of the role of C"terminal tensin"like (Cten) gene in colorectal cancer    
General discussion & future outlook 
176 
Cten co"localises with paxillin in focal adhesions and is involved in mediating the 
metastatic potential of mammary tumours (30). Cten contains a SH2 and a PTB 
domain, both of which have been shown to be involved in protein"protein interactions 
(5, 11, 14). FAK has also been reported to localise to focal adhesions via its interaction 
with paxillin (91) thereby providing a theoretical mechanism for interaction. 
Therefore, we focused on FAK as a potential downstream signalling molecule for 
Cten. Our data have shown that Cten also appears to regulate FAK and P"FAK in CRC 
cell lines. This suggests that Cten may also mediate cell motility through FAK. In 
order to test whether this may occur in tumour tissue, we evaluated Cten and P"FAK 
proteins expression in a series of paired primary CRC and hepatic metastases. Using 
IHC we found that P"FAK is predominantly a nuclear protein. This is, however, 
contrary to previously published data that confirmed the autophosphorylated and active 
form of FAK (FAK Y397) is localised to the cytoplasm (247). We have no explanation 
for this discrepancy other than the differences in the tissue samples examined and the 
methodology used (such as differences in the source of the antibodies used for P"FAK 
immunodetection). Comparison of the Cten and P"FAK immunostaining showed that 
they were highly correlated thereby supporting the observations we have made in the 
cell lines. In addition, we have reported in BC the significant associations between 
increased Cten expression and up"regulation of P"Akt and PI3K proteins. Taken 
together, this data strongly indicated that Cten may be considered as a key target in 
FAK–PI3K–Akt signalling pathway.  
 
Nuclear expressions of FAK and P"FAK have been described in other studies and were 
confirmed in our study. Ssang"Taek et al described the functional implication of these 
and found that FAK may limit p53 activity through FAK N"terminal FERM domain 
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which localises to the nucleus and directly interacts and suppresses transcriptional 
activation of a number of p53 target genes including p21, Mdm2 and Bax that are 
important mediators of p53"induced apoptosis, which would propose the anti"apoptotic 
signal of FAK FERM"domain"initiated pathway (114). 
 
CD24 is a small 80 amino acids"spanning heavily glycosylated mucin"lik GPI"linked 
cell surface protein. CD24 expression is up"regulated in colorectal adenomas and it is 
thus an early event in CRC carcinogenesis (180). High expression of CD24 is reported 
in CRC, and this over"expression is associated with poor prognostic parameters (179). 
In addition, forced CD24 expression in CRC cell lines is associated with enhanced 
colony forming, transwell migration and invasion abilities (182). Conversely, knock"
down of CD24 reduced cell migration in both transwell migration assays and cell 
wounding assays (182). It has been shown in a previous study that CD24 promotes cell 
motility in a β1 integrin"dependent manner. Antibody"mediated blocking of β1 
integrin interaction significantly reduced the migration of the CD24"transfectants, 
while it had no effect on the motility of the CD24"negative control cells (225). Given 
that and the finding that CD24 can induce the lateral localisation of β1 integrins into 
lipid raft domains where it regulates its function and activity, we hypothesised that 
Cten may function through CD24 signalling. We tested this hypothesis using, again, 
our dual approach of forced Cten expression and Cten knock"down in cell lines 
respectively expressing low and high levels of Cten protein. Forced expression of Cten 
in the CRC cell line HT116 (a cell line shown to have low Cten/CD24 expression) 
resulted in up"regulation of CD24. In agreement with these results, the reciprocal Cten 
knock"down experiments in SW620 (a cell line shown to have high Cten/CD24 
expression) resulted in down"regulation of CD24. Having thus demonstrated that Cten 
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regulates expression of CD24, we tested whether Cten induces cell motility through 
CD24. To test this hypothesis, knock"down of CD24 in HCT116 cell line stably 
transfected with GFP"Cten was carried out and resulted in abrogation of the effect of 
Cten on cell migration and invasion, suggesting a functional relationship between Cten 
and CD24 molecules. Moreover, Western Blot analysis showed that CD24 knock"
down was associated with up"regulation of E"cadherin and down"regulation of ILK 
and FAK proteins. These data show that CD24 probably lies downstream of Cten and 
is involved in Cten induced cell motility. Moreover, it has been reported that CD24 lies 
upstream effector of PI3K–Akt signalling pathway in CRC (245). Taken together, this 
data strongly suggest that Cten probably also signals through PI3K–Akt signalling 
pathway at focal adhesions. 
 
It has been reported in previous studies that Cten is regulated by EGFR signalling in 
BC. This is of interest since EGFR signals through K"Ras and the EGFR/K"Ras 
signalling pathway is up"regulated in CRC and many other cancers (208, 234). For 
example, lung cancers commonly have K"Ras or EGFR mutation and Cten expression 
is also up"regulated in these (246). This is supported by increased Cten expression in 
pancreatic cancers (which have high frequency of K"Ras mutation) (236). These data 
clearly show that Cten probably mediates signals for EGFR"K"Ras signalling. 
However there are other mechanisms also regulating Cten expression since, in both 
CRC and pancreatic cancer, there are occasional cell lines containing K"Ras mutation 
which do not express Cten. 
 
In summary, we have shown that Cten is up"regulated in CRC and BC and that this is 
associated with poor prognostic variables and shorter disease free survival. The high 
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frequency of expression of Cten in adenomas shows that up"regulation is an early 
event in the development of colorectal tumours. Our study has also shown that ectopic 
expression of Cten in the HCT116 CRC cell line causes changes in cell morphology 
and increased cell motility (both migration and invasion). Conversely, the reciprocal 
Cten knock"down experiments in SW620 results in inhibition of both cell migration 
and invasion. Furthermore, high levels of Cten expression are significantly associated 
with advanced disease/metastasis in human CRC. In addition, Cten expression is 
capable of enhancing metastasis in an invivo model. The current study has clarified 
the mechanistic basis of Cten"mediated changes in cell motility. This may depend on 
ILK, FAK and CD24 focal adhesions signalling molecules and suggests that Cten may 
signal through PI3K–Akt signalling pathway. We have also shown that increased Cten 
expression is associated with up"regulation and down"regulation of N"cadherin and E"
cadherin proteins respectively suggesting the role of Cten in N"cadherin/E"cadherin 
switch and EMT process. This may therefore represent a novel method of E"cadherin 
control and provides further proof of integrin–cadherin crosstalk.  
 
Future directions for work may include further study of Cten and tensin regulation. 
Since Cten shares an extensive homology with other tensin members at its C"terminal, 
the promoter sequence of Cten could be compared with that of the promoters of other 
tensin genes. Areas of high sequence conservation could be identified and analysed for 
the presence of transcription factor binding sites in order to explore mechanisms of 
control of expression. The activity of the Cten promoter region could be tested in 
colorectal carcinoma cell lines and possibly pancreatic cancer cell lines. The function 
of conserved putative transcription factor binding sites can be tested by mutating these 
using site directed mutagenesis and testing activity with single and combined 
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mutations. In addition, it would be of interest to further explore, using 
immunoprecipitation (IP), proteomics, two"dimensional gel electrophoresis (2D 
PAGE) and yeast"2 hybrid assays, other binding partners of cten, map the regions 
responsible for the binding on cten and demonstrate if this interaction has any 
prognostic implication in tumourigenesis. 
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Chapter 9. Appendix 
Appendix 9.1 Table 1. CRC cell lines and their characteristics.  
Cell line Age Sex Duck Stage Differentiation Site 
C106 78 F A Moderate Lower Rectum 
C125 66 F A Moderate Colon 
C32 64 F C Well Colon 
C80 69 M C Poor Rectum 
C84 67 M C Poor Caecum 
Caco2 72 M A Well Colon 
COLO201 70 M D Poor Colon"Ascites 
COLO205 70 M D Poor Colon"Ascites 
COLO320DM 55 F C Moderate Sigmoid Colon 
DLD1 70 M C Moderate Colon 
GP2D 71 F B Poor Recurrence Colon 
HCA46 53 F C Poor Sigmoid Colon 
HCA7 58 F B Moderate Hepatic Flexur 
HCT116 64 M D Well Colon 
HRA219 66 F B Well Colon 
HT29 44 F A Moderate Colon 
HT55 54 F C Moderate Rectum 
HuTu80 53 M A Well Duodenum 
LoVo 56 M D Poor Colon, distant lymph node 
LS1034 54 M C Poor Caecum 
RKO 64 F C Moderate Colon 
SW1116 73 M A Moderate Colon 
SW1222 44 M C Moderate Colon 
SW480 50 M B Moderate Colon 
SW620 51 M C Moderate Colon lymph node 
SW837 53 M B Well Rectum 
SW948 81 F C Moderate Colon 
VACO10MS 72 F D Moderate Colon Omentum 
VACO5 78 F C Poor Caecum 
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Appendix 9.2  
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Appendix 9.3  
Table 3.  BC patient and tumour characteristics (n = 1,409) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter 
 
'umber (%) 
 
Age  
<40 
40"50 
51"60 
>60 
 
 
40 (5) 
600 (39) 
346 (25) 
410 (31) 
 
Tumour size 
<1.5 cm 
>1.5 cm 
 
 
530 (35) 
760 (65) 
 
L' stage 
1 (negative) 
2 (1–3 LN) 
3 (>3 LN) 
 
461 (28) 
558 (39) 
472 (33) 
 
Grade 
1 
2 
3 
 
'PI 
Poor                                                   
Moderate 
Good 
 
448 (31) 
316 (21) 
625 (48) 
 
 
296 (14) 
877 (54) 
316 (32) 
 
DM 
Negative 
Positive 
 
 
 
 
  796 (59) 
694 (41) 
Recurrence 
Negative 
Positive 
 
 
 
603 (42) 
788 (58) 
Vascular invasion 
Negative 
Positive 
 
 
 
571 (39) 
828 (61) 
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Appendix 9.4  
Table 4. CRC patient and tumour characteristics (n = 462) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter 
 
Category 
 
'umber (%) 
 
Age (years) 
 
Median 
Range 
 
72 
57"89 
Sex Male 
Female 
257 (57%) 
192 (43%) 
Status Alive 
Dead (cancer related) 
Dead (unrelated causes) 
Unknown 
167 (37%) 
221 (49%) 
60 (13%) 
1 
Histological type Adenocarcinoma 
Mucinous adenocarcinoma 
Columnar adenocarcinoma 
Signet ring mucinous 
adenocarcinoma 
Unknown 
382 (85%) 
49 (11%) 
4 (1%) 
6 (1%) 
 
8 (2%) 
Histological grade Well differentiated 
Moderately differentiated 
Poorly differentiated 
Unknown 
28 (6%) 
345 (77%) 
67 (15%) 
9 (2%) 
Tumour site Colon 
Rectal 
Unknown 
230 (52%) 
177 (39%) 
42 (9%) 
Duke’s stage A 
B 
C1 
C2 
D 
Unknown 
66 (15%) 
175 (39%) 
133 (30%) 
20 (4%) 
52 (11%) 
3 (1%) 
T'M stage 0 (Tis) 
1 
2 
3 
4 
Unknown 
3 (1%) 
67 (15%) 
172 (38%) 
149 (33%) 
51 (11%) 
7 (2%) 
Extramural vascular invasion Negative 
Positive 
Unknown 
219 (49%) 
121 (27%) 
109 (24%) 
  An investigation of the role of C"terminal tensin"like (Cten) gene in colorectal cancer     
Appendix 
203 
Appendix 9.5 Sequencing of pCR2.1"HPRT plasmid. Sequencing results confirmed the presence of 
HPRT insert in pCR2.1  
pCR2.12HPRT M13 Reverse 
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pCR2.12HPRT T7 Forward 
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Appendix 9.6 Sequencing of pCR2.1"Cten plasmid. Sequencing results show that Cten was inserted into 
pCR2.1 vector in reverse (HindIII to BamH1) orientation. 
pCR2.12Cten M13 Reverse 
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pCR2.12Cten T7 Forward 
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Appendix 9.7 Sequencing of pCR2.1"Cten plasmid (middle areas of gene) 
Cten Reverse primers 
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Cten Forward Primers 
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